SACHS
ASSOCIATES

16TH ANNUAL

BIOTECH IN EUROPE FORUM

FOR GLOBAL PARTNERING & INVESTMENT

27TH – 28TH SEPTEMBER 2016

CONGRESS CENTER BASEL
SWITZERLAND

CONFERENCE GUIDE

www.sachsforum.com

Sachs Associates are delighted to welcome you to the:

16TH ANNUAL

BIOTECH IN EUROPE FORUM

FOR GLOBAL PARTNERING & INVESTMENT

27TH – 28TH SEPTEMBER 2016
CONGRESS CENTER BASEL
SWITZERLAND

Sachs Associates are delighted to welcome you to the 16th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe's Biotech industry.

The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year's programme features more than 100 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners.

GENERAL INFORMATION

The registration desk will be open from 8am on September 27th and 28th although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. There will be a Networking Lunch.

Coffee stations will be set up in the rooms and the presentation rooms throughout the event.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.

EVENTS DIARY

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com

10TH ANNUAL
EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION
PARTNERING & INVESTING IN BIOTECH & PHARMA INDUSTRY
6TH – 7TH MARCH 2017 • HILTON ZURICH AIRPORT HOTEL, SWITZERLAND

Back for its tenth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year's event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

The conference will feature up to 80 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners.

Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

2ND ANNUAL
NEUROSCIENCE BIOPARTNERING & INVESTMENT FORUM
SHOWCASING EARLY & LATE STAGE INVESTMENT OPPORTUNITIES
27TH MARCH 2017 • NEW YORK ACADEMY OF SCIENCES, USA

The 2st Annual Neuroscience BioPartnering & Investment Forum will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. We anticipate around 250 delegates and 30 presenting companies. We will have our usual online One-2-One partnering system in place and meeting facilities.

5TH ANNUAL
CANCER BIOPARTNERING & INVESTMENT FORUM
SHOWCASING EARLY & LATE STAGE INVESTMENT OPPORTUNITIES
28TH MARCH 2017 • NEW YORK ACADEMY OF SCIENCES, USA

The 5th Annual Sachs Cancer Bio Partnering Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment.

We expect around 300 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of presentations by research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotech's seeking licensing/investment. The Forum will feature an online one-to-one meeting system with designated meeting space available to all attendees.

THE FORUM WILL COVER THE FOLLOWING TOPICS IN THE PROGRAM:
• Deal Making • Public Markets • Early and Late Stage Investment • Immuno-Oncology
• Advances Cell Therapies • Rare & Orphan and Pediatric Cancers • Reimbursement

SPEAKERS

Agnete B. Fredriksen

CSO, Vaccibody AS

She joined Vaccibody as Chief Scientific Officer in 2007. She holds a M.Sc., PhD from Institute of Immunology, University of Oslo, Rikshospitalet Medical Center, Oslo where she designed and developed the first Vaccibodies. Previous employments include Researcher at Affitech AS, Oslo and Medinnova AS. Agnete is one of the inventors of the Vaccibody technology and received the King's Gold Medal for her PhD thesis on Vaccibodies

Alain Huriez

Partner, Advent Life Sciences

Alain Huriez, MD, is Partner at Advent Life Sciences London he joined in June 2012. He brings 25 years of experience in the life sciences sector, including CEO of immunology and MDx companies TcLand-Effimune (2006-2012), Neovacs (2003-2006), Associate Partner at Truffle Capital (2002-2003) and Vice President at Quintiles International (1995-2002). Alain's experience includes private equity financing, tech transfer & scouting, business development and general management in the areas of vaccines, antibodies, molecular diagnostics, devices & technology platforms. Alain is a Medical Doctor and holds an MBA and a Masters of Pharmaco-Economics from Paris La Sorbonne University.
Alain has been responsible for several lobby initiatives at the European level (EMA, EC, Parliament) in the area of personalised medicine through his work as chairman of EPEMED, the European Personalised Medicine Association www.epemed.org he founded in 2009. As an entrepreneur, he co-founded five French biotechnology companies.

Alexander Nuyken

Head of Life Sciences Transaction Advisory EMEIA, Ernst & Young GmbH

Alex joined EY in 2015 having held previous roles in investment banking, most recently as an Executive Director and coverage officer for the healthcare sector at UBS and previously at Nomura and Lehman Brothers. He is based in Frankfurt/Eschborn.
Alex is a German lawyer and earned his MBA at INSEAD. 12 years of M&A and strategic advisory experience. Expertise across all aspects of advisory work with public and private companies, including acquisitions, divestments, takeover defense, capital raising and portfolio optimization.mExperience in Life Sciences, Healthcare Services and Chemicals including multiple cross-border assignments with a German context.

Alexandra Richardson

Head of Business Development, Clayton Biotechnologies, Inc.

Alexandra Richardson, PhD, CLP, is head of marketing and business development for Clayton Biotechnologies, Inc. (Houston, Texas). Her responsibilities include developing and implementing strategies for the commercialization of medical discoveries made by the Clayton Foundation for Research (Houston, Texas) and its supporting entities. She also is also scientific advisor to the Institut Clayton de la Recherche (Geneva, Switzerland) and the Clayton Foundation. The Clayton Foundation is a nonprofit medical research organization that conducts and sponsors research at leading research institutions, hospitals and universities. Alexandra's focus is on partnering early-stage research projects with companies and investors to translate the research into products. Through her work in licensing and starting new companies, the Foundation's research has been developed into a rich clinical pipeline. Eight products have been brought to the market resulting from the Foundation's research, including Exparel launched by Pacira Pharmaceuticals, a Clayton portfolio company.
In 2009, Alexandra founded ARBbiotech SàrL, a consulting firm that offers business development and strategy consultancy in life sciences with a focus on licensing-out early stage biotech assets. The company's clients include a University hospital, medical research foundation, several biotech companies in Germany, the US and Switzerland and a pharmaceutical company. ARBbiotech works with a network of PhD consultants with extensive experience in research, pharmaceutical business development, and pre-clinical and early clinical drug development.
Alexandra was previously a Licensing Officer at Unitec, the technology transfer office for the University of Geneva and University Hospitals of Geneva (2000-2008). She holds an ACS-accredited BA in Chemistry from Swarthmore College and a doctoral degree in biochemistry from the University of Geneva, with award for the best PhD thesis at the Medical School. Alexandra is on the Board of Directors for Stemergie, SA and is a jury member for Venture Kick. She has completed courses and certificates in intellectual property, entrepreneurship and technology transfer licensing at leading organizations such as AUTM, the Swiss Federal Institute of Intellectual Property and LES, and is a Certified Licensing Professional (CLP).

Anthony DeBoer

Director, Business Development, Synaffix BV

Prior to joining Synaffix in 2014, Anthony served as the Associate Director of Business Development at Allozyne, a Seattle-based biotech, where he was focused on partnering efforts around pipeline programs and antibody-drug conjugate technology leading up to an acquisition by MedImmune. Previously, he studied in the laboratory of Dr. Irv Weissman at the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Anthony is a published co-author in Nature and PNAS and holds a BSc in Biotechnology from Seattle Pacific University.

Armin Mäder

CEO, Memo Therapeutics AG

Dr. Armin Mäder held senior positions in Neurotune AG, Institut Straumann AG and AC Immune SA in Lausanne, Switzerland. He is also a co-founder of the medtech company Qvanteq AG in Zürich. Armin Mäder started his professional career in the UBS Investment Bank.
Armin Mäder holds an M.B.A. from IMD in Lausanne. He graduated from the ETH Zurich with a Master's degree in Natural Sciences and holds a PhD in Molecular Biology and Biophysics from ETH Zurich.

Arthur Roach

Director of Research, Parkinson's UK

Arthur Roach is responsible for the strategy to convert the demands and priorities of people living with Parkinson's into better treatments and a deeper understanding of the condition. He brings to this role over 25 years of experience of research into neurodegenerative diseases and the discovery and development of new treatments, conducted in leading universities and drug companies in both North America and Europe.

Austin Smith

Medical Director, Theradex (Europe) Ltd.

Dr. Austin Smith, Medical Director, is trained in medical oncology and is currently undertaking pharmaceutical medicine training. A graduate of the Royal College of Surgeons in Ireland, Dr. Smith has over fourteen years of experience in the clinical practice of hematology and oncology and eight years within clinical development in the pharmaceutical industry. Dr. Smith provides medical expertise and strategic input into the clinical development programs of our European clients. He also represents clients at national Competent Authorities and the European Medicines Agency for both scientific and regulatory advice meetings. Dr. Smith provides clinical training, support and expertise to project teams working on hematology/oncology/immunology studies primarily in the EU. Dr. Smith also plays a pivotal role in study feasibility assessments and selection of sites and investigators for upcoming studies. Dr. Smith regularly attends and presents at scientific and industry meetings. Dr. Smith also explores and maintains dialogue with pharma and biotechs to establish working collaborations and opportunities for new and innovative development of cancer therapeutics.

Beth Jacobs

Managing Partner, Excellentia Global Partners

EGP serves US, European and Asian-based clients on a range of engagements, raising capital, global strategy and growth through both organic and M&A approaches. She is active in scientific and social service not-for-profits, serving on the boards of The New York Academy of Sciences, as Governor and Executive Committee member, EF Foundation, Cambridge, Massachusetts, Harvard Kennedy School Womens Leadership Board, William J. von Liebig Foundation for Medical Research, Susan G. Komen Foundation – Global Ambassador, and as a special advisor to the Board of Positive Exposure.

Since 1982, Beth has built, managed and executed with some of the largest International Divisions in global investment banking, including Prudential Bache, Morgan Stanley, Shearson Lehman and ING Barings – Furman Selz. She held the position of Senior Vice President for Laureate Education (private), working across all business units in a corporate development role with a distinct focus on identifying and executing on opportunities in China. Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, BA, cum laude, from Boston College and studied at Centre d'Etudes Internationale, Geneva, Switzerland diplomatic program.

Bibhash Mukhopadhyay

Principa, New Enterprise Associates

Bibhash is a Principal at New Enterprise Associates (NEA), where he focuses on investing in emerging therapeutics and device companies, assisting them grow and create value. Previously, he was at AstraZeneca / MedImmune as an Associate Director of Business Development, where his responsibilities spanned end-to-end in the deal-making spectrum, from search and evaluation to transactions, with focus on the immune-oncology and immunology spaces. He started his career at Johnson and Johnson, where he held multiple Business Development roles, at different times, in Global Surgery, Oncology and Emerging Technologies. Bibhash's doctoral research work focused on pathophysiology of retinal diseases using tools of cell biology and mathematical modeling, during which he also consulted for venture funds and start-ups.

Bob Pooler

Sr. Healthcare Analyst, valuationLAB AG

Bob Pooler is a senior healthcare analyst with more than 20 years experience in the financial and healthcare industry. He started his career at Merck, Sharp & Dohme in the Netherlands in cardiovascular sales, introducing the cholesterol-lowering drug Zocor. He became one of the first buy-side analysts in Europe covering the life science industry at ABN AMRO Asset Management in Amsterdam. In 2000 he moved to Zurich, Switzerland to become a senior pharma/biotech sell-side analyst where he worked for Cheuvreux, Lombard Odier and Bank am Bellevue. In 2012 he founded valuationLAB AG, an independent research boutique that provides financial analyses and related services to the life science industry. Clients include public and privately held life science companies. With his research and extensive network, he helped raise more than CHF 370 million in 3 IPO's and several private placements for the life science industry.

Carol Routledge

Venture Partner, SV Life Sciences

Carol Routledge joined SV as a Venture partner, focused on the DDF, in 2015.
Prior to this, Carol was Head of Translational Medicine in Biopharm Discovery, Biopharm R&D. She has over 25 years' experience in preclinical and clinical research and development for both NCEs and biologics. She holds a degree from Nottingham University and a PhD in neuropharmacology. Carol's career has spanned various positions in major pharmaceutical and biotechnology companies both in the UK and in the US including ICI, Syntex, Wyeth, SmithKline Beecham, BTG and GSK.
Her focus has been on drug discovery and development across a number of different therapeutic areas particularly in the areas of neuroscience and immuno-inflammatory diseases with an emphasis on translational medicine.

Carolyn Porter

Deputy Head of Technology Transfer, Oxford University Innovation Ltd.

Carolyn has led or supported the formation of 11 spin-out companies from Oxford University commercialising a diversity of innovative technologies addressing distinct challenges in healthcare. She sits on the board of 4 of these companies. Recent Oxford spin-outs include Vaccitech, Evox and Oxstem collectively raising £36.9M in seed financing. Prior to Oxford University Innovation, Carolyn worked in senior Business Development roles in Novartis and Chiron and in corporate finance at Ernst & Young. She has a PhD in Immunology and an MBA.

Chandra Leo

Investment Advisor, HBM Partners AG

Dr. Leo has more than 15 years of experience in venture capital, clinical practice and biomedical research. He is a member of the private equity team at HBM, a healthcare-focused investment group managing >USD 1 billion in assets. Dr. Leo is currently a board member or board observer at CardiacAssist, Gynesonics, i-Optics, ObsEva and Symbiomix. He previously served as a board representative at Anthera Pharmaceuticals (IPO NASDAQ), ChemoCentryx (IPO NASDAQ), Delenex (acquired by Cell Medica), ESBATech (acquired by Alcon/Novartis) and Panomics (acquired by Affymetrix). Dr. Leo completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD.

Charles Stacey

President and CEO, Accera, Inc.

Dr. Stacey has over 15 years of experience in healthcare; working as a healthcare provider, executive, entrepreneur and investor. Prior to joining Accera, he was with Inventages, a global healthcare venture capital and private equity group with $1.5Bn under management. Dr. Stacey received his medical degree from King's College London and practiced as a trauma and reconstructive surgeon. His undergraduate degree and basic research were in the neurosciences at University of College London. Dr. Stacey also completed an MBA at the London Business School and the Wharton School. Dr Stacey is also the Chairman of the Alzheimer's Association Business Consortium (AABC) and the not-for-profit group, Data in Dementia.

Chris Britten

Managing Director, Torreya Partners

Chris is a Managing Director at Torreya Partners, a leading global investment bank focused on facilitating partnerships, M&A transactions and financings in the pharmaceutical sector worldwide. He joined Torreya from Sanofi Pasteur-MSD where he had responsibility for all business and corporate development activities. He is also a Non-executive Director at Phico Therapeutics Ltd.
Prior to Sanofi Pasteur-MSD, Chris held positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising). Previously, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D. He holds a PhD in Biochemistry and an MBA in Finance.

Chris Maggos

Managing Director, Europe, LifeSci Advisors

Chris has over 20 years of experience in the life sciences industry covering investor relations, media relations, business development (i.e. out-licensing), journalism, investing, and molecular neurobiology. Chris opened in late 2015 the European headquarters of the leading investor relations firm LifeSci Advisors, in Geneva, Switzerland. Chris also is founder of BioConfidant Sàrl a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals. At Addex Therapeutics (SIX:ADXN), Chris was a member of the executive management board and held the positions of Head of Investor Relations & Communication (2007-2010) and Director Business Development (2010-2013). He co-founded in 2013 a not-for-profit social enterprise, Alpine Institute for Drug Discovery, whose mission is to help commercialize academic discoveries. Chris also has worked as: a journalist for the leading biotechnology trade publication BioCentury (2001-2007); an Associate at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies.

Christian Lach

Senior Portfolio Manager, Bellevue Asset Management AG

Bellevue Asset Management, BB Adamant -Team, Lead Portfolio Manager Since October 2014
Adamant Biomedical Investments 2008-2014, Senior Portfolio Manager Biotech
Bellevue Asset Management, BB BIOTECH AG Team 2001-2008
Education: Dr. oec. HSG (phD in Innovations management), lic.oec.HSG (MBA), dipl.Natw.ETH (MSc Biochemistry)

Christopher Viehbacher

Managing Partner, Gurnet Point Capital

Gurnet Point is a Boston based investment fund associated with the Bertarelli family and has a $ 2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc and is the Chairman of Vedanta, a Pure Tech portfolio company. He is a member of the Board of Trustees of Northeastern University
Chris is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.
Prior to joining Sanofi, Chris spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a Member of the Board of Directors of GSK plc in London and Co-President of GSK's Portfolio Management Board. Chris began his career with Price Waterhouse after graduating with a degree in Commerce at Queen/s University in Canada.
Chris has been a strong advocate for the healthcare industry. Current and past advocacy roles include:
*Former Co-chair with Bill Gates, the CEO Roundtable on Neglected Diseases
*Past-Chairman of the CEO Roundtable on Cancer. Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington
*President of the European Federation of Pharmaceutical Industries and Associations in Brussels.
*Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living.
*Member of the International Business Council.
Chris has in the past served on various advisory groups at MIT, Duke University and Queen's University at Kingston, Ontario.
Chris has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France's highest civilian honor, the Legion d'Honneur.

Dani Bach

Investments Director, Investments Director

Dani joined Innovations in January 2016 from Aravis, where as managing partner he co-led the design of the investment strategy, fund raising and investment process. He focuses on early stage, at times matching technologies with passionate management teams. His areas of investment have ranged from medical devices to protein therapeutics.
Prior to Aravis, Dani worked at Index Ventures, helping build companies such as Acutus Medical, Levicept, and Versartis.
Dani holds a PhD in molecular biology from the University of Barcelona and an executive MBA from the Escuela de Organización Industrial (Madrid).

Daniel Barton

Director of Business Development, Biosceptre International Ltd.

Daniels background is Molecular Biochemistry and Law at University of New South Wales, Sydney Australia, and throughout his career he has worked across strategy, legal, product development and marketing in the technology and biotech sector. Daniel began working with Biosceptre in 2012 to advance therapeutic candidate BIL010t through Phase I clinical trials, and since 2015 has led Biosceptres' industry outreach program to expand awareness of Biosceptre's unique IP portfolio surrounding the noel oncology target nfP2X7, and to explore out-licensing, funding, and partnership opportunities with the broader biotech and pharmaceutical community.

David Reynolds

CSO, Alzheimer's Research UK

Alzheimer's Research UK is UK's leading research charity aiming to defeat dementia. Previously David worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain research site head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain. David's external work included representing Pfizer at EFPIA (European Federation of Pharmaceutical Industries and Association) for Europe's Innovative Medicines Initiative (IMI) and coordinating Pfizer's participation in over 30 projects. He has served as a member of the Medical Research Council's Neuroscience and Mental Health Board and on the Scientific Advisory Board of a pain-focussed biotech. David holds a BA in Natural Sciences and a PhD in Neuropharmacology both from the University of Cambridge.

David Venables

CEO, Synpromics Ltd

David Venables recently completed two successful fund raising rounds of £2.25M, and secured total deal terms with leading gene therapy companies in excess of £100M. He has previously served as VP – CMC for NightstaRx, an ophthalmology focused gene therapy company; CEO of Anatara Therapeutics (a life sciences company managed through to IPO in Australia); CEO of Ark Therapeutics, leading the company through a business transition and sale as a gene therapy CDMO. Previously at Intercell, he was responsible for building Intercell's manufacturing capabilities in Europe and the USA. Initially as Site Head for vaccine manufacturing operations in the UK followed by Chief Operating Officer of Intercell USA Inc. based in Maryland, USA.

Denise Hirsch

Director, Protection and Institutional Partnerships and Board Member, Inserm Transfert

Before joining Inserm Transfert in 2006 as Head of the Intellectual Property department and then Director of Protection and Institutional partnerships in 2015, Denise worked as a patent attorney for thirteen years with Cabinet Lavoix, then for three years as Head of Patents International Therapeutic Area "Allergies and Lung Disease" at Pfizer, and subsequently as Head of Patent Group - IP Department Pfizer Europe.

Denise is a graduate of CEIPI, and holds a Master Degree in Organic Chemistry, Université Louis Pasteur and a Master Degree in Business Law, Robert Schumann University. She is an expert in intellectual property as a European patent attorney in the field of Life Sciences. She is currently a member of the Patent Group of LEEM (the French Pharmaceutical Companies Association) and Co-Chair of the Patent Committee of the French group of the AIPPI.

Dior Baumjohann

Technology Manager, Ascenion GmbH

Ascenion is a technology transfer company working at the interface between science and business with exclusive partnerships with numerous research institutions of the Helmholtz and Leibniz Associations, the Charité – Universitätsmedizin Berlin, the Hannover Medical School and associated organizations for translational research.
Prior to joining Ascenion, Dior advised and supported scientists of the Max Planck Society in technology transfer as a Life Science Senior Patent and License Manager at Max-Planck-Innovation and at the University of California San Francisco (UCSF) Office of Innovation, Technology & Alliances she was responsible for intellectual property management from evaluation of inventions developed by UCSF clinicians, scientists and staff to negotiation of commercialization agreements as a Licensing Officer in Technology Management. She holds a master's degree in virology from Harvard University and earned a PhD in cell biology from the University of Bern in Switzerland. Her doctoral research in the field of immunology was conducted at the Institute for Research in Biomedicine in Bellinzona, Switzerland.

Edwin Constable

Vice-Rector Research, University of Basel

Professor Edwin (Ed) Constable was born in Scotland in 1955 but moved to the south of England shortly afterwards. He studied chemistry at St. Catherine's College, Oxford, and doctoral studies were also in Oxford, where he worked with Professor Ken Seddon on the design of metal complexes for solar cells. He then moved to Cambridge where he held sequentially an 1851 Research Fellowship, a University Demonstratorship and Lectureship and was a Fellow of Darwin and Robinson Colleges. In 1993 he accepted a call to the Chair of Inorganic Chemistry in Basel where he remained until 2000 when he returned to the United Kingdom to a Chair of Chemistry in Birmingham.In 2002 he returned to Basel where he currently holds a Chair of Chemistry. He was Research Dean of the Faculty Sciences and is currently Vice-Rector for Research of the University.
His scientific interests and expertise lie in metallosupramolecular and materials chemistry, especially in the use of metal ions for the assembly of novel architectures incorporating specific electronic or photophysical properties. He is a highly cited researcher and has published over 500 research papers and many books. and is actively involved in industrial collaborations, national and EU funded programs relating to interfacial and heterogeneous chemistry and their application to nanoscale electronic, catalytic and electrocatalytic devices. Interest centres upon the development sustainable materials chemistry for dye-sensitized nano crystalline solar cell and OLEDs and related lighting technologies. He received an ERC Advanced Grant (2011-2016) for his project LiLo (Light-In, Light-Out) relating to sustainable materials chemistry and is actively involved in the Swiss Nanoscience Institute. He runs the research group jointly with his wife, Professor Catherine Housecroft.
He has been involved in the assessment and development of educational programmes in many European and middle Eastern countries and is a frequent speaker at public and scientific meetings for the public awareness of science as well as presentations on sustainable next generation technologies.

Eric de La Fortelle

Venture Partner, Seventure Partners

A Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, diagnostics and nutraceuticals. The specific 'core' of Seventure's investment strategy is 'nutrition, health and wellness', with particular focus on the intestinal microbiome and the diseases associated with dysfunction of this symbiotic relationship, notably in the inflammation/autoimmune area. Eric sits on the Board of directors of Mint Solutions, Maat Pharma and TargEDys as a representative for Seventure, and of Sensorion (France) as an independent director

Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche's global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations).

Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.

Eric Halioua

President and CEO, PDC*line Pharma

Serial entrepreneur that combines strong managerial, technological, product development and fund-raising experience in biotechnology and cell therapy.

Eric Halioua is President and CEO of PDC*line Pharma, a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic cells (PDC*line).

He is as well Board member of the biotechnology company Bioxodes (Belgium) and HairClone (UK) and member of the strategic advisory board of OncoDNA (Belgium), Innobiochips (France).

He was CEO at at the liver cell therapy company Promethera Biosciences. The company, under his leadership, raised successfully more than 65M€ in capital, grants and loans and established a team of close to 50 persons. He is as well co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy.

Eric is as well co-founder of two biotechnology companies called Myosix and Murigenetics. Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been sold to Genzyme mid-2002. Murigenetics is a Biotechnology company developing therapies for genetic disorders. Eric was also a Board Member of a French public biotechnology company called Valneva, which specializes in the development and commercialisation of vaccines and monoclonal antibodies.

He was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during 11 years. He has led work in the areas of strategy, Due Diligences, M&A and technology & innovation management for biotechnology and pharmaceutical companies. Eric also worked as a strategic marketing manager for the "Centre Européen de Bioprospective" and as project leader in the corporate R&D centre of Astra-Zeneca in UK.

Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

Ernst Hafen, PhD

President, Bio-Technopark Zurich

Ernst Hafen is a Professor of Systems Genetics at ETH Zurich (Institute of Molecular Systems Biology) and former President of ETH. In addition to over 30 years of academic research, he has founded and advised several biotechnology companies and is the president of the BIO-TECHNOPARK Schlieren-Zurich. Ernst Hafen endeavors to assist scientific discovery and its efficient translation into products that help society and the economy.

As a trained geneticist, Ernst Hafen has a strong interest in human genetics and personalized medicine. He posits that an individual's control over his or her personal health data will be a key asset for better and more effective health care. In 2012 he acted as a founding member of the Association Data and Health (DatenundGesundheit.ch) whose aim it is to discuss legal, ethical and societal issues about digital self determination and the control over the secondary use of personal (health) data and to find commercial models permitting owners, not third parties, to benefit from their personal data assets. In 2015 he co-founded the personal data cooperative MIDATA.coop.

Esteban Pombo-Villar

Independent Consultant

Esteban Pombo-Villar is an independent BioPharma consultant. He was previously a Board Member and Chief Operations Officer for Oxford BioTherapeutics, a privately owned company developing antibody-based drugs to proprietary targets for oncology indications. During his tenure, he managed the alliance with Menarini which resulted in the first of Oxford's projects to enter clinical development. Among other duties, in addition to alliance management, he was also responsible for establishing the supply chain, leading development and manufacturing aspects of toxin, antibody and antibody-drug conjugates as well as for the IP department. Dr. Pombo-Villar was at Novartis for over 23 years, the last 12 of which he was involved in all aspects of identification, evaluation, creation and management of alliances. As Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), he was responsible for alliances across all therapeutic areas and technologies up to proof-of-concept in man. Prior to his involvement in business development, he was responsible for medicinal chemistry in the Neuroscience Research group and its Management Board, led multiple projects in small-molecule drug discovery, as well as initiating and leading collaborative projects investigating the applications of technologies such as microwaves and microfluidics in drug discovery and development. He obtained his PhD in organic chemistry from the University of Warwick (UK) and carried on postdoctoral studies at the ETH in Zurich with Professor Albert Eschenmoser before joining Sandoz Neuroscience Research in Basel in 1988. While at Sandoz and Novartis, he pursued business courses at IMD, Harvard Business School, and the Tuck School of Business at Dartmouth University. Dr. Pombo-Villar is a Chartered Chemist and Fellow of the Royal Society of Chemistry.

Fabian Buller

Director New Ventures, Johnson & Johnson Innovation

Fabian is based in Zurich, Switzerland, and affiliated with Covagen AG, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Before joining the Johnson & Johnson family, Fabian was Director of Business Development at Covagen, a company acquired by Janssen in August 2014. In this role, he helped grow a successful biotech company and was instrumental in entering a strategic research & licensing partnership and ultimately, in the sale of the company. Prior to this, Fabian led immuno-oncology discovery research at Covagen with a focus on multi-specific protein therapeutics.
Fabian holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.

Fabrizio Gasparini

Director, Novartis Institutes for BioMedical Research

For more than two decades, FG research has focused on identification, characterisation and development of novel modulators of the metabotropic glutamate receptor family (mGluR). With his group at Novartis, he has identified several selective antagonists of the mGluR5 subtype; Mavoglurant (AFQ056), is the most advanced candidate. Negative modulation of the mGluR5 subtype has been involved as therapeutic target for a range of disorders including addiction, anxiety, Parkinson's disease L-dopa-induced dyskinesia (PD-LID) and fragile X syndrome (FXS). Mavoglurant has shown promising effects in proof of principle clinical trials and reduced the L-dopa induced dyskinesia in PD patients as well on behavioural symptoms in a subgroup of patients with FXS. In his current position FG is leading the research efforts on neuroinflammation within the Neuroscience research department.

Fintan Walton

CEO and Founder, PharmaVentures

In 1992 Dr Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures.
Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups.
In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012.
Educated at Trinity College (Dublin, Ireland), Fintan subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Florence Dal Degan

R&D Innovation Sourcing Director, Novo Nordisk

She is responsible for scouting and evaluating biotherapeutics, ranging from discovery to early clinical development stage within diabetes, obesity, haemophilia and growth hormone disorders, the focus areas of Novo Nordisk. Her activities also include scouting and evaluation of protein and peptide related technologies.
Florence has a PhD in biochemistry from The National Institute of Agronomy (Paris, France). She has over 20 years of experience in Research and Development in academic and biotech environment. Since 2000, Florence has worked with protein and peptide drug discovery and early development and has held several positions as group leader with in R&D.

Florian Schödel

Owner, Philimmune, LLC

Philimmune LLC is a consulting firm which provides strategic advice in the development of biologics, vaccines and pharmaceuticals.
Florian has > 20 years of successful experience in leading teams in the development of vaccines and biologics in the pharmaceutical and biotech industry and in academia.
His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics.
Florian has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development.
He has directed the design and execution of clinical studies for licensure and routinely interacted with international and national regulatory agencies.
A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories and has led the clinical teams responsible for several successful vaccine filings before he founded Philimmune.
Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. Florian's research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid.

François Conquet

CEO, Prexton Therapeutics

He defended his PhD in 1991, at the Pasteur Institute in Paris and did his Post-doc at Genentech. After that, he joined the GSK Research Institute of Geneva where he worked as a scientist in CNS research until 2001. His main field of interest was to validate metabotropic Glutamate receptors for CNS diseases. Then, he left GSK to found Addex Pharmaceuticals in Geneva, where he stayed CEO until 2005. Addex is a Biotech company dedicated to the discovery of novel treatments for CNS diseases. In 2005, he worked as an acting CEO for a VC firm in three different French Biotechs, before joining Merck Serono in September 2006 as Director, Early Stage Licensing, where he managed the in-licensing of several novel preclinical programs. In 2012, François became the founding CEO of Prexton Therapeutics, a biotech dedicated to the development of mGluR4 compounds for Parkinson's disease.

Frédéric Legros

VP Business Development, Valneva SE

He is a dedicated, experienced business professional with passion for life sciences and business. He has over a decade experience in licensing and business management. He is currently the Vice President and Corporate Head of Business Development of Valneva SE.
Dr. Legros serves on the board of directors of the French biotechnology company Blink Biomedical, dedicated to the development of novel antibodies in the field of cancer target immunological checkpoints. (www.blinkbiomedical.com).
Until December 2007, Dr. Legros was Director of the Pasteur Institute's Tech Transfer office where he was in charge of the strategic partnership with Sanofi Pasteur and GSK Biologicals. He joined Valneva in 2008 to lead all licensing activities in the USA. In 2012, he was appointed to Head of Business Development and in 2013; he became Vice President and Corporate Head of Business Development. He is member of the Executive Committee and Research & Development Committee. He obtained his PhD in molecular biology (2002) and holds a business degree from NEOMA business school, France (2003). Dr Legros has published in the field of mitochondrial dynamics.

Genghis Lloyd-Harris

Partner, Abingworth LLP

Genghis joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Genghis was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before joining Equity Research at CSFB, he worked for CSFB's Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia. Genghis holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School.

Georges Rawadi

VP Business and Development, Celyad S.A.

He has served as Vice President Business Development since June 2014. Prior to joining the Company, Dr. Rawadi served as Vice President Business Development with Cellectis. He previously held business development management positions at Galapagos, ProStrakan France and Sanofi-Aventis France, and conducted consultancy assignments in Business Development and Alliance Management. His work included all aspects and stages of business development, driving several projects from target identification and negotiation to closing deals. He holds a Ph.D. in Microbiology from the Pierre et Marie Curie University (France), and a Masters in Management and Strategy in the Health Industry from the ESSEC Business School.

Gil Bar-Nahum

Managing Director in the Global Healthcare Investment Banking Group, Jefferies International

Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment Bank's Global Healthcare Group until 2009. Prior to that, Dr. Bar-Nahum worked as a Biotechnology Research Analyst for UBS where he served as an Associate Director covering companies in the Life Sciences space. Dr. Bar-Nahum has executed and advised on over 100 transactions in the life sciences space, with particular expertise in Biotechnology Mergers and Acquisitions, and in raising capital for highly innovative developmental stage growth companies. In the last few years, Dr Bar-Nahum has led follow-on financings and Initial Public offerings of numerous international Biotechnology Companies, including 15 foreign private issuers, 13 onto NASDAQ, raising north of $2bn in proceeds. Dr. Bar-Nahum received his PhD in biochemistry from the Sackler Institute at the New York University School of Medicine. The subject of Dr. Bar-Nahum's doctorate work was published twice in the journal Cell. Dr. Bar- Nahum also received an MS from New York University's School of Medicine in Cell and Molecular Biology and a BS from the University of Illinois in Microbiology

Göran Forsberg

CEO, Cantargia AB

He has been CEO of Cantargia since 2014. He has a PhD in biochemistry, and is an associate professor and the author of over 40 scientific publications. He has worked for pharmaceutical and biotechnology companies for more than 25 years in various positions, including at KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Forsberg's most recent position was Chief Business Officer at Active Biotech AB. He has long experience of drug development with a special focus on oncology.

Guillaume Vignon

Head of Immuno-Oncology Licensing & Business Development, EMD Serono

He is the Global Head of Immuno-Oncology Licensing & Business Development at Merck / EMD Serono, responsible for leading partnering activities in the field of Immuno-Oncology from evaluation stage till deal closure.
Throughout his career at Merck, Guillaume has held numerous positions of increasing responsibility within Global Licensing & Business Development and has played a key role in closing complex transactions and forging key partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery.
Guillaume Vignon holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Institut Pasteur, Paris, France and an MBA from Hult International Business School, Cambridge, USA.

Ian Wilson

CEO, Edinburgh Molecular Imaging Ltd.

20 years experience in development of in vivo medical diagnostics and imaging medical devices, as GE Healthcare's Head of Biology 2007-2013, CTO/COO of Xstrahl Ltd, and CEO Edinburgh Molecular Imaging Ltd. Responsible for development and management of GE Healthcare's Molecular Imaging agent Portfolio, in Cardiovascular, Oncology and Neurology. At Xstrahl, developing a surgical gamma camera for visualization of cancer, and overseeing operations of the radiotherapy business. At Edinburgh Molecular Imaging, Ian as CEO, lead a company focussed on developing optical fluorescent imaging agent to enable bedside diagnosis of cancer and lung disease, and improve surgical resection.

Isabella Schidrich

Senior Managing Director, Nasdaq

She joined Nasdaq International as Managing Director in 2001, responsible for business development and account management of Nasdaq in Western Europe. Following Nasdaq's acquisition of OMX, Isabella was promoted to Senior Managing Director, responsible for the listings business of Nasdaq in Europe. To date, Isabella supported over 60 European companies with a US listing.
Prior to that, Isabella gained extensive business development experience within the telecommunications industry, heading business units at British Telecommunications Plc and at Deutsche Telekom AG, and within the Services Industry.
Isabella graduated from Munich University with an MBA in Business Administration (Diplom Kauffrau).

Ivo Staijen

Head, Public Equity, HBM Partners AG

He has over four years of experience in the pharma industry and fifteen years of experience in investment analysis and portfolio management in the healthcare sector. He was senior biotechnology analyst at Bank Sarasin and a former department head at MDS Pharma Services. Ivo obtained a Master of Science degree in chemistry from the University of Groningen, the Netherlands, and a PhD in biology from the Swiss Federal Institute of Technology (ETH), in Zurich, Switzerland. He was a visiting scholar at the Department of Biology at the MIT, Cambridge, Massachusetts USA, and is a CFA Charterholder

Jan Groen

CEO, MDxHealth

He joined MDxHealth in 2010 and has over 30 years of executive and Board level experience in the clinical diagnostic and biotech industry, with a particular focus on emerging technologies, product development and commercialization. Dr. Groen was previously the president and COO of Agendia, a venture backed CLIA laboratory developing and commercializing proprietary genomic products and responsible for their United States and European diagnostic operations, respectively. Prior to this, he served as vice-president of research & development at Focus Diagnostics, Inc., a private owned company focusing on infectious diseases and immunology, which was acquired by Quest Diagnostics in 2006. Dr. Groen has held numerous management and scientific positions at ViroClinics B.V., the Erasmus Medical Center, and Akzo-Nobel. Dr. Jan Groen is a board member of MyCartis BvBa. Dr. Groen holds a Ph.D. degree in medical microbiology from the Erasmus University Rotterdam and published more than 125 papers in international scientific journals in the field of clinical diagnostics.

Jane Atkins

Senior Director, GI Business Development, Takeda Pharmaceuticals International GmbH

She is a member of The Center for External Innovation at Takeda, focused on novel platform technologies and pipeline programs to support the Gastroenterology therapeutic area. Jane joined Takeda 2 1/2 years ago and is based in Zürich. Prior to Takeda, Jane held various Business Development positions with Merck Serono, Mundipharma International and Hospira. Jane obtained her Ph.D. in Biochemistry from the University of Leicester and held research positions at the MRC Laboratory of Molecular Biology and Cambridge Institute for Medical Research in Cambridge, UK.

Jason Laufer

CEO, RDD Pharma

CEO, RDD Pharrma (2013 to Present)
Global BD&L - URL Pharma ; acquired by Takeda (2007 to 2012)
CEO, Elutex (2005 to 2006)
Managing Director, Mediatech/CELLGRO ; acquired by Corning (1986 to 2004)
Pfizer, Regulatory/Clinical Affairs (1982 to 1986)

Jasper Bos

Vice President and Head of Healthcare, Merck Ventures

He joined MS Ventures in 2009 and transitioned to Vice President leading the Healthcare investment team for Merck Ventures in 2016. Previously, Jasper was instrumental in the founding of IFHA, Investment Fund for Health in Africa, a private equity fund backed by large Dutch and international institutional investors. He was responsible managing private equity investments in emerging economies in the healthcare and insurance sectors. Prior to IFHA, he was responsible for health economics at the Netherlands Vaccine Institute. Jasper is a member of the Board of Directors of Calypso Biotech, Prexton Therapeutics, EpiTherapeutics (sold to Gilead), Neviah Genomics, MetaboMed, Galecto Biotech, VAXIMM, and an Observer to the Boards of RaNa Therapeutics and ObsEva.
He holds a PhD in Pharmacy from the University of Groningen, the Netherlands and has published more than 30 articles on health economics and vaccines.

Jens Holstein

CFO, Morphosys

He joined MorphoSys in May 2011 from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.
Mr. Holstein holds a Diploma in Business Administration from the University of Münster (Germany).

Jérémie Mariau

CEO, ILTOO Pharma

He is biotech entrepreneur in the service of healthcare industry. He built his multi-skilled profile on a 10-year field experience devoted to the transfer of highly innovative academic R&D projects into valuable industry-driven programs. He is CEO of ILTOO Pharma, a biopharmaceutical company dedicated to the development of breakthrough biotherapies for the treatment of autoimmune and inflammatory diseases. The lead product of the company (ILT-101) displays a unique biological activity allowing to tip immune cells balance towards immunoregulation. ILT-101 is evaluated within two phases 2 studies in patients with Systemic Lupus Erythematosus and recently diagnosed Type 1 diabetes. Formerly, he acted as COO at Alfact Innovation, a biotech company aiming at providing innovative treatments to patients with orphan acute and chronic liver diseases. He began his professional career as consultant in life sciences at Alcimed. Jérémie holds a MSc. in human genetics from Paris Diderot University and is agricultural engineer from Montpellier Supagro.

Jesus Martin-Garcia

CEO, GeNeuro SA

Jesús began his career in 1983 at the World Economic Foundation, and in 1989 at McKinsey & Co where he led studies in the pharmaceutical and food industries.
By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was for example a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and was sold to Migros.
In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. This unique structure was instrumental in the creation of GeNeuro, which Jesús has lead since its creation in 2006.
Jesús holds a bachelor's degree in industrial sciences, a master in law from Geneva University and an MBA from Harvard Business School. He serves on the board of several biotech companies and industrial and business associations.

Jörg Neermann

Partner, LSP

He joined LSP in 2007 as Partner. Jörg's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer's disease.Jörg holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US. Jörg lives in Munich with his wife and two children.

Joe Wiley

CEO, Amryt Pharma

He is CEO, founded Amryt and is a non-executive director of NASDAQ listed Innocoll AG. Mr. Wiley has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Mr Wiley opened and led Sofinnova Ventures' European office. He was previously a medical director at Astellas Pharma. Prior to joining Astellas, he held investment roles at Spirit Capital, Inventages Venture Capital and Aberdeen Asset Managers (UK).

Mr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. He is also a Member of the Royal College of Physicians in Ireland and also has an MBA from INSEAD.

John Gustofson

Sr. Director, Ventures & Early Stage Collaborations, AbbVie Inc.

He is primarily responsible for identifying and transacting both Venture and early stage opportunities across therapy areas including immunology, oncology, virology, renal disease and neuroscience.
Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 19+ years professional experience as a bench scientist and in various roles of market and business development. In addition John has worked in numerous biotechnology companies including Altus Pharmaceuticals and Therion Biologics and spent approximately 4 years in strategy consulting to the life sciences industry. He holds a bachelor's degree in Microbiology from Western Illinois University, a Master Degree in Molecular Biology from the Miami University and an MBA from the Boston University.

Joël Crouzet

CEO, InnaVirVax

He gained considerable expertise in business development and technology transfer at Inserm-Transfert (the subsidiary of the French Medical Research Council) where he was General Manager. In that position he negotiated licensing and collaborative deals with pharmaceutical and start-up companies, detected and/or coached technologies from INSERM with strong innovative potential for either out-licensing or the incorporation of start-ups for translation into successful new ventures.
During his previous 20 years of R&D experience in the Pharma and Biotechnology sector, he was Research Director of Neurotech SA and AP Cells, and Departmental Director at Rhône-Poulenc Rorer Gencell (now part of Sanofi-Aventis).
He has been the co-inventor of more than 25 patent applications or issued patent families, two of which have been used by industry since 1992 for the manufacture of vitamin B12, and two others which corresponded to a candidate gene therapy product that reached an advanced stage of clinical development (NV1FGF by Sanofi-Aventis). Other patents were licensed to a major pharmaceutical company and one patent family concerned a research tool that is now on the market.
Joël Crouzet holds a PhD from Institut National Agronomique of Paris (now AgroParisTech) and is a qualified professor in microbiology.
Joël Crouzet received two awards from Rhône-Poulenc (now part of Sanofi-Aventis) in 1990 &1996. He was also joint winner the Doistau-Blutet award from the French Academy of Sciences in 1992. In 2008, he received one of the awards for innovative start-up companies from the French Ministry for Higher Education and Research. Joël Crouzet has been a co-author of more than 50 publications in peer-reviewed journals.

John Rountree

Managing Partner, Onconova Therapeutics, Inc.

He has over 30 years of experience in management consulting and creating value with pharmaceutical and medical product companies.
He founded Novasecta in 2003 and has built the company by selecting and developing top quality consultants who work successfully with clients across R&D, corporate/business development and commercial disciplines. John has directed many strategic and management initiatives, achieving amongst others, strategic organisational change, major licensing deals, corporate transformation, optimised asset portfolios, and improvements in strategic partnerships.

John Wilkinson

Partner, Cooley LLP

John Wilkinson's practice focuses primarily on the life sciences sector, advising pharmaceutical, biotechnology and medical technology companies on a wide range of IP, regulatory, antitrust and transactional matters. Amongst other things, John's practice has involved a number of highly complex alliances and joint ventures, co-promotional and co-marketing arrangements, distribution and supply agreements, together with the operational, IP, antitrust and regulatory issues relating to such transactions.
Before qualifying as a lawyer, John obtained a degree in chemistry from Imperial College of Science Technology and Medicine and spent five years in the chemical and pharmaceutical industry working in drug development and other areas.
John advises pharmaceutical and biotechnology companies in the US, Canada, UK, Denmark, Hungary, Switzerland, Portugal, Sweden and Norway.

Jürgen Gamer

VP Business Development, Apogenix AG

He joined Apogenix AG as VP, Business Development in January 2006. From 2000 to 2005 he worked for Graffinity AG/ Santhera Pharmaceuticals AG as VP, Business Development and Project Management aquiring deals and leading alliance management. In the years from 1998 to 2000 Jürgen Gamer served at Clontech Lab. Inc., USA as Head of Business Development Europe where he was responsible for the licensing business in Europe. His industrial career started at BASF Pharma from 1995 to 1998 in the life science department. He obtained his Ph.D. in 1995 with „summa cum laude" from the "Zentrum für Molekulare Biologie" Heidelberg (ZMBH) at the University of Heidelberg.

Kai Brüning

Senior Portfolio Manager, apo Asset Management GmbH

Mr. Brüning works in the health care investment industry since 1999. Before joining apoAsset in 2011 he was with ADIG/ Cominvest, Deka Investment and Sal. Oppenheim. Mr. Brüning holds a degree in business administration (Diplom-Kaufmann) from the University of Cologne and is a DFVA/CEFA degree holder. He was awarded by Thomson Extel surveys in the past and is a board member of the DVFA Life Science Commission.

Katya Smirnyagina

Partner, Capricorn Venture Partners

Katya (Ekaterina) joined Capricorn Venture Partners (Belgium) in 2012 as a Partner in the Health Tech Fund. Prior to this, she was for 10 years with Alta Partners (San Francisco, CA) where she focused on European healthcare investment opportunities. She has worked in business development and management consulting before starting in venture capital.
Katya obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. She completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine and has co-authored a number of scientific papers.
Current and past board memberships include: Adocia, Confo Therapeutics, iSTAR Medical, Nexstim, Ablynx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma.
Katya is a member of the EVCA Venture Capital Council Platform.

Kevin Cox

CEO, Imanova Ltd.

Imanova is a world-leading translational biomedical imaging company, providing services to reduce risk in drug development through early knowledge of drug/target interaction in man. The company is a joint venture between the UK's Medical Research Council and three of London's leading Universities. Established to drive innovation in imaging sciences, Imanova has a strong focus on the development of novel imaging biomarkers and benefits from close links with academia.
Kevin's has led a number of high-growth life science businesses, and has established public/private partnerships with both the NHS and academia. He is experienced in biopharmaceutical development, laboratory diagnostics, and technology translation.
Kevin's public sector roles have included: Chair, UKTI's Bio/Pharma Advisory Committee, Chair, BioNow, UK Life Sciences Marketing Strategy Board, Innovate UK advisory board for stratified medicine. He is currently a non-executive director the British Neuroscience Association and the UK's Bio-industry Association.

Kia Motesharei

Head of Global Licensing, EMD Serono

He is responsible for all partnering and licensing transactions within the Immunology Franchise at Merck KGaA. Prior to EMD Serono, Kia was Vice President of Business Development & Alliance Management at Dyax, a biopharmaceutical company specializing in rare disease. Previously, Kia managed the US operation of Genfit -
a French biotech company – in Cambridge and led its global business development as the company's Chief Business Officer. Prior to Genfit and over the past 15 years, he has worked for multiple private and public biotech companies with increasing levels of responsibility in R&D, New Technologies, Technical Marketing, Product Management, Business Development and Alliance Management.
Kia has a successful track record of transactions which include strategic alliances, product and technology licensing, distribution, divestitures, and M&A agreements with major pharmaceutical and biotechnology companies in the US, Europe, Japan, China, LATAM, and Middle East. In addition, he has been involved in a number of financing activities.
Kia received his B.A. in Chemistry from The Colorado College and his Ph.D. in Organic Chemistry from University of California, Los Angles. He completed his postdoctoral training at The Scripps Research Institute as an NIH Fellow.

Kilian Guse

CEO, GeneQuine Biotherapeutics GmbH

He has more than 10 years experience in the field of gene therapy and is author of more than 30 scientific publications in international, peer-reviewed journals and book chapters on this topic. Previously he worked at Baylor College of Medicine, Houston, USA, focusing on development and evaluation of helper-dependent adenoviral vectors for gene therapy approaches for inherited and acquired diseases such as osteoarthritis. In 2011 the German Scholars Organization selected Dr. Guse as one of Germany's top 100 scientists working abroad. Dr. Guse received his PhD with distinction from the University of Helsinki, Finland, where he developed and evaluated gene therapy vectors for the treatment of cancer. Dr. Guse graduated with a degree in pharmacy from the Goethe University in Frankfurt/M., Germany and is a licensed pharmacist.

Klaus Mendla

Head of Global Business Development and Licensing CNS, Boehringer Ingelheim

He received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship in Neuropathology at the University of Heidelberg.
Since joining Boehringer Ingelheim (BI) in 1985, he has held several positions in Research and Development within the corporation. Before joining BI's international Business Development and Licensing organization, Dr. Mendla was director of the company's neurodegenerative diseases research unit.
Dr. Mendla currently acts as Global Head, Business Development & Licensing CNS at Boehringer Ingelheim. He is member of BI's CNS Therapeutic Area Leadership Team and heads up the cross-functional CNS Licensing Advisory Team which is responsible for BI's global partnering and licensing activities in the therapeutic area CNS Diseases.
The strategic partnering focus of Dr. Mendla and his team is on compounds and novel therapeutic approaches for the treatment of neuropsychiatric diseases (including Alzheimer's disease, schizophrenia and depression).

Kurt von Emster

Managing Partner, Abingworth LLP

Kurt joined Abingworth in January 2015 bringing 25 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies CRISPR Therapeutics, Kesios Therapeutics and SutroVax. In addition, he is on the board of CymaBay.
Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.

Laurent Audoly

He is a Senior Vice President and heads Research and Development at Fabre Pharmaceuticals for both novel medicines and consumer healthcare products. Laurent is also Managing Partner and Founder of the Pierre Fabre Fund for Innovation. In addition, he is president of the Medical Devices units within Pierre Fabre. Prior to this role, he was Chief Scientific Officer in biotech focused on next generation therapeutic proteins in oncology, immunooncology, and inflammation where he led the growth of the pipeline from no drug candidates prior to his arrival to a high value pipeline and multiple strategic partnerships with big pharma ultimately leading to a successful exit.
Laurent has held positions of increasing leadership responsibilities in the pharmaceutical industry (Pfizer, Merck, MedImmune) contributing to the identification of new drug projects and the development of five approved drugs in inflammation, dermatology, cardiovascular diseases, and oncology as well as leading large teams across the pharma value chain.
Throughout his career, he has championed high impact collaborations and established a world-wide network of academic and company-based partnerships. Many of these collaborations have resulted in significant value creation. Laurent is focused on strategic and business growth and has also established strong connections with internal and external commercial and manufacturing organizations. He studied medicine and chemistry for his Bachelor's degree and graduated with a Ph.D. in Pharmacology from Vanderbilt University. Laurent was awarded a fellowship from the American Heart Association during his post-doctoral training at Duke University. Laurent has maintained strong ties with the academic world as an Associate Professor (Adj) at Duke NUS Graduate Medical School. He has also served on NIH study sections, given seminars at universities across the world, and published > 70 peer-reviewed papers and patents. He is on the board and an advisor for multiple healthcare organizations across the world aimed at improving healthcare and accelerating the discovery and advancement of novel therapies for patients and their families.

Laurent Choppe

Managing Partner, Cukierman & Co. Life Sciences

Life Sciences since 2008 and has been involved in more than 50 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture-backed and middle market companies for fund raising, licensing deals and M&A transactions as well as strategic projects for key life sciences industry players. Laurent brings an extensive international life sciences experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, medical device, biotechnology, nutraceuticals, animal health and direct-to-consumer markets.
After a veterinary practice and a new venture management experience, he worked 10 years in Schering-Plough (today Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, General Manager in Israel and Vice President, Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE, dedicated to Alzheimer's disease and AA amyloidosis).
Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d'Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD (Fontainebleau, France). He is married, father of 3 and lives in Lausanne (Switzerland).

Lesley Bester

Business Development Director, F. Hoffmann-La Roche Ltd.

She has over 25 years of experience within the global pharmaceutical industry, currently as a Global Business Development Director in Roche Pharma Partnering, Basel. She has spent the last few years dedicated to Roche's re-entry into Antibiotics and early Immunology development.
Lesley is an accomplished Healthcare Industry professional, with extensive experience in Business Development, Sales and Marketing, Drug Development, Project Management and Clinical Research. She comes from South Africa, and is a Pharmacist by training.

Loïc Vincent

Head of Oncology External Innovation, Sanofi

He is an Oncology Scientist with 15+ years of international biotech / pharma industry experience. He is pharmacologist by initial training, and holds a PhD from the University of Rouen, France, and is a former fellow of the Oncology Dpt of Weill Medical College of Cornell University, New-York, NY, USA. He has held various industry positions in scientific, managerial and now external innovation departments.
He joined Sanofi Oncology in 2007 as Head of Pharmacology until 2013 and led the Immunotherapy cluster. He is currently Director in the Evaluation & Expertise team in the Strategy, Science Policy & External Innovation Dpt. He is also the head of Sanofi Oncology External Innovation team.
Prior to joining Sanofi, he was Head of Pharmacology and Oncology program leader at Endotis Pharma.
Loïc is married, has two children and two cats.

Lubor Gaal

Head of Licensing and External Innovation, Almirall S.A.

He is responsible for leading global scouting, diligence and negotiating transactions to secure external innovation for Almirall. Almirall is a European Specialty Pharma company based in Barcelona, Spain with a strong presence in the US and Europe focused on Dermatology with prescription pharmaceuticals and Aesthetics devices.
Lubor has extensive international business development experience having worked for small and large companies in Europe and the U.S. for almost 20 years. Prior to joining Almirall, Lubor held various senior global BD positions for Bristol-Myers Squibb such as Head of Europe, Search and Evaluation and Global Head of Fibrosis, Neuroscience and Immunoscience.
Before that, he was the Head of Business Development for CNS company Neuro3d in France and Chief Business Officer for Immuno-oncology company Vectron Therapeutics AG in Germany. In the U.S., Lubor was the Global Head of CNS and CV Licensing for Schering AG based in New Jersey. He started his professional business development career at Burrill & Co. in San Francisco. Lubor received his Ph.D. from the University of California at Berkeley, and his B.Sc. in Neuroscience from the University of Sussex in Brighton (UK) having studied biology at the Universities of Mainz and Tubingen in Germany.

Luc Otten

Business Development, The Alpine Institute for Drug Discovery

He is responsible for business development activities, licensing, negotiating and managing collaborations with universities and industry partners, financing and competitive intelligence. In addition to AIDD, Luc Otten is involved in operations of Phi Pharma SA (Switzerland).
Luc Otten has seven years of experience in finance. He worked as Investment Principal at Vinci Capital in Lausanne from 2010-2015 for the Life Science part of the portfolio (Addex, Anergis, Evolva, Immatics, Sensimed, Symetis). Prior to that, at Helvea, a leading Swiss brokerage company and spin-off of Pictet & Cie, from 2008-2010, Luc worked as equity research analyst in the biotech and pharma industry and conducted company research (Ablynx, Actelion, Arpida, BioInvent, Galenica, Genmab and MorphoSys). He also produced sector reports on GLP1 drugs for treating diabetes and monoclonal antibodies.
Luc Otten studied Medicine in Geneva with internships in Australia, and holds a doctorate in Medicine and Biology from the University of Geneva in immunogenetics (1999). He was co-awarded a Histiocytosis Research Trust Grant award in 2005 for the very first animal model of histiocytosis. He co-authored 22 peer-reviewed publications. He followed post-graduate course in clinical research in 2008 and also holds a Certificate of Advanced Studies in Management of Biotech, Medtech and Pharma Ventures from EPFL (Lausanne, 2011). He is one of the founding members of the Swiss MD-PhD Association.

Malcolm Weir

Co-Founder and CEO, Heptares Therapeutics

Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemical Biology Advisory Board at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004-2011. Malcolm received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry's Biological and Medicinal Chemistry Sector, in recognition of his contribution to GPCR drug discovery.
Malcolm is Executive VP and Chief R&D Officer of Sosei Group Corporation.

Maria Bobadilla

Roche Partnering Innovation, F. Hoffmann-La Roche Ltd.

She holds an MD and PhD degree and obtained a Master certificate in Project management, by the George Washington University. Maria has more than 20 years' experience in drug development gained at different large pharmaceutical companies. All over these years she hold different positions of increasing responsibility, developing expertise across the entire drug development value chain. Since 2006, Maria works for F. Hoffman La Roche. For the last 4 years she had a position as Senior Director at Roche Partnering Innovation. Maria is leading business development and asset management activities for the External Innovation Program in Europe. The Program is aiming at capturing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies.
Maria has co-authored more than 30 peer reviewed publications with several patents also filed.

Marina Udier

COO, Nouscom AG

COO of Nouscom AG is an immuno oncology biotech with operations in Basel and Rome. Nouscom has one of the most potent genetic vaccines platforms which is being developed for oncology. The platform has been validated in multiple clinical trials (for infectious diseases) with demonstrated strong and durable T cell response in over 4,000 patients. Marina is responsible for all aspects of business operations and business development for Nouscom, whose goal is to develop a personalized neoantigen based cancer vaccine, which could be combined with checkpoint inhibitors.
Prior to joining Nouscom, Marina was an Operating Principal with Versant Ventures, a global biotech venture fund. Based in Versant's European office in Basel, she collaborated with multiple new as well as existing portfolio companies; her responsibilities included pre-IPO activities, full scientific and commercial diligences, as well as new company creation.
Prior to Versant, Marina spent 6 years with Novartis Pharma in Basel in various development and business roles; as the Global Commercial Head, Near Patient Testing Unit, Marina developed the global strategy for a point of care diagnostics platform in respiratory and cardio-metabolic therapy areas. Her experience in molecular diagnostics extends to In Vitro Diagnostics (IVDs) in oncology where she led development of a companion diagnostics for an AML drug candidate (concurrent NDA and PMA submission ongoing). She managed the Global Alzheimer's and Parkinson's portfolio for Novartis Neuroscience where she drove her Brand to a blockbuster status by focusing on operational implementation of global strategies.
Marina spent 5 years with McKinsey & Company in Chicago, working with Fortune 500 companies on strategy and marketing projects, as well as managing a professional development program for 70+ associates.
Marina received her B.S in Chemistry from the University of Zagreb in Croatia (summa cum laude) and her PhD in Organic Chemistry from Yale University.

Mark Schwartz

President & CEO, Galena Biopharma, Inc.

Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry and was appointed President and Chief Executive Officer in 2014. Previously, he was Galena's Executive Vice President and Chief Operating Officer following Galena's 2011 acquisition of Apthera, Inc. where he served as the company's President and CEO. Prior to Apthera, Dr. Schwartz served for five years as President and CEO of Bayhill Therapeutics, a company developing an innovative DNA vaccine platform for the treatment of autoimmune diseases where he completed a successful partnership with Genentech for the development of the company's Type 1 diabetes vaccine. He had also served as President and CEO of Calyx Therapeutics, which expanded significantly, and completed key Phase 1 and Phase 2 international clinical trials of novel anti-inflammatory compounds during his tenure. Earlier in his career, Dr. Schwartz held a range of positions in R&D, marketing, sales, business development and executive management at Trega BioSciences, Incyte Genomics, Synteni, Tripos Inc., Applied Biosystems and DuPont Diagnostics.

Mark Vaeck

CEO, Complix NV

Dr. Mark Vaeck has more than 25 years of experience in the biotech and pharma industry and has raised over €80 million in venture financing for his companies. In 2008 he co-founded the biopharmaceutical company Complix (Belgium) and was appointed as its CEO in May 2010. Before that, from 2006 until 2010 he was the founding CEO of ActoGeniX (Belgium). From 2001 until 2006 he was the CEO of Ablynx (Belgium), which he co-founded in June 2001. Prior to joining Ablynx, Mark was Chief Operating Officer of Ceres Inc (US). From 1993 until 1998 he served as Director Business Development and thereafter as CEO of Keygene (The Netherlands). Between 1983 and 1993 he held several research management and business development positions in the biotech and pharma industry.
Mark has a PhD in Immunology from the University of Brussels (1982).

Markus Hosang

General Partner, BioMedPartners AG

He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and personalized medicine/diagnostics. Before joining BioMedPartners in 2005, Dr. Hosang was a Venture Partner at MPM Capital, where he managed the firm's European office in Munich, was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions of increasing importance in the Pharma R&D organization, including Head of Vascular Diseases Research, Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, member of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Pharma Portfolio Board, and most recently, as the Deputy Head and Chief Scientific Officer of Roche Pharma Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.
Dr. Hosang obtained his Ph.D. in Biochemistry from the ETH in Zurich with summa cum laude and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular diseases. He was on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) from 1994-2002. He currently serves on the boards of Aleva Neurotherapeutics AG, Anergis SA, Biotectra AG, Genkyotex SA, Hookipa Biotech and Imevax GmbH. Earlier he was a member of the boards of SuppreMol GmbH (until its acquisition by Baxter in March 2015), Okairos (until its acquisition by GSK in May 2013), Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.

Martien van Osch

Managing Partner, Forbion Capital Partners

Martien is a founding partner at Forbion Capital Partners and acts as its CFO. For this reason he splits his time between operational activities and the finance function.
In terms of investment focus, Martien spearheads the medical device related activities at Forbion and as such was responsible for the recent exits of Circulite (sold to Heartware in 2013) and PneumRx (sold to BTG in '14) and Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently actively contributes to the boards of Mitralign, Inc and ATI, Inc.
His experience in the life sciences industry also includes prior non-executive board positions at Santaris Pharma AS (sold to Roche in '14), Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Impella Cardiosystems (sold to Abiomed, Inc. in 2005), Acadia Pharmaceuticals (IPO on Nasdaq in 2004) and Flowmedica, Inc. (sold to Angiodynamics in 2009).
After joining ABN AMRO as a Senior Analyst in Group Planning and Control, in 1998 Martien switched to ABN AMRO Capital and decided to join the newly formed life sciences team in 2000 as an investment director. There he developed the Medical Devices investment strategy e.g. by joining the ATI (Accelerating Technologies, Inc.) incubator initiative, focused on start-ups in Interventional Cardiology.

Matthew Foy

Partner, SR One

He joined SR One's London office in 2011. Previously he was a Vice President at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York. Matthew studied Molecular Biology at The University of Oxford; Drug Discovery at UCL; Corporate Finance at The London Business School and holds various FSA & SEC qualifications. His portfolio companies include Asceneuron, Atopix, AtoxBio, Progenitor, PsiOxus, Puridify and VHSquared.

Matthias Bünte

Managing Partner & Advisory Leader Industries Switzerland, Ernst & Young AG

He joined EY recently to build the Operational Transaction Services (OTS) and Lifescience Strategy Team in Switzerland. He brings extensive management consulting and industry experience from 8 years at BCG and 8 years at Booz Allen Hamilton with a focus on life sciences
He also gained line management experience at Amgen developing and implementing their strategy for Central & Eastern Europe and managing Poland and the Baltic States.
Before joining EY he was General Manager Middle East & Africa for Celgene.

Michal Silverberg

Senior Director External Innovations, Takeda Ventures

She has been involved in the life science space since 1998, in various sectors, government, venture capital and global pharmaceutical, biotech companies. Most recently she worked for Novo Nordisk as Senior Director Business Development and New Product Commercialization and a member of the BioPharm leadership team. Prior to Novo Nordisk she worked in Business Development for OSI Pharmaceuticals.
Prior to joining OSI Pharmaceuticals, she held various positions in a biotech company (MGVS), an investment group (Ofer Brothers Hi tech) and the Office of the Chief Scientist of Israel (The Incubator program).
She received her B.A. in Economics and Business Management from Haifa University, her M.B.A from Tel-Aviv University and M.A. in Biotechnology from Columbia University in the US.

Mike Ward

Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence, Informa

He has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Medi-science Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.

Monique Schiersing

Investment Director, F. Hoffmann-La Roche AG Roche Venture Fund

Monique joined Roche Venture Fund (RVF) in 2009, and is managing the RVF investments in Aileron Therapeutics, Macrolide Pharmaceuticals, Minoryx Therapeutics, Opsona Therapeutics, Symphogen, Xenon Pharmaceuticals and other. Monique is also serving as a board director for Macrolide Pharmaceuticals, Minoryx Therapeutics and Opsona Therapeutics and as board observer for Aileron Therapeutics.
Prior to joining RVF, Monique held positions at BankInvest Biomedical Ventures in Copenhagen and Roche Partnering in various roles, incl. Global Alliance Director being responsible for Roche Pharma's early stage biologics collaborations, Bay City Capital and Tularik, Inc.
Monique holds a M.S. in Microbiology from the University of Zurich and an MBA with focus on Finance from the University of San Francisco.

Nathalie ter Wengel

European Head Global Scouting External R&D Innovation, Pfizer

She is the European Lead Global Scouting External R&D and Innovation at Pfizer, where she is responsible for establishing new collaborations and exploring licensing and other corporate development opportunities across all therapeutic areas. She has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in internal medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father's illness, that convinced her of the urgent need for change in the pharmaceutical industry. Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in partnering filgotinib.

Nicholas Benedict

CEO & Co-Founder, Allecra Therapeutics GmbH

Nicholas has 25 years experience in the Biotechnology and pharma industries, starting his career in finance in F. Hoffmann-La Roche before moving to marketing and sales and subsequently General Management. Roles included Worldwide Head of Anti-infectives Business Unit at Novartis; COO of Novartis UK; Chief Commercial Officer at antiinfectives company Basilea Pharmaceutica where he successfully co-led the company's follow-on offering raising over CHF320million; and CEO of privately held Swiss biotech Lumavita AG prior to co-founding Allecra. Nicholas lives in Basel, Switzerland.

Nicolas Demierre

COO, Novigenix

He has 10 years of experience in the industry of medtech and diagnostic with management responsibilities in the fields of new product development, commercialization, and business development. Today Nicolas is Chief Operating Officer at Novigenix SA, a Swiss molecular diagnostic company which commercializes the blood test Colox for early detection of colorectal cancer. Prior to this, Nicolas was Head of Sales and Business Development at Mycartis, and Head of Engineering during 7 years at Biocartis where he was the second employee to join. During this timeframe the company grew to more than 200 employees and went public in early 2015 with the valuation of 460M€. Nicolas holds a PhD in Applied Sciences from the Swiss Institute of Technology in Lausanne and an Executive MBA from HEC Lausanne, the Faculty of Business and Economics of the University of Lausanne. During his academic and industrial career, Nicolas has co-authored 12 peer-reviewed scientific papers and is co-inventor of 10 patents.

Nooman Haque

Director of Life Sciences, Silicon Valley Bank

He leads a team dedicated to supporting early, growth-stage and established businesses in all sectors of life sciences. Nooman is responsible for developing new relationships, identifying lending opportunities and working with the global life sciences team to support companies with all aspects of their business. He is actively involved within the sector, sitting on the BIA's Finance and Tax Committee and is a frequent participant on panel and seminars, and writes frequently on the sector.
Nooman joined Silicon Valley Bank from a venture capital firm in London and previously ran a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes strategic and financial advisory, debt and equity structuring and investment banking
Nooman has a Bsc in psychology and Msc in economics, both from the University of London, and an MBA (finance) from Imperial College. He is a member of the British Psychological Society.

Omar K. Haffar

Founder, President and CEO, Eos Biosciences, Inc.

He is a cell biologist with 30 years experience in the Biotech industry. He began his career at Genentech, Inc. (South San Francisco, CA) and then worked at Bristol-Myers Squibb (Seattle, WA). He was co-founder and Vice President of Anti-infectives at Cytokine Networks (Seattle, WA), and subsequently Founder and President of International Therapeutics, Inc. (Seattle, WA). Dr. Haffar served as Managing Director at Global Solutions for Infectious Diseases (South San Francisco, CA). Dr. Haffar was the principal Founder, President and CEO of Presidio Pharmaceuticals, Inc. (San Francisco, CA). Dr. Haffar is currently Founder, President and CEO of Eos Biosciences, Inc., a nanomedicines company in Los Angeles, CA. Dr. Haffar serves on the Boards of Directors of Eos Biosciences, Presidio Pharmaceuticals and Naia Pharmaceuticals
Dr. Haffar received his Bachelor's of Science degree in Biology from the American University of Beirut (Beirut, Lebanon), and his Masters of Science degree in Biology from the University of Oregon (Eugene, OR). Dr. Haffar completed his Ph.D. at the University of California, Berkeley, in the department of Physiology-Anatomy.

Otello Stampacchia

Managing Director, Omega Funds

Previously, Otello was in charge of life sciences direct investments at Alpinvest Partners, one of the largest private equity asset managers worldwide. At AlpInvest, Otello was responsible for the direct life sciences investments, as well as assisting in due diligence for healthcare venture fund of funds investments. Before Alpinvest, Otello was the portfolio manager of the Lombard Odier Immunology Fund, a USD $3bn listed investment vehicle, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and NY offices). Before joining Goldman, Otello helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva (Switzerland), and a PhD in Biotechnology.

Paola Casarosa

Corporate Vice President, Business Development & Licensing, Boehringer Ingelheim Gm

She joined BI in 2007. Currently she is the Corporate Vice President for Business Development & Licensing. In her career at BI she occupied different positions within the R&D part of the organization, as well as PM Strategy and Portfolio Management.
Before joining BI, Paola was employed at Organon NV/Shering Plough in R&D. Paola received a Ph. D. in molecular pharmacology at Vrije Universiteit in Amsterdam and had a Post-Doc experience at Bichat Hospital in Paris.

Paul Hermant

Head of Corporate Life Sciences, Bird & Bird

He also heads the firm's corporate life sciences practice. Paul assists clients in their corporate and financial transactions and provides the full range of advice in these fields. He has particular expertise in mergers and acquisitions, private equity, joint ventures, securities offerings, take-over bids, as well as project and acquisition finance. Paul also represents clients in corporate and financial litigation, including shareholders disputes, directors' liability and cases relating to financial products and services.
Paul is one of our leading corporate and finance partners. He joined us in 2000 with his team, coming from another leading international law firm.
Paul speaks English, French, Dutch and German and, besides his legal education, also holds a masters' degree in business administration from the Solvay Business School (University of Brussels).
Paul has written and spoken widely on corporate and financial law topics and teaches at the University of Brussels and at the Cooremans Institute. He also serves on the Board of the Solvay Alumni.

Peter Dudek

Principal, Wellington Partners

He joined Wellington Partners in 2016. Prior to this he was at Entrepreneurs Fund, a London-based pan-European venture fund with more than $200m of assets under management. Peter served as a Board Observer on Vasopharm and Optinose, and supported multiple transactions across the life sciences portfolio including investments in Vasopharm, Optinose, Cytoo, Sequana Medical and Prosonix.
Before EF, Peter consulted for a number of European venture-backed biotechnology startups and was an interned Analyst at Novartis Venture Funds. In his prior life as a scientist, he worked as a Research Fellow at the University of Oxford (Queen's), obtained his PhD from the University of Geneva and a BSc (Hons) from the University of British Columbia. He also conducted research at the BC Centre for Disease Control.

Raghuram Selvaraju

Chairman of the Board Directors, Relief Therapeutics Holding AG

He also known as Ram, Ph.D., M.B.A., currently serves as a Managing Director and Senior Healthcare Equity Research Analyst at Rodman & Renshaw, a unit of H.C. Wainwright & Co. He rejoined Rodman & Renshaw. Earlier, he started his sell-side research analyst career with Rodman & Renshaw in 2005. Prior to rejoining the firm, he served as a Managing Director and Senior Healthcare Analyst at MLV & Co., LLC, Research Division. Dr. Selvaraju was employed at MLV & Co. till August 2015. He covered the biotechnology, specialty pharmaceuticals and diagnostics space within the healthcare sector at the firm. Prior to this, Dr. Selvaraju served as Managing Director and Head of Healthcare Equity Research at Aegis Capital Corporation, Research Division since March 2012. Before that, he served as a Senior Vice President in Equity Research and Senior Biotechnology Analyst at Morgan Joseph TriArtisan LLC, Research Division since May 2011. From 2010 to March 2011, Dr. Selvaraju served as a Senior Equity Research Analyst covering the biotechnology and pharmaceuticals sectors at Noble Financial Group, Inc., Research Division. From 2009 to 2010, he served as the Senior Vice President and Head of Healthcare Equity Research at Hapoalim Securities USA, Inc., Research Division, covering biotechnology, specialty pharmaceuticals, molecular analytics, and diagnostics. Prior to research, he started his career at the Serono Pharmaceutical Research Institute in 2000. Dr. Selvaraju served as a Technician and Pharmaceutical Researcher at Serono Pharmaceutical until 2004. He designed models and user interfaces for analysis of gene expression data from quantitative real-time RT-PCR; led multi-disciplinary teams developing animal models to identify novel therapeutic products; and discovered the first novel protein candidate.

In total, Dr. Selvaraju has over 15 years of total experience in the biotechnology and pharmaceutical sectors. He has been Chairman of the Board of Directors at Relief Therapeutics Holding AG, a publicly-listed Swiss biotechnology company, since June 2, 2016. Dr. Selvaraju is widely quoted in national publications such as Barron's and The Wall Street Journal, as well as healthcare industry publications such as The Pink Sheet, BioWorld Today, and BioCentury, and has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV to comment on drug development trends, healthcare reform policy, and pharma and biotech M&A. He has published articles in leading peer-reviewed journals, presented research at various international scientific conferences, and is a co-inventor on several drug patents. Dr. Selvaraju has published sector reports on Alzheimer's disease, multiple sclerosis, stroke, orphan neurological disorders, and the most comprehensive Wall Street research published on United States healthcare reform policy. He has been ranked on StarMine for earnings accuracy since 2010 and also by The Wall Street Journal's Best on The Street survey on the basis of portfolio return performance in 2006. While at Serono Pharmaceutical Research Institute, Dr. Selvaraju became the youngest-ever recipient of the Serono Inventorship Award for exceptional innovation and creativity in 2003. Dr. Selvaraju graduated in 1999 with a Bachelor of Science in Biological Sciences and Technical Writing from Carnegie Mellon University, a Ph.D. in Cellular Immunology and Molecular Neuroscience in 2004 and a Master's of Science in Molecular Biology from the University of Geneva in Switzerland in 2001, both of which were on the basis of his drug development research, and an M.B.A. from Cornell University's accelerated one-year program for scientists and engineers in 2005.

Rainer Metzger

VP Global Business Development Pharma, QIAGEN GmbH

Since 2013 he works for QIAGEN where he is leading the QIAGEN Pharma Partnership and Precision Diagnostics program. Dr. Metzger joined QIAGEN from a Danaher company, Leica Biosystems, where he has worked for 2 years as Vice President, Head Pharma Partnerships, with responsibilities Pharma collaborations in the field of advanced staining and histogenetics. Prior to joining Danaher Dr. Metzger has worked for Roche Diagnostics as Vice President, Head BD Oncology and for Roche Pharma / Genentech as Vice President, Head of Clinical Biomarkers for more than 10 years. Dr. Metzger has founded several biotech companies and has worked in the Biotech field for more than ten years.

Ramesh Kumar

President and CEO, Onconova Therapeutics, Inc.

Dr. Kumar co-founded Onconova in 1998. He received his Ph.D. in Molecular Biology from the University of Illinois, Chicago, and trained at the National Cancer Institute. He has held positions in R&D or management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he was President of the Genomics and Transgenics Division. Dr. Kumar has more than 50 publications spanning molecular oncology, transgenic animals, gene therapy and recombination. He is an inventor in eight U.S. patents and many patent applications. He co-edited the 1993 book "Molecular Basis of Human Cancer."

Randy Milby

CEO, CorMedix, Inc.

He was appointed Chief Executive Officer in January, 2013. He joined CorMedix in May 2012 as Chief Operating Officer. Previously, Mr. Milby was co-founder and a managing director of WaterStone Bridge, LLC, a healthcare consulting services firm. During his 11 year tenure at DuPont Company, he held several management positions, the most recent as Global Business Director, Applied Biosciences. From 1998 through 1999, Mr. Milby was also a Healthcare Analyst at Goldman Sachs & Company. Mr. Milby received his Pharmacy degree at the University of Kansas and his MBA from Washington University, St. Louis.

Rao Movva

Novartis Distinguished Scientist (retired) & Currently Independent Pharma and Biotech Advisor

He was born in India and pursued his studies leading to M.Sc degree from Nagpur university in India. He completed my Graduate studies with a Ph.D degree in Molecular Biology at SUNY at StonyBrook, New York in 1980. Subsequently,he joined Biogen S.A , then , a novel start-up biotech company in Geneva, Switzerland as a research scientist in 1980 and worked there until 1987 in various capacities as Project leader, Program executive and Senior research scientist focusing on cloning of novel genes and the expression of recombinant protein He moved to Sandoz AG in Basel, Switzerland in 1987 and have been with the organization since in several research environments and in various capacities. As a group leader in the Biotechnology (1987-92), he had developed methods for successful production of various recombinant proteins, including lymphokines IL-3, IL-6 and LIF from E.coli. From 1992-1996, as the head of Signal transduction Biology group, he contributed to elucidate the of Mechanism of action of action of immunesuppressive drugs, including , notably the identification of TOR protein as the target of Rapamycin, the active component of Novartis transplant (Certican) and cancer(Affinitor) drug. As the Head of Molecular biology and Gene therapy unit in the (1996-2004), he led very early efforts to evaluate the gene therapy technologies and developed screening strategies for small molecules to identify tool and lead compounds for drug development. In the past 10 years, he focused his efforts in chemical biology to connect the chemicals with their biological targes toaccelerate drug discovery. In addition he is involved in setting up multiple collaborations between Novartis and the various leading academic instituitions of the world by acting as a scout to identify and initiate new drug discovery projects including the Human microbiome efforts in Novartis Institute for Biomedical research (NIBR). Overall, Rao has more than 30 years of biotech and large pharma research and drug discovery experience and has authored several peer reviewed publications.

Reza Halse

Head, European Innovation Hub, MSD

He serves as head of the European Innovation Hub in London, leading business development and licensing activities, with a focus on early-stage therapeutics for MSD, i.e. pre-clinical to proof-of-concept, and novel technology platforms.
He is also a partner in the MRL Venture Fund. The European Innovation Hub offers a range of partnering constructs to match the interests of European innovators: collaborations, licensing and independent venture investments.
Previously, Rez was a partner with the corporate venture capital arm of Partners HealthCare, a large academic medical center and Harvard Medical School affiliate, based in Boston, US. In this role, he led investments and had Board responsibility for a number of therapeutics and technology platform companies, spanning infectious disease, oncology, neurology, inflammation and genome editing. Prior to this, he was a founding member of a US-based product development company, BioMed Valley Discoveries, that in-licensed and advanced a number of oncology assets into clinical trials. He also had management roles of increasing responsibility at Novartis, based in the US, initially in the diabetes and metabolism group, and then in an internal incubator with a mandate to develop programs outside the core disease areas. Earlier in his career, he led research at Xcellsyz Ltd, a venture-backed start up in the UK. Rez holds a B.Sc. and Ph.D. from Newcastle University, UK.

Ronald Kempers

President and CEO, Mymetics SA

Mymetics in July 2009 as Chief Operating Officer and was appointed President and CEO of Mymetics Corporation in November 2012 while assuming as well the function of Chief Financial Officer. Mr. Kempers is a senior business leader and entrepreneur, with over 20 years of international business management, business development and finance experience with leading global corporations (Hewlett Packard, Oracle) and medical and IT start-ups. Mr. Kempers has a M.Sc. in Business Administration from the Erasmus University, Rotterdam School of Management and has continued further education with various executive courses, among which at IMD, Lausanne.

Ryan Richardson

Vice President, Healthcare Investment Banking, JP Morgan Healthcare

Ryan Richardson is a Vice President in the healthcare investment banking team of J.P. Morgan in London, where he works with biopharma, diagnostics and healthcare services companies on a range of transactions including IPOs, follow-on equity raises, mergers and acquisitions, divestitures and debt issuances. Prior to J.P. Morgan, he worked as an Engagement Manager with Campbell Alliance Group in New York and also as a Consultant with Roland Berger Strategy Consultants in Germany, providing a range of strategic and operational management consulting services to pharma and biotech companies in the U.S. and Europe. Mr. Richardson is a recipient of the Robert Bosch Foundation Fellowship, and worked as a visiting health economist with the IQWig in Germany. He holds an International MBA from The University of Chicago Booth School of Business, an MSc in Health Policy from the London School of Economics, and a BS in Genetics from the University of Kansas.

Selected transactions:
Molecular Partners, Accelerated Book Build, Joint Bookrunner mm (2016)
Molecular Partners AG, IPO, Global Co-ordinator and Joint Bookrunner CHF 106mm (2014)
Sale of Waterland's minority stake in Arseus €293mm (2014)
MorphoSys, Accelerated Book Build, Joint Bookrunner €84mm (2013)
Smith & Nephew's acquisition of ArthroCare $1.7bn (2014)
UNILABS, Bond - Refinancing, Bookrunner €685mm (2013)

Ronald Notvest

Executive Vice President, Commercial Planning and Development, Tonix Pharmaceuticals Holding Corp.

Hehas focused his career on advancing drug development pipelines, having played key roles in the discovery, development, and commercialization of new therapeutics. Dr. Notvest joined Tonix Pharmaceuticals as Senior Vice-President, Commercial Planning and Development in June, 2014.
He began his career with Ayerst Research heading up a drug discovery program for novel glutamate antagonists, while also being involved in the pharmacological characterization of potential drugs for Alzheimer's and diabetic neuropathy. Subsequently, Dr. Notvest had the responsibility of providing early commercial input and guidance for a portfolio of over twenty early to late-stage development assets at Wyeth Pharmaceuticals. He served as commercial team leader for several products that advanced into late-stage development, and as one of his leads progressed, he transitioned into brand management and successfully launched and marketed a new immunosuppressant to prevent organ rejection after transplantation. In 2002, Dr. Notvest founded Evidec, a consultancy that focused on commercial and financial assessments, as well as creating marketing and commercialization plans for drug candidates being developed by small and mid-size pharmaceutical companies. While at Evidec, he consulted for Tonix, before joining full-time in 2014.

Sarah Holland

rope, External Science and Partnering, Sanofi SA

She responsible for cultivating relationships and bringing forward innovative external opportunities from key stakeholders located across Europe.
Sarah joined Sanofi from Roche where she was the Life Cycle Leader for alectinib, an ALK inhibitor licensed from Chugai. The Life Cycle Team she led was responsible for all aspects of the program, including manufacturing, development and marketing.
Previously, Sarah was Global Head of Strategic Partnering at Roche and a member of the Partnering Leadership Team. Her team's projects included pharma M&A transactions, including rapid company integrations, spin-outs and major strategic partnerships. Sarah championed Roche's entry into rare diseases and re-entry into anti-bacterials. Prior to that, Sarah was the Global Head of CNS Partnering, responsible for all Partnering activities across neurology and psychiatry. Her first role at Roche was as Oncology Finder, when Sarah led the deal with Plexxikon that resulted in the launch of 'Zelboraf'. Prior to Roche, Sarah was Global Brand Director at AstraZeneca during US and EU launch. This followed roles in strategic planning, pricing and health economics. Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies.
Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D. Phil. and first degree at the University of Oxford.

Sascha Alilovic

Vice President, Head of Corporate Finance and Corporate Development, MorphoSys AG

Sascha Alilovic joined MorphoSys in 2007 and is in charge of all M&A and capital market transactions, corporate development, asset management, financings and financial modeling. On top, he leads MorphoSys' Innovation Capital, its corporate venture capital arm. In his position, Sascha has executed a number of acquisitions, divestitures, investments and capital increases. Sascha has built an extensive network in investment banking and venture capital in Europe and the US. Prior to MorphoSys Sascha has worked on major transactions in his roles at large multinational corporates and corporate finance boutiques, either acting as project leader or manager of a team of deal makers.

Sascha Alilovic holds degrees in economics and computer science.

Simon Blake

Sr. Director Scientific Licensing Immunology, Johnson & Johnson

My PhD in Biochemistry was obtained whilst at the Kennedy Institute of Rheumatology, London, UK. I then served multiple Post-Doctoral Research appointments, where I continued to study the pathogenesis of inflammatory joint disease, focusing on the role of the cytokines IL-1 and TNF. I moved into industry in 1994 spending 5yrs each at Celltech Therapeutics and GlaxoSmithkline respectively, leading small and large molecule discovery research teams. In 2004 I joined Centocor and was appointed Director of Cardiovascular and Metabolic Diseases team in 2005. I am currently Senior Director for Scientific Licensing in Janssen Business Development, supporting the Immunology and Janssen Biotherapeutics teams within Janssen Pharmaceuticals R&D.

Sofia Ioannidou

Investment Director, Life Sciences, Edmond de Rotschild Investment Partners

She joined EdRIP in 2009 and is an Investment Director in the Life Sciences team. Previously, Sofia was an Associate Consultant at the Life Sciences team of L.E.K. Consulting in London, and before that, she was a Research Scientist in the Drug Development department of Eyetech Pharmaceuticals, Inc, in Boston. At EdRIP, she is actively involved in new investment activities, as well as in the support of a number of portfolio companies. Sofia completed undergraduate studies at the University of Oxford in Molecular and Cellular Biochemistry (2000) and obtained a PhD in Cell Biology from the University of London (2004).

Stefan Luzi

Associate, Gilde Healthcare Partners

He joined Gilde Healthcare in 2015. He is focusing on therapeutic investment opportunities in Europe. Prior to joining Gilde, Stefan worked at Merck KGaA for two years. As part of the Global Graduate Program he completed several international assignments, most notably with the Global Business Intelligence and MS Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono's innovation competitions. Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK) where he developed a bicyclic peptide based drug discovery platform. He is a Swiss citizen based in Gilde's Utrecht office.

Stephane Degove

CEO, GamaMabs Pharma SA

Stéphane is a biotech entrepreneur with 20 years' experience in Biotech/Pharma and Strategy. Graduated from ESCP Europe (majoring in Finance), he started his career at Sanofi in Finance. Prior to founding GamaMabs in 2013, Stéphane was co-founder and CFO of the biotechnology company in cancer and thrombosis, Endotis Pharma.

Stephanie Léouzon

Partner, Torreya Partners (Europe), LLC

Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012
Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.
She has advised life sciences clients on more than 25 strategic transactions, valued at over
$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.
Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

Steve Dickman

CEO, CBT Advisors

He has worked in the biotechnology and venture capital industries for more than fifteen years. He founded CBT Advisors in 2003 after completing a successful four-year stint as a venture capitalist with TVM Capital in Boston and Munich, where he invested in therapeutics, personalized medicine and life science research tools. His investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio (then Genetix Pharmaceuticals), which went public on Nasdaq (BLUE) in 2013 and had a $3 billion valuation in December, 2015. Steve publishes from time to time on Forbes and Boston Biotech Watch.
CBT Advisors works in all areas of life sciences including drug discovery and clinical development, molecular diagnostics, genomics, research tools and bioinformatics and software. A growing area of focus is healthcare information technology (healthcare IT). CBT Advisors pursues projects of four basic types:
- Drafting of prospectus text
- Business development
- Investor and partner pitches
- Market analysis

Stewart Kay

Director, Business Development, GSK

He started his career at Amersham International (now part of GE) and held various sales, marketing and business development positions in the Life Science and Technology Platforms division. He joined Evotec in 2002 as SVP Business Development for Europe and was part of the operational management team. In 2005 he joined Pharmagene as VP Commercial Development and as a member of the Executive Management team took the company into a merger with Asterand. Stewart joined GSK in 2008 and is currently Director Transactions in Worldwide Business Development, Pharma R&D. Stewart hold s Bsc in Biochemistry and a MBA from Warwick Business School.

Tamar Raz

CEO, Hadasit Ltd.

With more than 12 years' experience in Technology Transfer, Dr. Tamar Raz is serving as director in private and public companies in the medical field. Prior to joining Hadasit, Tamar served as VP Marketing and Strategy at Ramot, the Technology Transfer Company of Tel Aviv University, and was responsible for the company strategic alliances, marketing activities and commercialization.

Dr. Tamar Raz managed the establishment and served as the CEO of Allergene Ltd., an Israeli start-up company that was founded as an incubator company, and raised more than $ 1M from private investors.

Dr. Raz PhD and MSc were earned in Cell Biology from Tel Aviv University School of Medicine. Expertise include; commercialization of medical technologies from the academic/ laboratory bench to the industry in order to turn ideas into viable products and services; establishment and management of corporate and academic relationships, pre-clinical development operations; raising funds including investment of venture capital, corporate collaborations, contractual research relationships and government grants.

Thomas Hanke

EVP, Head of Immunology & Inflammation, Evotec International GmbH

Since November 2013, Thomas is responsible for a growing portfolio of preclinical R&D projects in the areas of inflammation and immuno-oncology for Evotec. Thomas' particular focus is on building high-value, performance based drug discovery alliances with academia and pharma.
From 2007 to 2013, Thomas was Sourcing Director at the Biopharm. Research Unit of Novo Nordisk, where he identified and evaluated partnering opportunities related to compounds, targets and technologies within haemophilia, autoimmune/inflammatory diseases, growth disorders and protein technologies and where he initiated multiple agreements with academic institutions and biotech companies both in Europe and the US.
Prior to joining Novo Nordisk, Thomas was co-founder and Chief Scientific Officer at TeGenero, a German biotech company where he headed the R&D efforts to develop first-in-class immunomodulatory monoclonal antibodies (2002-2007). Preceding his entrepreneurial activities, Thomas was group leader and Assistant Professor for Immunobiology at the University of Würzburg (1999-2002) following a PostDoc at the University of California in Berkeley where he researched basic cellular immunology (1996-1999). Thomas received his Ph.D. in Biology from the University of Würzburg in 1995. He is (co-) author of approx. 30 scientific papers in peer-reviewed journals.
Today, Thomas has 20+ years of experience in research and drug development in academia, biotech and pharma. Fostering innovation and continuous improvement, Thomas manages cross-functional teams as an assessor / developer, sets directions and builds trust in a company.

Thomas Stockman

Director, Healthcare Investment Banking, Royal Bank of Canada

He has over 14 years of investment banking experience, focusing on Life Sciences. Thomas recently joined from Citi, where he had been part of their EMEA Healthcare team since 2002. Tom holds an MA in Biological Sciences from Oxford University. Capital markets and financing transactions include: Mereo's IPO on the UK AIM, Santhera's follow-on on SIX, Biotie's directed issue of convertible notes and warrants and US listing on Nasdaq, Shire's financing facilities for the acquisition of Baxalta and Dyax, Abivax's IPO on Euronext Paris, GSK on the increase in ownership of its Nigerian listed subsidiary GSK Consumer Nigeria, DBV Technologies on its US IPO, Huvepharma's syndicated loan financing, Prosensa on its US IPO, GSK's selldown in Aspen Pharmacare, Merck on its rights issue in relation to the Serono acquisition, Shire's issue of convertible bonds, Hikma's Accelerated Equity Offering, Gambro's syndicated loan acquisition financing, Bayer on its equity offering in relation to the Schering acquisition, Hikma on its UK IPO.
Select M&A experience: Shire's defence following an unsolicited approach by AbbVie, GSK on its three-part deal with Novartis (sale of oncology, acquisition of vaccines, consumer JV), Hikma on the acquisition of Bedford Laboratories from Boehringer Ingelheim, Permira's acquisition of Norwegian animal health player Pharmaq, Nabriva on its structured sale agreement with Forest Labs, Roche on its hostile offer for Illumina, Hikma on the acquisition of Promopharm, Roche on its acquisition of Anadys, Huvepharma on the sale of a stake to CVCI, Solvay on the sale of its pharmaceutical business to Abbott, Numico on is sale to Danone, BUPA on the sale of its hospital business to Cinven, Savient Pharmaceuticals on the sale of Rosemont to Close Brothers Private Equity.

Tibor Papp

Senior Director, Business Development, Haematology / Oncology / Transplantation, Shire Pharmaceuticals

In Shire's Global Business Development Dr Papp has been responsible for transactions relating to the therapy areas of Haematology and Genetic Diseases across all geographies. Previously, he worked in pharmaceutical product strategy, licensing and M&A transaction advisory for 12 years. He is also a medical doctor, a PhD and an MBA.

Tim Luker

Senior Director, External Innovation, Corp BD, Eli Lilly and Company

He leads Lilly's external innovation process in Europe within Global Corporate Business Development. In this role Tim interacts with external VC funds targeting transformational early stage research across multiple therapy areas that work with Lilly and also supports global due diligence and search and evaluation initiatives.
Tim is an experienced drug hunter with 17 years' experience and is an inventor / author on >60 patent applications and publications. Prior to Lilly he has worked in spin out biotech as well as roles at Shire pharmaceuticals (Director Exploratory projects, 2011-2014) and AstraZeneca (several R&D and medicinal chemistry roles, 1999-2011), leading multiple drug discovery projects through to candidate molecules as well as providing input into early development projects and managing scientific teams.
Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager. https://uk.linkedin.com/in/timluker

Timothy Herpin

Vice President, Head of Transactions (UK), Business Development, AstraZeneca

He heads a group of business development professionals involved in all aspects of transactions negotiation and execution at AstraZeneca. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS& Pain and more recently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Timothy Morris

CFO, Head of Business Development, AcelRx Pharmaceuticals, Inc.

Mr. Morris has over 30 years of professional finance and accounting experience, 19 as Chief Financial Officer. He has raised over $980 million in equity and convertible securities for six companies. He has extensive deal experience with over 65 transactions and combined value in excess of $2.0 billion. He has served as the Chief Financial Officer of AcelRx Pharmaceuticals since 2014 and assumed the responsibilities as Head of Business development in 2015. AcelRx is a publically traded specialty pharmaceutical company with two late stage products for acute pain. One of the products, Zalviso has launched in the EU and is being sold by Grunenthal. Mr. Morris completed a $65 million royalty monetization for the European royalty stream from Zalviso. Previously, Mr. Morris served as a Chief Financial Officer, Senior Vice President Finance and Global Corporate Development of VIVUS, Inc. from November 2004 to December 2013. At VIVUS Mr. Morris oversaw finance, corporate development, IT, human resources, legal, and investor relations functions. During his tenure at VIVUS he was part of the executive team that oversaw the approval of two NDA and one MAA. Prior to VIVUS, Mr. Morris was CFO, Senior Vice President Finance, Manufacturing and Administration from September 2001 to November 2004, and was a member of the Office of the President from August 2004 to November 2004 for Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development, acquisition, and marketing of pharmaceutical products. Mr. Morris serves as a non-executive director of PAION Inc, the US subsidiary of PAION AG, a publically traded company based in Germany. Mr. Morris graduated cum laude with a BS in Business with emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant.

He has had experience in the following therapeutic areas:

pain, acute care products, infectious disease, metabolic disorders, male and female sexual function

Tobias Wilson Waterworth

CEO, Atlantic Healthcare plc

He is a strategist, commercially focussed senior executive and healthcare entrepreneur with a track record of developing high growth companies and investor returns. Being involved in the healthcare industry across Europe and the USA since 1992, Toby has a deep knowledge of hospital, healthcare and pharmaceutical environments and a track record in originating deals, corporate management, in/out licensing, fundraising, R&D, IP, M&A, product development, manufacturing, commercialisation and regulatory matters. He has raised over £100m/$170m in both public markets and in private equity transactions and been involved in building companies with a combined value of c£450m/$760m.

Toby has a BSc in Business Economics from Hull University, UK and with BDO (Stoy Hayward) qualified as an English Chartered Accountant in 1990. In 1992 he was involved in merger and acquisition activity and restoring profits in the UK companies of pharmaceutical packaging equipment group Robannic NV. In 1994 he joined Chiroscience Group plc, a biotech and manufacturing process R&D company on its £150m/$250m London Stock Exchange IPO, being involved in running finances, public reporting and fundraising, commercial development, licensing, a £6m/$10 manufacturing acquisition and integration prior to the £100m/$170m sale of the manufacturing division to Ascot Group and later £300m/$535m acquisition of the drug division by London listed Celltech plc (now part of UCB). In 1996 he joined Europe's first virtual biotech company, Alizyme plc, on its £10m/$17m AIM IPO and, with a team of eleven, was involved in licensing, progressing the clinical development of four GI programmes, public reporting and IR, raising £35m/$60m and taking the value to £200m/$340m prior to its Admission to the Official List on the London Stock Exchange. In 2001 he left to become involved in the start-up, acquisition, corporate development and funding of a number of private healthcare businesses including Expedeon, HD Clinical, and Lipoxen plc (subsequently completing a £14m/$24m AIM IPO). For the 5 year period to 2010, he was also a global adviser in healthcare and medical innovation to the British Government seeking overseas assets (IP, talent and investors) to start UK companies with global potential and remains a member of its UKTI Catalyst Business Ambassador programme. Toby founded and established Atlantic Healthcare plc in 2006 and the company is now progressing its lead asset, Alicaforsen in a pivotal phase 3 trial for the treatment of pouchitis.

Tony Rosenberg

Managing Director, MPM Capital LP

He joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.

Ulf Grawunder

CEO & Founder, NBE-Therapeutics Ltd.

NBE-Therapeutics is a new Swiss Biotech company that was created in April 2012, and which focuses on the development of "next-generation" antibody-drug conjugates for cancer therapy.
Prior to that, Ulf Grawunder had co-founded 4-Antibody Ltd in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and since 2006 as CSO. Ulf Grawunder obtained his PhD from University of Basel for work performed at the Basel Institute for Immunology. After his PhD he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles in the U.S. After this he returned to Europe and held positions as principal investigator at the Basel Institute for Immunology, the University of Ulm, Germany, and the University of Basel, Switzerland, before starting his first biotech company.
Ulf Grawunder is member of a number of national and international boards of for profit and non-profit organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).

Vladimir Cmiljanovic

CEO, PIQUR Therapeutics AG

He has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical & biochemistry) essential to the discovery of PI3K-Akt-mTOR pathway products. Vladimir built up the team of well-known and recognized experts from the field and is leader of the team creating PIQUR's industry leading next generation PI3K agents. For his scientific contribution in PI3K-AKT-mTOR research field he was awarded in 2009 with the Camille and Henry Dreyfus Award of the University of Basel and in 2011 with the Novartis and University of Basel Excellence Scholarship for Life Sciences. In 2014, Vladimir was the winner of the Northwest Switzerland Young Entrepreneurs' Award (Jungunternehmerpreis Nordwestschweiz) and in 2015, PIQUR won the prestigious Swiss Economic Award.

William Pao

Global Head of the Oncology Discovery and Translational Area (DTA), Roche Pharmaceutical Research & Early Development (pRED), F. Hoffmann-La Roche Ltd.

He obtained his MD and PhD degrees at Yale University, did his housestaff training in Internal Medicine at New York Presbyterian Hospital-Weill Cornell Campus, and completed his medical oncology and postdoctoral fellowship training at Memorial Sloan-Kettering Cancer Center (MSKCC). He joined the faculty at MSKCC and was eventually recruited to Vanderbilt, where he became Professor of Medicine, Director of the Division of Hematology/Oncology, and Director of Personalized Cancer Medicine at Vanderbilt-Ingram Cancer Center.

Yigal Yanai

CEO, PlasmaMedic Ltd.

Yigal Yanai is a graduate of Electronic Engineering from the Technicon, Israel institute of technology, and then proceeded to obtain 2 advanced degrees in power electronics and solid state physics, from the University of California in Los Angeles (UCLA). For over 40 years Yigal has founded and managed In Israel, several startup companies, all in the field of power electronics which matured to be market leaders in their respective field.
For the past 18 years he was heavily involved in developing, manufacturing and marketing worldwide, state of the art Plasma drivers for a wide range of applications.
In 2014 Yigal founded his 6th company PlasmaMedic Ltd, a company dedicated to combat Hospital Acquired Infections through revolutionary technologies based on Cold, Atmospheric Pressure Plasma (CAPP). Yigal holds over 12 patents. He is currently the president and CEO of PlasmaMedic.

Zhizhong Yao

Analyst, Sofinnova Partners

He joined Sofinnova Partners in 2015 and focuses on investments in the biopharma/biotech sector. Zhizhong holds a Ph.D. in Chemistry and Chemical Biology from Harvard University, where he developed quantitative single-cell methods to determine the mechanism of action of antibiotics as well as drug-drug/gene-drug/gene-gene interactions. He also holds a B.S. in Chemistry and Molecular Engineering from Peking University

ADDRESS
Einsiedlerstrasse 32, 8820
Wädenswil
Switzerland

TELEPHONE
+41 813227086

WEBSITE
www.3brain.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2011

3BRAIN GMBH

3Brain has developed world's first high-resolution biosensor for studying the brain and related illnesses. 3Brain's patented technology enables brain-on-chip, where brain cells can be cultured out of the human body to test the effect of medication.

After a period of incubation that helped to improve the technology, 3Brain's newest product series is sold to research institutes since 2015, while in September 2016 the first industrial customer (a medium-size player in the pharmaceutical market) has been acquired.

Brain diseases represent a high-potential market giving the burden they place on public health systems and on our society. Moreover, brain technologies offer growth opportunities in frontier areas as personalised medicine and rehabilitation.

MANAGEMENT TEAM

We are a multidisciplinary team covering knowledge on technologies (K. Imfeld for hardware, M. Gandolfo for software and data analysis) and on applications (E. Castagnetti as expert in drug development and A. Maccione for biosensors). Moreover, M. Gandolfo has been already involved in a former start-up and in other business initiatives.

4D pharma plc

4D PHARMA PLC.

4D pharma plc is a clinical-stage pharmaceutical company and a world-leader in the development of live biotherapeutics – a new class of medicines derived from the human microbiome. Leveraging its MicroRx discovery platform, the company has 15 programs in development, spanning diverse therapeutic areas including GI, autoimmune, oncology, respiratory and CNS. 4D's lead program – Blautix – is a live biotherapeutic for the treatment of irritable bowel syndrome (IBS), which recently completed a successful Phase I study in IBS patients.

ADDRESS
9 Bond Court
Leeds LS1 2JZ
United Kingdom

TELEPHONE
+44 (0) 113 895 0130

WEBSITE
www.4dpharmaplc.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2014

FINANCIAL SUMMARY

Raised >$140 M since IPO in 2014.

ADDRESS
3005 Center Green Drive,
Suite 205
Boulder, Colorado, 80301,
USA

TELEPHONE
+1 303 999 3700

WEBSITE
www.accerapharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2001

ACCERA, INC.

Accera is a clinical stage biotechnology company developing therapies for central nervous system disorders. Accera's proprietary scientific platform addresses numerous unmet needs in brain health in particular Alzheimer's disease.

Accera's lead compound, AC-1204, addresses the metabolic deficit that is fundamental to the pathophysiology of Alzheimer's disease. Accera is one of only 11 companies globally with a compound in phase 3 for Alzheimer's disease, and the only private company. The first of the phase 3 studies, the NOURISH AD study, is due to readout in early 2017.

MANAGEMENT TEAM

Charles Stacey, MD - President & CEO
Evan Ballantyne - Chief Financial Officer
Michael Gold, MD - Chief Medical Officer
Taryn Boivin, PhD - VP, CMC
Samuel Henderson, PhD - VP, Research & Development
Jerris Knaisch - VP, Finance
Ernest Wong, PhD - VP, Corporate Development

D

AcelRx Pharmaceuticals, Inc.

ACELRX PHARMACEUTICALS, INC.

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain in medically supervised settings. The Company's two late-stage product candidates, ARX-04 and Zalviso™, were developed using our non-invasive, sublingual formulation technology that delivers sufentanil, a strong opioid analgesic.

ADDRESS
351 Galveston Drive,
Redwood City, CA 94063,
USA

TELEPHONE
+1 650 216 3500

WEBSITE
www.acelrx.com

COMPANY TYPE
Listed

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2005

MANAGEMENT TEAM

Howie Rosen-CEO
Pam Plamer-CMO
Tim Morris-CFO
Anil Dasu-Chief Enginerring Officer
Larry Hamel-Chief development Officer
Gina Ford-VP Commercial Strategy
Financial Summary
Cash on hand June 30, 2016: $98 million
Shares outstanding: 45 million
Employees: 40

PIPELINE GRAPHIC



AcelRx Pharmaceuticals, Inc.

ADDRESS
351 Galveston Drive,
Redwood City, CA 94063,
USA

TELEPHONE
+1 650 216 3500

WEBSITE
www.acelrx.com

COMPANY TYPE
Listed

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2005

PIPELINE PRODUCT 2:

Zalviso® (sufentanil sublingual tablet system) Approved Europe, Phase 3 in United States

DESCRIPTION

Zalviso® (sufentanil sublingual tablet system)-Approved in EU

Currently, patients experiencing moderate-to-severe acute pain in the hospital may have intravenous patient controlled analgesia (IV PCA), as an option to treat their pain, typically utilizing morphine or hydromorphone. However, the use of IV PCA has been associated with deficiencies that can negatively impact patient safety and recovery. These include: a) side effects from morphine or hydromorphone and their active metabolites; b) medication delivery errors typically related to misprogramming IV PCA pumps; and c) complications associated with IV delivery such as infection risk and decreased mobility potentially related to the invasive nature of IV delivery.

Zalviso is designed to address these problems by delivering 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary non-invasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system.

Zalviso has completed three Phase 3 clinical trials: two placebo-controlled efficacy and safety trials and one open-label active comparator trial, in which Zalviso was compared to IV PCA morphine. Each of the three Phase 3 trials successfully achieved its primary endpoint. Based on FDA feedback, AcelRx is planning to conduct a fourth study in a diverse post-surgical population, which will further evaluate the overall performance of the Zalviso System.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

ARX-04, sublingual sufentanil 30 mcg

DESCRIPTION

Europe, ex-US rights available to license

ARX-04 (sufentanil sublingual tablet, 30 mcg)

ARX-04 is designed to provide a non-invasive treatment option for patients with moderate-to-severe acute pain, in multiple medically supervised settings ranging from the battlefield, civilian emergency departments, ambulatory surgery centers, physician's offices and hospitals. In September 2015, AcelRx reported that ARX-04 met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) in patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

ARX-04 is also being assessed in an open-label Phase 3 study (SAP302) in adult patients who present to the emergency room with moderate-to-severe acute pain associated with trauma or injury. The study is expected to be completed in early 2016. A third Phase 3 study (SAP303) is ongoing in postoperative patients with moderate-to-severe acute pain. This open-label study will focus on enrolling up to 100 adult patients from a wide variety of age groups and types of surgery.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

Zalviso, sufentanil subligual tablet system

DESCRIPTION

US and ROW (except EU) commerical rights rights available to license

Zalviso® (sufentanil sublingual tablet system)-Approved in EU

Currently, patients experiencing moderate-to-severe acute pain in the hospital may have intravenous patient controlled analgesia (IV PCA), as an option to treat their pain, typically utilizing morphine or hydromorphone. However, the use of IV PCA has been associated with deficiencies that can negatively impact patient safety and

recovery. These include: a) side effects from morphine or hydromorphone and their active metabolites; b) medication delivery errors typically related to misprogramming IV PCA pumps; and c) complications associated with IV delivery such as infection risk and decreased mobility potentially related to the invasive nature of IV delivery.

Zalviso is designed to address these problems by delivering 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary non-invasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system.

Zalviso has completed three Phase 3 clinical trials: two placebo-controlled efficacy and safety trials and one open-label active comparator trial, in which Zalviso was compared to IV PCA morphine. Each of the three Phase 3 trials successfully achieved its primary endpoint. Based on FDA feedback, AcelRx is planning to conduct a fourth study in a diverse post-surgical population, which will further evaluate the overall performance of the Zalviso System.

ADDRESS
351 Galveston Drive,
Redwood City, CA 94063,
USA

TELEPHONE
+1 650 216 3500

WEBSITE
www.acelrx.com

COMPANY TYPE
Listed

SECTOR
Pharmaceuticals/Licensing

YEAR FOUNDED
2005

ADDRESS
Bâtiment Inserm U1148
Hôpital Bichat, secteur
Claude Bernard
46 rue Henri Huchard
75877 Paris
France

TELEPHONE
+33 970 468 640

WEBSITE
www.acticor-biotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

ACTICOR BIOTECH SAS

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective treatment of the acute phase of ischemic stroke which account for 80% of all strokes.

MANAGEMENT TEAM

- CEO - Gilles Avenard, M.D.
- COO - Olivier Favre-Bulle, Ph.D.
- Finance Advisor - Eric Cohen

FINANCIAL SUMMARY

Acticor raised a seed round in 2015 and 2016 of 2.0 M€ in Equity and 900 K€ of Grants.

Acticor Biotech is looking for 5 M€ until Phase 1 and 5 M€ until end of Phase 2a.

PIPELINE PRODUCT 1:

ACT017 is a Fab directed against GPVI platelet glycoprotein.

The lead compound ACT017 is at preclinical stage and phase 1 will occur end of 2017.

DESCRIPTION

Acticor has developed ACT-017, a humanized Antigen Binding Fragment (Fab) targeting Glyco Protein VI “GPVI” ACT-017 has shown clear & strong anti-thrombotic activity without bleeding risk Proof of Concept validated In vitro, Ex Vivo (Monkeys) & In Vivo (Humanized Mice) ACT-017 could be used both as an add-on therapy (on top of Alteplase or thrombectomy) or as a stand alone in rtPA-non eligible patients CMC validated and Tech transfer in process for GMP batch Worldwide pending protection on the compound and methods of treatment (PCT filing date 08/2016)

ADDEX THERAPEUTICS LTD.

ADDRESS
12, chemin des Aulx
1228 Plan-les-Ouates,
Geneva
Switzerland

TELEPHONE
+41 22 884 1555

WEBSITE
www.acticor-biotech.com

COMPANY TYPE
Listed

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2002

Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and has been granted orphan drug status by the US FDA for PD-LID. Dipraglurant is currently being prepared to enter phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Johns Hopkins University. In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder, nicotine and cocaine dependence with support from the US CMT Association (CMTA), the US National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the US National Institute on Drug Abuse (NIDA), respectively. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders, which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM, which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Allosteric modulators are an emerging class of small molecule drugs, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

MANAGEMENT TEAM

Tim Dyer, CEO
Sonia Poli, CSO

ADDRESS
Im Kränzliacker 9
79576 Weil am Rhein
Germany

TELEPHONE
+41 79 592 2005

WEBSITE
www.allecra.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

ALLECRA THERAPEUTICS GMBH

Allecra is a clinical stage biopharmaceutical company established in 2013 in the European BioValley Life Sciences region located in the Upper Rhein valley and encompassing northwest Switzerland, southwestern Germany and the Alsace Region of France. Allecra is focused on the development of novel treatments to combat multi drug-resistant bacterial infections. The company is based on a strategic partnership between its Founders, Orchid Chemicals and Pharmaceuticals Ltd. (Chennai, India) and its lead investors Forbion Capital Partners and Edmond de Rothschild Investment Partners. Allecra's mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving lives of patients whose infections may otherwise may be inadequately treated.s.

MANAGEMENT TEAM

- Nicholas Benedict, CEO & Co-founder
- Brice R. Suire, Chief Financial Officer
- Stuart Shapiro, Head of Microbiology & Co-founder
- Stefano Biondi, Head of Chemistry, Mfg and Controls
- Omar Lalhou, Director of Regulatory Affairs
- Marcin Mankowski, Chief Medical Officer (ad interim)

ADDRESS
Parc d'innovation
650 Boulevard Gonthier
d'Andernach
67400 Illkirch
Graffenstaden
France

TELEPHONE
+33 3 88 43 10 08

WEBSITE
www.anagenesis-biotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2011

ANAGENESIS BIOTECHNOLOGIES

A start-up dedicated to developing treatments for muscle dystrophies through two complementary, cutting-edge approaches

a) NCE from cell-based in vitro HTS based on stem cell-derived normal and disease in vitro models

b) Cell therapy in vivo using stem cell-derived satellite cells

Exclusive rights to know-how and patents generated by Prof. Olivier Pourquié (Strasbourg/Harvard) for the high-yield, high-abundance generation of muscle cells in vitro

Partnership opportunities for pharma companies to develop customized in vitro assays for compound testing (e.g. Ksilink) and develop cell-based therapies (e.g. CRISPR Therapeutics)

First investors in 2013 (AFM, French Muscular Dystrophy Association) and 2014, Cap Innov'Est. Now seeking new co-investors (16 M€) for 2 programs up to IND in 3 years.

MANAGEMENT TEAM

Jean-Yves Bonnefoy, Ph.D, CEO & President

AnimaBiotech

ADDRESS
10 Hanechoshet st., Tel Aviv 69710,
ISRAEL

TELEPHONE
+972 72 214 8770

WEBSITE
www.animabiotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2005

ANIMA BIOTECH LTD.

Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel drug discovery platform enables for the first time the visualization and control of the synthesis of proteins by ribosomes, opening a new way to approach hard or undruggable targets. Our current pipeline is in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (RSV - interfering with viral protein translation) and Autism (regulating protein synthesis in the synapses of the brain's neurons) With our nearly universal platform, we intend to grow our pipeline to many additional diseases. We further extend the reach of our platform by partnering with Pharma in the discovery of drugs that control the synthesis of a partner's targets of interest. Our technology has achieved strong validation with 5 granted patents and 2 more pending, 17 scientific collaborations and 13 peer reviewed publications in multiple therapeutic areas. So far we have raised $22m, including $10m in NIH research grants. You may watch the movie about our vision and technology at https://youtu.be/XNIr6MqfSYE

FINANCIAL SUMMARY

Raised $22m (incl. $10m NIH grants)

COMPANY FACTS:

Technology developed over a decade of collaboration with Penn university
15 people in a highly interdisciplinary team
Raised $22m (incl. $10m NIH grants)
11 publications in leading journals
5 patent families granted, 2 pending
15 partnered scientific collaborations

"How to stand out from the competition and what happens if you don't"
https://www.youtube.com/watch?v=dGB8gKAAwhU

Forbes article: "The one great thing that every great leader does"
http://www.forbes.com/sites/augustturak/2012/01/21/the-one-great-thing-that-every-great-leader-does/

FINANCIAL SUMMARY

Raised $22m (incl. $10m NIH grants)

PIPELINE PRODUCT 1:

Fibrosis - preclinical discovery stage The basic fibrotic process, in all types of fibrosis, is related to the over-production of the protein collagen. The key issue in finding anti-fibrotic drugs is that collagen is not a "target" in the common sense – it is not an enzyme and is not involved in chemical reactions. It exists in huge quantities as it is used to build the body's skin, bones, and connective tissues. Thus, searching for small molecules that will bind to collagen to "neutralize" it is not a valid therapeutic strategy. With Anima's platform we can see the process of collagen production in living cells, monitor the translation of collagen by ribosomes, and discover molecules that interfere with the over-production of collagen.

DESCRIPTION

RSV - discovery of drugs that inhibit translation of the viral proteins by ribosomes.

ADDRESS
10 Hanechoshet st., Tel Aviv
69710, ISRAEL

TELEPHONE
+972 72 214 8770

WEBSITE
www.animabiotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2005

PIPELINE PRODUCT 2:

Autism - discovery of drugs that regulate protein synthesis in the synapses of the brain's neurons

INVESTMENT & LICENSING OPPORTUNITY 1:

Fibrosis

DESCRIPTION

Raising funds to support the development of our pipeline.

INVESTMENT & LICENSING OPPORTUNITY 2:

Out licensing - Fibrosis & Anti virals

DESCRIPTION

Looking for Pharma partners for our Fibrosis and RSV programs.

Partnering / collaboration deals around our technology platform using the platform against Pharma partner's hard / undruggable targets:

Anima's technology enables a new approach for the discovery of molecules that control the translation of the target protein. This enables us to approach targets that cannot be approached by existing methods.

"How to stand out from the competition and what happens if you don't"
https://www.youtube.com/watch?v=dGB8gKAAwhU

Forbes article: "The one great thing that every great leader does"
http://www.forbes.com/sites/augustturak/2012/01/21/the-one-great-thing-that-every-great-leader-does/

ADDRESS
Im Neuenheimer Feld 584
69120 Heidelberg
Germany

TELEPHONE
+49 (0) 6221 58608 0

WEBSITE
www.apogenix.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2006

APOGENIX AG

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.

Apogenix' lead drug candidate APG101 is a CD95 ligand checkpoint inhibitor. APG101 is being developed for the treatment of solid tumors and malignant hematological diseases and has been evaluated in the treatment of glioblastoma and myelodysplastic syndromes (MDS). Clinical efficacy data has been demonstrated in a controlled PII study in glioblastoma and a PI/II study in MDS.

In addition Apogenix has developed a proprietary platform for the construction of novel hexavalent TNF superfamily receptor agonists (HERA) to stimulate receptors such as CD40, CD27, OX40, TRAILR and more with unique properties..

Efficacy data are available showing that the HERA-Ligands indeed are superior to other biologics such as agonistic antibodies. The TRAIL program has been exclusively licensed to Abbvie.

MANAGEMENT TEAM

Dr. Thomas Hoeger, CEO
Dr. Harald Fricke, CMO
Peter Willinger, CFO

PIPELINE PRODUCT 1:

APG101
- PII in glioblastoma
- PII in MDS

DESCRIPTION

HERA agonist technology:
HERA-TRAIL
HERA-CD27L
HERA-CD40L
HERA-GITRL
HERA-OX40L
HERA-41BB
HERA-LIGHT

INVESTMENT & LICENSING OPPORTUNITY 1:

APG101

INVESTMENT & LICENSING OPPORTUNITY 2:

HERA-CD27L

INVESTMENT & LICENSING OPPORTUNITY 3:

HERA-CD40L

arsanis

ADDRESS
890 Winter Street
Suite 230
Waltham, MA 02451-1472
USA

TELEPHONE
+1 781 819 5704

WEBSITE
www.arsanis.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

ARSANIS, INC.

Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company's current programs address pathogenic processes selectively, rather than aiming to broadly eliminate bacteria, potentially allowing Arsanis to address critical infections without contributing to the problem of antibiotic resistance. The company is building a broad product pipeline addressing the most important Gram-positive and Gram-negative bacterial pathogens threatening hospitalized and high-risk patients. Its lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections. A Phase 1 clinical trial of ASN100 has recently been completed, and Arsanis expects to initiate a Phase 2 study of ASN100 in 2016.

MANAGEMENT TEAM

René Russo, PharmD, BCPS; President and Chief Executive Officer
Eszter Nagy, MD, PhD, Co-Founder and Chief Scientific Officer
Michael Gray, MBA, CPA, Chief Financial and Chief Business Officer
Chris Stevens, MD, Chief Medical Officer
David Mantus, PhD, Chief Development Officer

PIPELINE GRAPHIC



ADDRESS
890 Winter Street
Suite 230
Waltham, MA 02451-1472
USA

TELEPHONE
+1 781 819 5704

WEBSITE
www.arsanis.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

PIPELINE PRODUCT 1:

ASN100: Phase 2:

ASN100 is a combination of two fully human monoclonal antibodies that collectively neutralize six important S. aureus cytotoxins associated with pneumonia pathogenesis. ASN-1 neutralizes alphahemolysin (Hla), a key S. aureus toxin responsible for lung epithelial cell damage, in addition to four S. aureus leukocidins responsible for lysis of human phagocytic (immune) cells: the Panton-Valentine leukocidin (PVL), leukocidin ED, and gamma-hemolysins AB and CB. ASN-2 inactivates the remaining S. aureus leukocidin, LukGH, which is a particularly potent human cytotoxin that is also responsible for lysis of human phagocytes. Arsanis has recently completed a Phase 1 clinical study of ASN100, and plans to initiate a Phase 2 study in 2016.

DESCRIPTION

ASN200: Preclinical:A Monoclonal Antibody Program Targeting Multi-drug Resistant Escherichia coli

The ASN200 program is currently in preclinical development. Within the program, Arsanis discovered a unique monoclonal antibody, ASN-4, that has multiple modes of action against E. coli ST131-O25b:H4. ASN-4 is directly bactericidal and provides anti-inflammatory effects without the need for innate immune cells and therefore has the potential to be beneficial even in immunocompromised patients. In addition, ASN-4 potentiates the activity of antibiotics, potentially minimizing the use of last-line antibiotics with less favorable toxicity profile (e.g., colistin). ASN-4 is highly potent and elicits a high level of protection at very low doses in relevant animal models and therefore has the potential to be used both for prevention of disease in colonized, high-risk patients and treatment of serious infections, including those where antibiotics have failed.

PIPELINE PRODUCT 2:

ASN300: Preclinical: A Monoclonal Antibody Program Targeting Klebsiella pneumoniae

For the ASN300 program, Arsanis is developing monoclonal antibodies targeting K. pneumoniae surface structures that exhibit limited diversity. These monoclonal antibodies have rapid and targeted activity through different modes of action and provide high efficacy in relevant animal models of severe K. pneumoniae infections.

DESCRIPTION

ASN400: Targeting Streptococcus pneumoniae (Pneumococcus)

The ASN400 program is currently in the discovery phase and is designed to counteract the bacterium's most important virulence mechanisms, thus supporting the patient's ability to defeat Streptococcus pneumoniae.

ATLANTIC HEALTHCARE PLC.

Atlantic Healthcare plc is an international specialty pharmaceutical company. We focus on the development and commercialisation of products that address niche unmet needs. These products are intended for patients under the management of physicians in the hospital and specialist care sector which is showing one of the highest growth rates in the pharmaceutical industry. We are building a portfolio of products that address needs in clearly defined patient groups. These target groups' needs are either poorly served or have no approved treatment. Our portfolio contains products that have unique positioning characteristics, intellectual property protection and market exclusivity. Key medical opinion leaders have confirmed they will consider these products for their patients once approved. This provides Atlantic Healthcare with the potential to be a high growth profitable company.

ADDRESS
Atlantic House
10 Rose & Crown Walk
Saffron Walden Essex
CB10 1JH
UK

TELEPHONE
+44 1799 513391

WEBSITE
www.atlantichc.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2007

MANAGEMENT TEAM

Karl Keegan, Chief Financial Officer
Chris Dunk, Director of Clinical Development
Janette Thomas, Director of International Operations
Dr Lorin Johnson, Chief Scientific Advisor
Sireesh Appoajosyula, Vice President Product Commercialisation
Jonathan Drutz, Vice President Business & Corporate Development

PIPELINE PRODUCT 1:

Alicaforsen
Phase 3 Trials

WEBSITE
www.atriva-therapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2015

ATRIVA THERAPEUTICS GMBH

Atriva Therapeutics GmbH is an emerging company based on patented research for the application of MEK inhibitors in the treatment of certain viral infections and located in Tübingen, Germany.

This is a kind of universal mechanism that the virus cannot escape e.g. through surface alterations. Since our inception in 2015 we have built a pipeline of four preclinical projects on –Strand RNA Viruses, for none of them existing an effective cure so far, among them Influenza, Flu and bacterial Co-infections, Hanta and Corona (MERS, SARS). Extensive grant applications to NIH for all targets have been filed in 2016, with a maximal support in excess of $ 3 Mn.

Influenza viruses are the immediate focus for our required funding to achieve the clinical milestones. We repurpose clinically known off-patent MEK inhibitors and finalize the clinical phase 2b studies in 3 years based on challenge studies with established CRO's.

Last, but not least, we discovered that MEK inhibition also displays a strong inhibitory effect of bacterial super-infections following often the viral infections. Actually, we believe that this is a very crucial finding as often the aftermath of the viral infection causes the fatal progression of the influenza disease, especially for high risk patients (>65 years and or co-morbidities such as CHF, COPD, diabetes, etc.). These intriguing findings are the basis of recent patents.

Atriva is still financed by its 8 founders amnong them three of Europe's leading virologists and 5 seasoned biotech/pharma executives.

We are currently prceeding in a seed round on Mn 2.4 € and anticipate a first closing in mid October 2016

MANAGEMENT TEAM

Rainer Lichtenberger, Ph.D., MBA, CEO and founder

Oliver Planz, Ph.D., CSO (interim) and founder

Sebastian Canisius, Chief Medical Officer (designated) and founder

Henrik Luessen, PH.D., CBO and founder

Emilie Hofstetter, M.Sc., Chief strategy officer and founder

FINANCIAL SUMMARY

Past/current:

Founders Seed 2015 and 2016: Mn 0.3 €

Seed round (ongoing) 2016: Mn 2.4 €

Planned

Series A Round (Q2 2017): Mn 5 €

Series B Round (Q3 2018): Mn 8 €

Atriva Therapeutics

WEBSITE
www.atriva-therapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2015

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

ATR-001
Indication: Influenza in high-risk patients
Stage Clinical candidate

DESCRIPTION

Compound
Small Molecule, MEK-Inhibitor
Indication
Therapy of Influenza in high-risk patients
Development Status of Originator
Development up to Ph 2b, patents expired, own global strong patents
Target Dose (mg/d)
250 mg – 500 mg
5 – 7 days treatment
Target price
Price € 250 per treatment cycle
Benefit/Risk Profile

FAVORABLE PRECLINICAL & PHASE 1 TOXICITY DATA:

- treatment-specific side effects for antiviral cure expected,
- short treatment period (1 week)
- lower effective dose compared to oncological treatment

PIPELINE PRODUCT 2:

ATR-005:
Bacterial Co-Infections of viral infections
Stage Preclinical

DESCRIPTION

ATR-005 targets multiresitant bacteria as MRSA, which often cause cocomitant respiratory disease and severe complications of viral respiratory diseases. Most prominent hier pneumonia, which in the cause of 95% og fatalities associtated with influenza.

Our MEK Inhibitor ATR-005 exhibitis a profound bacteriostatic activity against a broad range of gram-positive and select gram-negative bacteria.

WEBSITE
www.atriva-therapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2015

This opens a great potential for a safe treatment for severe bacterial infection, complementaryto reserve antibiotics, as typical resistance patters are not possible in the case of MEK inhibitors

PIPELINE PRODUCT 3:

ATR-004:

preclinical

DESCRIPTION

ATR-004 targets the Hanta Pulmonal Syndrom and the Hanta Renal Syndrom, both caused by Hantavirus. HPS ist a severe viral respiratory disease, where severe lungs complications may cause up to 40% fatalities.

No treatment or vaccination against Hantavirus infection is available yet.

We plan to submit an Orphan Drug Designation during 2017 and to enter clinial development still in 2018.

ADDRESS
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland

WEBSITE
www.aurealispharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

AUREALIS PHARMA AG

At Aurealis Pharma we are dedicated to develop an effective, safe and economical treatment method to improve the quality of life for patients suffering from chronic inflammatory diseases or cancer.

Thanks to the advancements in modern biotechnology and our research and development in cell-based therapies we have developed a proprietary technology, which utilizes genetically modulated probiotics delivering multiple therapeutic proteins in chorus to the diseased tissue. This technology allows us to modulate the local immune system and its environment to enable healing.

A life-changing breakthrough that offers a much-improved, safer, and more cost-effective treatment option to patients being affected by severe and chronic inflammation or cancer.

MANAGEMENT TEAM

Dr. Juha Yrjanheikki, CEO

Dr. Thomas Wirth, CSO

Dr. Dirk Weber, CMO

ADDRESS
Norwegian University of Science and Technology
Høgskoleringen 5
N-7491 Trondheim
Norway

TELEPHONE
+47 73 59 61 07

WEBSITE
www.avexxin.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2005

AVEXXIN AS

Avexxin AS is a clinical stage pharmaceutical company focused on developing novel first in class small molecules for patients suffering from various inflammatory conditions. Current pipeline includes compounds against psoriasis and other dermatological disorders, rheumatoid arthritis and glomerulonephritis. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of chronic inflammatory disorders. Compounds have also been successfully tested in various cancer models. The NCE's specifically target the group IVa cPLA2 enzyme regulating the cytokine-induced activation of the pro-inflammatory transcription factor NF-κB.

We are seeking funding and/or partnering opportunites for the following programs:

(1) AVX001 is being developed for the topical treatment of psoriasis (and other dermatological inflammatory disorders). The small molecule targets the group IVA phospholipase A2 (cPLA2) enzyme regulating the cytokine-induced activation of the proinflammatory nuclear transcription factor-kappa B (NF-kappa B). A

(2) AVX002 and AVX235 are pre-clinical stage assets that also target cPLA2. They are being developed for the treatment of rheumatoid arthritis and glomerulonephritis, respectively. In preliminary animal testing, AVX235 exhibited significant anti-cancer activity. AVX001, AVX002 and AVX235 are lead compounds from two distinct chemical families being developed by Avexxin.

(3) We have also patented a new family for the AVX 4 Series with better potency and target affinity.

Biologics Resources
Vaccine & BioPharma Company

ADDRESS
20271 Goldenrod Lane,
Suite 2072
Germantown, MD 20876
USA

WEBSITE
www.biologicsresources.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Other
Other Sector
Health care, pharmaceuticals and biologics (vaccines and therapeutics)

YEAR FOUNDED
2011

BIOLOGICS RESOURCES LLC

Biologics Resources LLC is a privately owned biologics company. It was created in 2011 by Dr. Lallan Giri who has had successful career in biodefense biologics, pediatric vaccines, and biologic therapeutics (antibodies) with multi-national pharmaceutical companies such as Wellcome - Pharmaceuticals, Sanofi Pasteur, Glaxo Wellcome, and Emergent Biosolutions, Inc. Dr. Giri's expertise are in the areas of vaccine and therapeutics development.

Biologics Resources was founded in 2011, in Germantown, Maryland with Dr. Giri's personal investment of $ 2 Millions to develop a conjugate anthrax vaccine by licensing the technology from N.I.H. In 2012, Biologics Resources was awarded a grant of approximately $5 million for 5 years from N.I.H. to develop a conjugate anthrax vaccine.

MANAGEMENT TEAM

The company was founded by Dr. Lallan Giri the CEO. Dr. Giri and has the following management team and scientists.

Dr. Lallan Giri, CEO

Mr. Aseem Giri, President, Cosmoceuticals Product, Singapore

Dr. Hyeon Park, Director of Product Development and Manufacturing.

Dr. Christine Ferragine, Manager of Government Relations and Immunology.

Dr. Doo, Senior Scientist, Fermentation System, cosmoceutical development.

Dr. Selva Murugesan, Manager, Quality System

Technical/Technician staffs: 2

FINANCIAL SUMMARY

1) Investment by Dr. Giri, $2 Million

2) N.I.H. Grant, approximately $5 Million

PIPELINE PRODUCT 1:

Conjugate anthrax vaccine for children and adults - under development

PIPELINE PRODUCT 2:

Therapeutics: Monoclonal antibodies for post-exposure treatment in the case anthrax attack/ terrorism - under development

PIPELINE PRODUCT 3:

Cosmoceuticals – skin care product - under development

biophytis

ADDRESS
Parc Biocitech –
102 Avenue Gaston
Roussel – 93230
Romainville
France

WEBSITE
www.biophytis.com

COMPANY TYPE
Listed

COMPANY TICKER
ALBPS

SECTOR
Biotechnology

YEAR FOUNDED
2006

BIOPHYTIS

Biophytis is a biotechnology company created in 2006 as a spin-off of Université Pierre et Marie Curie (Paris). It develops first-in-class drugs to treat degenerative illnesses associated with aging for which there is curently no treatment. Biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenia (Sarconeos) and dry age-related macular degeneration (Macuneos).

MANAGEMENT TEAM

Stanislas Veillet, CEO

Jean-Christophe Montigny, CFO

Susanna del Signore, CMO

René Lafont, CSO

FINANCIAL SUMMARY

Biophytis is listed on Alternext Euronext in Paris, with a market cap of 36M€ (09/15/2016).

It raised 16 M€ in July 2016 for its IPO and the last cash position was 10 M€ (dec 2015).

The main shareholders are Founders (23%), french VC funds (Seventure, 10%, CM-CIC, 10%) and two biotech companies (Metabrain, Iris Pharma). 49% is public.

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

Sarconeos, Phase 2b

DESCRIPTION

Sarconeos is a drug candidate, Mas activator, for the treatment of Sarcopenia. Phase 2b on 300 patients to be started H1 2017.

PIPELINE PRODUCT 2:

Macuneos, Phase 1-2

PIPELINE PRODUCT 2:

Macuneos is a drug candidate for the treatment of dry AMD. It is a PPAR agonist in clinical developement (Phase 1-2).

Biosceptre

ADDRESS
Jonas Webb Building
Babraham Research
Campus Babraham,
Cambridge CB22 3AT
United Kingdom

TELEPHONE
+44 1223 496 090

WEBSITE
www.biosceptre.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Diagnostics
Pharmaceuticals/Licensing

YEAR FOUNDED
2002

BIOSCEPTRE INTERNATIONAL LTD.

Biosceptre is a UK based biotech R&D business investigating and exploiting a promising new target for the treatment of cancer – nfP2X7. nfP2X7 is a highly specific cancer target. Its very low cross reactivity with normal tissues along with the breadth of its presence in cancer, promises disruptive potential in the field of immunotherapy oncology.

Biosceptre has multiple programs in pipeline that exploit this new nfP2X7 oncology target via a range of therapeutic modalities. Each has the potential to be a blockbuster in the treatment of cancer either individually or in combination with other treatments

Biosceptres' IP portfolio and expertise around the unique biology of the nfP2X7 target also promises significant potential for application & licensing across advanced therapeutic technologies, diagnostic and veterinarian uses.

MANAGEMENT TEAM

Mr Gavin Currie
Chief Executive Officer
Dr Shaun McNulty
Chief Science Officer
Mr Daniel Barton
Director - Business Development

FINANCIAL SUMMARY

Biosceptre is a closely held, privately funded business. Biosceptre is currently undertaking a private round fund raise currently underway for £25m with Peel Hunt (UK), and is anticipated to list in 2017.

PIPELINE GRAPHIC



Biosceptre

ADDRESS
Jonas Webb Building
Babraham Research
Campus Babraham,
Cambridge CB22 3AT
United Kingdom

TELEPHONE
+44 1223 496 090

WEBSITE
www.biosceptre.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Diagnostics
Pharmaceuticals/Licensing

YEAR FOUNDED
2002

PIPELINE PRODUCT 1:

BIL03 / Phase I

DESCRIPTION

BIL03s is a systemic antibody developed via phage display which binds specifically to nfP2X7 (a conformationally distinct variant of the P2X7 receptor that occurs on many cancer cell types) but not to P2X7 which is present on cells in a range of healthy tissues.

BIL03s is intended to treat a range of solid tumours by infusion.

The nfP2X7 form of P2X7 is associated with proliferation and survival signaling pathways which have a role in cancer cell survival and proliferation. Binding of BIL03s drives internalization of the nfP2X7 receptor, reducing aberrant signalling.

BIL03s has shown an excellent safety profile in man via compassionate access programs, and will enter the clinic in a Phase I trial in 2016.

PIPELINE PRODUCT 2:

BIL06v / Phase I

DESCRIPTION

BIL06v is a peptide-protein conjugate vaccine intended as a therapeutic against a range of solid tumours. BIL03s elicits a titre of endogenous antibodies specifically against the nfP2X7 receptor which is a conformationally distinct variant of the P2X7 receptor that occurs on many cancer cell types. This antibody response does not bind to the P2X7 receptor which is present on cells in a range of healthy tissues.

The nfP2X7 form of P2X7 is associated with proliferation and survival signaling pathways which have a role in cancer cell survival and proliferation.

BIL06v is intended to be used as a therapeutic treatment for a range of solid tumours by vaccination.

BIL03s has shown an excellent safety profile in man via compassionate access programs, and will enter the clinic in a Phase I trial in 2016.

PIPELINE PRODUCT 3:

BIL010t - Phase 2

DESCRIPTION

BIL010t is a topical product intended as a therapeutic against skin cancers including Basal Cell Carcinoma. BIL010t is an antibody forumlation that binds to the nfP2X7 receptor which is a conformationally distinct variant of the P2X7 receptor that occurs on many cancer cell types. BIL010t does not bind to the P2X7 receptor which is present on cells in a range of healthy tissues.

BIL010t has successfully completed a Phase 1 trial which delivered an excellent safety profile, as well as showing signs of efficacy in man.

BIL010t will enter a Phase II trial in late 2016 seeking an efficacy signal in Advanced BCC (ABCC)

ADDRESS
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

TELEPHONE
+46 46 2756260

WEBSITE
www.cantargia.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2009

CANTARGIA AB

Cantargia is developing an antibody against the IL1RAP target molecule for cancer treatment. Preclinical data indicate that the antibody has the potential to be used for treatment of several forms of cancer. Cantargia will be focusing the initial development activities on non-small cell lung cancer (NSCLC) and pancreatic cancer. A product candidate CAN04 has been selected and a clinical phase I/IIa study in these cancers will be initiated in late 2016. The goal is to develop a new treatment for future cancer therapies.

MANAGEMENT TEAM

Göran Forsberg, CEO

Liselotte Larsson, VP Operations Lars Thorsson, VP Clinical Development David Liberg, VP Cancer Research

PIPELINE PRODUCT 1: NAME/STAGE

CAN04/Preclinical

PIPELINE PRODUCT 1: DESCRIPTION

CAN04 is a fully humanized antibody against IL1RAP (interleukin-1 receptor associtated protein) which is one of components in the IL-1 receptor complex. CAN04 is designed to give enhanced ADCC and blocks signalling induced by IL-1. Phase I/IIa clinical trials focused against NSCLC and pancreatic cancer is planned to start Q1 2017.

CELLESTIA BIOTECH

CELLESTIA BIOTECH AG

Cellestia Biotech is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. Our anti-cancer CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.

ADDRESS
Technology Park Basel
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland

TELEPHONE
+41 61 633 2980

WEBSITE
www.cellestiabiotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

MANAGEMENT TEAM

Dr. Michael Bauer, CEO

Prof. Freddy Radtke, Chariman

Dr. Rajwinder Lehal, CSO

Dr. Dirk Weber, CMO

FINANCIAL SUMMARY

SEED A and SEED B successfully closed

SEED C ongoing for completion of preclinical development of lead compound CB-103

SERIES A in peparation (for funding clinical developopment Phase I-II)

PIPELINE PRODUCT 1:

Lead Compound: CB-103, a new mode of action pan-NOTCH inhibitor for treatment of NOTCH positive cancer.

Preclinical development is close to completion and start of clinical development, Phase I is anticipated for 1Q2017.

DESCRIPTION

Preclinical proof of concept confirming strong anti-cancer activitiy in NOTCH postive cancers (solid tumors and leukemia). Confirmed activity in patient derived blood samples (T-ALL). In contrast to all competitors, CB-103 can control also NOTCH positive tumors driven by constitutive activation of the pathway. It is the only compound in development that can control NOTCH pathway activation regardless of molecular cause.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

SERIES A Investment

OPPORTUNITY 1: DESCRIPTION

Cellestia has successfully completed SEED A and B financing rounds, a SEED C financing round is ongoing.

Cellestia is seeking up to 10 million SERIES A investment for funding the clinical program.

Investment & Licensing (In/Out) Opportunity 2: Name

Corporate Investment / Partnership

CELLPROTHERA
DISCOVERY · CELL CULTURE · TRANSPLANT

ADDRESS
12, Rue du Parc
68100 Mulhouse
France

TELEPHONE
+33 3 69 71 97 71

WEBSITE
www.cellprothera.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Medical Devices
Regenerative Medicine

YEAR FOUNDED
2008

CELLPROTHERA SAS

Established in 2008, CellProthera is a clinical stage pioneer in regenerative medicine / cell therapy.

CellProthera has initially developed an innovative, proprietary cell therapy technology platform and is now focusing on a cardiovascular ATMP/MTMM candidate allowing the regeneration of myocardial tissue to treat acute myocardial infarction and prevent secondary congestive heart failuremore....

CellProthera is currently in a Phase I/IIb in Europe (France and UK) after a very successful proof of principle study showing outstanding clinical benefit and an excellent safety.

Having already raised about €20M (~US$22M), the company is now seeking an additional €25M (~US$27M) to fund phase III as well as preparing market phase.

MANAGEMENT TEAM

Philippe HÉNON | Chairman & CSO Jean-Claude JELSCH | CEO Christophe VALAT | Chief Development Officer Jean-Philippe VEILLARD | Chief Financial Officer Anthony CRIQUET | Chief Medical Officer Stephan DIETRICH| Chief Regulatory Affairs and Quality Insurance Officer | Qualified Person

PIPELINE PRODUCT 1:

ProtheraCytes® currently in clinical Phase I/IIb

DESCRIPTION

CellProthera is bringing to market an ATMP/MTMM in the cardiac field, ProtheraCytes®, following a very successful proof of principle study showing outstanding clinical benefits and an excellent safety profile.

ProtheraCytes® allows the regeneration of myocardial tissue to treat acute myocardial infarction (AMI) and prevent secondary congestive heart failure (CHF). With a large patient population and few if any alternative treatments, ProtheraCytes® could be classified as a potential blockbuster. It is currently in Phase I/IIb (France & UK) and CellProthera is about to launch another trial in Singapore later this year.

INVESTMENT & LICENSING OPPORTUNITY 1:

Participation in current financing round

DESCRIPTION:

Current financing round of €25M to prepare next clinical phase

ADDRESS
Axis Business Park
Rue Edouard Belin 2 1435
Mont-Saint-Guibert
Belgium

TELEPHONE
+32(0) 10 39 41 00

WEBSITE
www.celyad.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2008

CELYAD S.A.

Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products.

MANAGEMENT TEAM

Celyad management team: http://www.celyad.com/about-celyad/our-management

ADDRESS
One Riverway, Suite
1520 Houston, TX 77056
USA

EMAIL
arichardson@claytonbiotech.com

WEBSITE
www.claytonbiotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Diagnostics
Independent Investment
Research Organisation
Not-for-Profit
Regenerative Medicine

CLAYTON BIOTECHNOLOGIES, INC.

At the Clayton Foundation, we conduct medical research to discover the cause, prevention and cure of diseases, and we translate our research into products for the benefit of mankind through finding development partners with the assistance of Clayton Biotechnologies.

THE MISSION OF THE CLAYTON FOUNDATION FOR RESEARCH IS TWO-FOLD:

1. To conduct medical research for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind

2. To transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products.

The Clayton Foundation and its supporting entities have multiple medical research projects at ten institutions in the United States and Switzerland. By agreement with each hosting institution, the Foundation has the rights to the intellectual property arising from these projects.

Several cutting edge biomedical technologies discovered by the Clayton Foundation have been successfully commercialized through the creation of start-up companies and out-licensing. These technologies have been developed into significant medical products that are currently marketed.

PIPELINE GRAPHIC

CANDIDATE COMPOUND	DEVELOPMENT STAGE	PARTNER
Lenti-D Indication: Cerebral ALD	Phase II / III	bluebirdbio
LentiGlobin Indication: Beta-thalassemia	Phase II / III	bluebirdbio
LentiGlobin Indication: Sickle Cell Disease	Phase I / II	bluebirdbio
bb2121 BCMA Indication: Multiple Myeloma	Phase I	Celgene
RetinoStat Indication: AMD	Phase I	OxfordBioMedica
EncorStat Indication: Corneal Graft	Phase I	OxfordBioMedica
Urocortin Indication: Congestive Heart Failure	Phase II	Available to Partner CONTACT US >
VC-01 Indication: Type I Diabetes	Phase I	ViaCyte Regenerating Health
alpha-TEA Indication: Metastic Carinoma, Sarcoma and Lymphoma	Phase I	VEANA THERAPEUTICS

ADDRESS
One Riverway, Suite
1520 Houston, TX 77056
USA

EMAIL
arichardson@claytonbiotech.com

WEBSITE
www.claytonbiotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Diagnostics
Independent Investment Research Organisation
Not-for-Profit
Regenerative Medicine

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Filaggrin for treatment of dermatological disorders

DESCRIPTION

Icthyosis vulgaris and atopic dermatitis are often associated with a lack of filaggrin (FLG) protein. In healthy patients, the FLG protein is expressed in the cytoplasm of epithelial cells and plays an essential role for proper keratinization and squamification of epithelial cells, formation of epidermal barrier, and hydration.

We have developed a recombinant filaggrin combined with a cell importation signal, rFLG-RMR. Our pre-clinical studies demonstrate that topical application of rFLG-RMR leads to its internalization by epithelial cells and restoration of regular epithelial cell function.

As we advance in the pre-clinical development of rFLG-RMR, we are seeking a for-profit partner to bring this candidate product into the clinic.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

Safety Switch for Stem Cell Therapy

DESCRIPTION

Stem-cell derived grafts hold great therapeutic promise but recent clinical cases have highlighted the potential dangers associated with the presence of proliferating cells in the graft. We have developed a method to specifically eliminate proliferating cells in stem cell-derived grafts of neurons and other cell-based therapies where the final target consists of post-mitotic cells.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 3:

Zika Vaccine

DESCRIPTION

Clayton is funding and developing an arboviral vaccine platform with vaccine candidates for Dengue and Chikungunya in advanced pre-clinical stages as well as a Zika vaccine program, initiated at the end of 2015.

The technology is a unique approach to production of vaccines for mosquito-borne virus. The key breakthrough was the realization that deletion mutants of arboviruses in certain trams-membrane regions would result in a virus which could be replicated in insect cells (the normal vector) but would have poor ability to be replicated in mammalian cells, that is in man. These mutants present the same epitopes to the human immune system as wild type (WT) DV but are not pathogenic and can therefore serve as a live attenuated vaccine (LAV) with unique properties relative to other vaccines in development.

CorMedix Anti-Infective Solutions

ADDRESS
1430 U.S. Highway 206
Suite 200 Bedminster,
NJ 07921
USA

TELEPHONE
+1 908-517-9500

WEBSITE
http://www.cormedix.com/

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2006

CORMEDIX, INC.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin is currently in a Phase 3 clinical study in patients undergoing chronic hemodialysis via a central venous catheter. The company is planning to conduct its second Phase 3 study in patients with cancer receiving IV parenteral nutrition, chemotherapy and hydration via a chronic central venous catheter, subject to sufficient resources. If successful, the two pivotal studies may be submitted to the FDA for potential approval for both patient populations. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, contributing to potentially accelerated FDA review and up to 10 years of market exclusivity upon potential U.S. approval. It is already a CE Marked product in Europe and other territories. CorMedix is also seeking to unlock additional value for its taurolidine-based technology by establishing collaborative partnerships in oncology and medical device applications. For more information visit:www.cormedix.com.

MANAGEMENT TEAM

Mr. Randy Milby, Chief Executive Officer

PIPELINE PRODUCT 1:

Neutrolin, Phase 3 in U.S./CE Marked in EU

Non-antibiotic antimicrobial solution designed to fill the lumen of central venous catheters between uses to maintain sterility and prevent thrombosis

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Taurolidine

DESCRIPTION

Antimicrobial, anti-inflammatory molecule able to be incorporated into various medical devices such as sutures, nanofiber meshes, wound closure materials, and coatings for implantable devices

ADDRESS
2 Carlson Pkwy N
#165, Minneapolis, MN
55447
USA

TELEPHONE
+1 763-270-0603

EMAIL:
info@diamedica.com

WEBSITE
www.diamedica.com

COMPANY TYPE
Listed

DIAMEDICA INC.

DiaMedica is a biopharmaceutical developing difficult to manufacture recombinant proteins. The Company's lead product DM199 (recombinant KLK1 protein) has completed 4 clinical studies. Proof-of-concept has been established for diabetic kidney disease (DKD) and acute ischemic stroke (AIS) with a porcine sourced KLK1 approved for DKD in China and hypertension in Japan and with a human urine sourced KLK1 approved for AIS in China. DM199 is positioned as biobetter opportunity to replace approved KLK1 products in China & Japan and to enter markets in rest of world. The Company is initiating a clinical study to identify optimal dose of DM199 for treatment of DKD & AIS. A Fosun Pharma/SK Group Investment Fund has recently completed a strategic investment.

MANAGEMENT TEAM

Rick Pauls, President & CEO

Todd Verdoorn, CSO

PIPELINE:

DM199 - Phase I/II Diabetic kidney disease and acute ischemic stroke



DOUBLE BOND Pharmaceutical

ADDRESS
Rapsgatan 7, Uppsala Business Park
SWEDEN

WEBSITE
www.doublebp.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2014

DOUBLE BOND PHARMACEUTICAL AB

Double Bond Pharmaceutical is going to start clinical trials in 2017 with two revolutionary products for treatment of liver and brain cancer.

MANAGEMENT TEAM

Igor Lokot, Dr

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

Temodex (brain cancer)/marketed in Belarus, pre-cinic in Europe

DESCRIPTION

Video: https://www.youtube.com/watch?v=iweOQPq316o

Temodex is a locally acting form of temozolomide developed by the Research Institute of Physical and Chemical Preparations at Belorussian State University in Minsk, Belarus, and has successfully been tested in clinical trials. Belorussian State University has in 2015 received a 1-st grade Diploma and a gold medal at RESTEC® HiTech exhibition forum in St. Petersburg for the development of Temodex in the category "Best Innovation Project: successful product marketing, best manufacturing, best stock handling and best logistics". Temodex is registered as a first line treatment of glioblastoma in Belarus since 2014.

DBP was granted by EMA Orphan Drug Status for Temodex in June 2016

DBP is going to start pivotal phase II trials with Temodex in 2017

PIPELINE PRODUCT 2:

SA-033 (liver cancer)/pre-clicnic in Europe

DESCRIPTION

Video: https://www.youtube.com/watch?v=2PKi51PW75Q

SA033 is a novel treatment for cancers in liver. It is the first drug candidate that DBP has developed using it's first-in-class paradigm-shifting technology BeloGal® which provides direct targeting of a drug into the selected organ, which in case of SA033 means targeting doxorubicin directly to the liver.

Doxorubicin is one of the most well known and proven anticancer drugs and it is the

ADDRESS
Rapsgatan 7,
Uppsala Business Park
SWEDEN

WEBSITE
www.doublebp.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2014

active pharmaceutical ingredient used in the SA033 formulation. Doxorubicin is packed into a BeloGal® technology-based carrier and programmed to be delivered to the liver. After a simple intravenous administration and a safe transport of the formulation to its organ of destination, doxorubicin is released and provides its strong local therapeutic action without harming healthy organs.

Treatment with SA033 is therefore designed to significantly increase the success of liver cancer treatment and dramatically reduce systemic (whole body) side effects of chemotherapy. SA033 is a new generation of anticancer drugs.

Double Bond Pharmaceutical AB (DBP) has been granted Orphan Drug Designation for SA-033 by the European Medicines Agency for the treatment of hepatoblastoma (HB), which is a primary malignant liver tumour and the most common type of liver cancer that affects children. The aetiology of HB is unknown but it is found in greater incidence in children with low birth weight, and has also been associated with Beckwith-Wiedemann syndrome and familial adenomatous polyposis. Five-year survival is about 63% after diagnosis of HB and there is therefore an urgent need for more effective and safer therapy for these children. Orphan Drug Designation for SA033 obtained by DBP for treatment of HB gives ten years of market exclusivity for the indication and various kinds of support from EMA to further facilitate and accelerate the development of the product. DBP is planning to start a Phase I trial of SA-033 in 2017 in patients suffering from hepatocellular carcinoma – the most common type of primary liver cancer in adults.

INVESTMENT & LICENSING OPPORTUNITY 1: Out-licencing (partnering) of Temodex

DESCRIPTION

DBP is looking for potential partner for coming pivotal clinical trials phase II (EMA Orphan Drug status granted 2016) of Temodex. Investment needed: $10m

INVESTMENT & LICENSING OPPORTUNITY 2: Out-licencing (partnering) of SA-033

DESCRIPTION

DBP is looking for potential partner for coming pivotal clinical trials phase I/II (EMA Orphan Drug status granted 2015) of SA-033. Investment needed: $10m

EDINBURGH MOLECULAR IMAGING LTD.

Edinburgh Molecular Imaging is an Edinburgh BioQuarter spin-out company from the University of Edinburgh, developing an Optical Molecular Imaging technology that can help diagnose and monitor of several major diseases. The company's innovative technology revolves around the development of fluorescent imaging reagents that detect harmful processes deep inside the human body, at the bedside, in real time and at molecular resolution. The company is initially focusing on lung conditions, but the technology is applicable to a wide range of diseases.

ADDRESS
Nine Edinburgh BioQuarter
9 Little France Road
Edinburgh
United Kingdom

EMAIL
info@edinimage.com

WEBSITE
www.edinimage.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

ADDRESS
Industriestrasse 9
6300 Zug
Switzerland

TELEPHONE
+ 41 79 771 25 35

WEBSITE
www.elthera.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2016

ELTHERA AG

Elthera AG is a Swiss biopharmaceutical start-up company bringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs using a personalized health care approach.

Elthera is developing antibodies against a novel target whose expression is strongly correlated with an agressive tumor phenotype and poor prognosis in various types of cancer.

By combining targeted therapy with companion diagnostics, Elthera is aiming at providing new personalized treatment options for patients with the most agressive malignancies.

MANAGEMENT TEAM

Dr. Anne Schmidt, CEO

Dr. Jacques Gaudreault, COO

Dr. Gunther Spohn, CSO

Financial Summary

SEED, CHF2.8 MIO

Deliverable:Identification of clinical candidate (2017)

- generation of humanized, ADCC optimized lead compound
- confirmation of pre-clinical Proof-of-Concept in murine ovarian cancer model
- confirmation of safety in transgenic mouse model

SERIES A, CHF 12 MIO

Deliverable: Clinical candidate IND ready (2018/19)

- GLP toxicity in non-human primates (NHP)
- GMP material available
- bioanalytical assays developed (NHP assays validated)
- companion diagnostic developed and validated

SERIES B, CHF 32 MIO:

Deliverable: Clinical proof-of-concept (2020)

- conduct of first in human / phase 2a study in ovarian cancer and PDAC
- Proof-of-Concept in pancreatic and ovarian cance

EOS BIOSCIENCES, INC.

Eos Biosciences Inc. is a privately held Los Angeles-based Nanomedicines company founded in 2013. The Company has secured an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center (Los Angeles). The technology is based on generating self-assembling, nanobiologic particles (Eosomes) that entrap and encapsulate a chosen therapeutic and specifically deliver it to the interior of the target disease cell. Such specific targeting allows for improved efficacy and safety profiles of the therapeutic payload.

MANAGEMENT TEAM

Omar Haffar, Ph.D., Founder President & CEO

Thomas Plotts, MBA, CFO

Pipeline Product 1: Name/Stage

Eso-001: Preclinical

Eos-002: Preclinical

Eos-003: Validation

Eos-004: Validation

ADDRESS
1999 Avenue of the Stars,
Suite 1100
Los Angeles, CA 90067
USA

TELEPHONE
+1 (424) 253-1186

WEBSITE
www.eosbiosciences.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug Delivery

YEAR FOUNDED
2013

ADDRESS
Galileilaan 19
2845 Niel
Belgium

TELEPHONE
+ 32 3 369 17 40

WEBSITE
www.etherna.be

COMPANY TYPE
Private

COMPANY TICKER
Not applicable

SECTOR
Biotechnology
CMO

YEAR FOUNDED
2016

eTheRNA IMMUNOTHERAPIES NV

eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA's proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient's immune system than any other similar approach investigated until now.

MANAGEMENT TEAM

The management team includes:

Dirk Reyn CEO

Dr Kajo Kallen Chief Medical Officer

Prof. Kris Thielemans Chief Scientific Officer

Alain Deloof Production Lead

Carlo Heirman Production Development Lead

Luc Lammens Finance Lead

Dirk Van Broekhoven General Counsel and Operations Lead

Marina Cools Clinical Lead

FINANCIAL SUMMARY

In addition to EUR 12 million of non-dilutive funding that was raised between 2013-2016, eTheRNA secured in March 2016 EUR 24 million in a Series A investment with a strong international syndicate of investors.

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

The TriMIx technology platforms offers different products depending on the added antigens added.

Trimix in combination with 4 melanoma specific or breast cancer specific TAA is currently in phase I/IIa development

DESCRIPTION

eTheRNA's TriMix contains three naked, injectable mRNA molecules (coding for natural-

ly occurring proteins called CD40L, CD70 and constitutive active TLR4) that together generate a safer and potent enhancement of the patient's own 'dendritic cell-mediated' immune response against cancer or microbial antigens. TriMix is unique in the way it uses these three mRNA molecules to circumvent some of the main obstacles faced by other immunotherapy concepts, but also because of its potential to induce a long-lasting immune response.

INVESTMENT & LICENSING OPPORTUNITY 1:

TriMix technology

ADDRESS
Galileilaan 19
2845 Niel
Belgium

TELEPHONE
+ 32 3 369 17 40

WEBSITE
www.etherna.be

COMPANY TYPE
Private

SECTOR
Biotechnology
CMO

YEAR FOUNDED
2016

ADDRESS
Ole Maaloesvej 3
2200 Copenhagen N,
Denmark

TELEPHONE
+ 45 31 26 26 15

WEBSITE
www.evaxion-biotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Bioinformatics

YEAR FOUNDED
2010

EVAXION BIOTECH

Evaxion Biotech aspires to become a world-leading immuno-informatics company with a novel platform technology for the discovery of vaccines within infectious diseases and immuno-oncology. Our proven business is highly scalable and we are seeking experienced investors to help us capture the large potential of our platform technology and the full value of the existing pipeline of vaccine assets.

1. Evaxion has a proven model for building a very attractive business based on our immuno-informatics technology which can capture a large share of the future infectious disease and immuno-oncology market.

2. We have proven our highly scalable approach to vaccine discovery and development using our immuno-informatic platforms EDEN for infectious diseases and PIONEER for immuno-oncology with a patented and validated portfolio of vaccine candidates.

3. Evaxion has built an early pipeline of best in class vaccines against infectious diseases

4. Our novel immuno-oncology platform PIONEER shows great promise in preclinical models and will help us solve key challenges in cancer neo-epitope discovery and development.

5. Our organization includes world-leading bioinformaticians and is a strong base on which to build risk reduced asset development, world-class core capabilities and shared values.

6. We offer an attractive time to invest relative to opportunities and value infliction points for early-stage investors.

MANAGEMENT TEAM

- Niels Moeller: MD, CEO and co-founder
- Andreas Mattsson: CSO and co-founder

FINANCIAL SUMMARY

Opening for series A fundraising in Q1 2017.

exscientia

ADDRESS
Lab 12 Dundee Incubator
James Lindsay Place
Dundee
DD1 5JJ
United Kingdom

TELEPHONE
+ 44 (0)1382 202136

WEBSITE
www.exscientia.co.uk

COMPANY TYPE
Private

SECTOR
Biotechnology

EX SCIENTIA LTD.

Exscientia develops small molecule candidates by applying advanced Artificial Intelligence (AI) systems that encode proven medicinal chemistry techniques. When seeded with appropriate experimental data these systems are faster and more reliable than human-led approaches. We have several commercial relationships, which include Sunovion, Evotec (Immuno-oncology) and Sumitomo Dainippon.

We apply our platform to three areas.

Single target discovery: Here we design well-balanced compounds with good selectivity in a highly productive manner.

Bispecific small molecules: Our methods can also design a small-molecule that will independently interact with two disease-relevant targets. Only exscientia technology can encode this design process.

Phenotypic drug design. We have successfully adapted our target-based approaches to design against phenotype, a situation where the targets are not fully known even though a positive phenotypic response can be observed through experiment.

FINANCIAL SUMMARY

Collaborations with major pharma. See press releases for Sunovion and Sumitomo Dainippon Pharma.

Other financial information at Companies House UK.

PIPELINE PRODUCT 1: NAME/STAGE

a2AR and CD73 for immuno-oncology : Bispecific and Single Target compounds. Discovery Stage

F2G
Advancing Antifungal R&D

ADDRESS
Lankro Way
Eccles
Manchester
M30 0LX
United Kigdom

TELEPHONE
+ 44 (0)161 785 1270

WEBSITE
www.f2g.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
1998

F2G LTD

F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity. These novel series form the basis of the F2G development pipeline.

MANAGEMENT TEAM

Ian Nicholson, Chief Executive Officer

GALENA BIOPHARMA

ADDRESS
2000 Crow Canyon Place,
Suite 380
San Ramon, CA
United Kigdom

TELEPHONE
+1 (925)-498-7700

WEBSITE
www.galenabiopharma.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2007

GALENA BIOPHARMA, INC.

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena's pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302.

MANAGEMENT TEAM

Dr. Mark W. Schwartz, Ph.D. - President & CEO

Dr. Bijan Nejadnik, M.D. - Executive VP, Chief Medical Officer

Ms. Remy Bernarda, IRC - SVP, Investor Relations & Corporate Communications

Mr. John Burns, CPA - VP, Finance & Corporate Controller

Mr. Tom Knapp, Esq. -Interim General

Mr. Joe Lasaga -VP, Business Development & Alliance Management

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

GALE-401 (Anagrelide Controlled Release)

Phase 3 initiation expected in Q2,2017

DESCRIPTION

GALE-401 contains the active ingredient anagrelide. The currently available immediate release formulation (Agrylin® or anagrelide IR) is approved by the FDA for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Adverse events associated with anagrelide IR, such as nausea, diarrhea, abdominal pain, palpitations, tachycardia, and headache, may be dose and plasma concentration dependent. Reducing the maximum plasma concentration (Cmax) is expected to reduce side effects, but preserve efficacy. GALE-401 is a reformulated, controlled release version of anagrelide. A Phase 2 pilot study with GALE-401 has been completed.

PIPELINE PRODUCT 2:

NeuVax™ (nelipepimut-S)

GALENA BIOPHARMA

ADDRESS
2000 Crow Canyon Place,
Suite 380
San Ramon, CA
United Kigdom

TELEPHONE
+1 (925)-498-7700

WEBSITE
www.galenabiopharma.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2007

Two breast cancer studies ongoing in combination with trastuzumab (Herceptin®; Genentech/Roche):

Phase 2b trial in node positive and triple negative HER2 IHC 1+/2+ (clinicaltrials.gov identifier: NCT01570036);

Phase 2 trial in high risk, node positive or negative HER2 IHC 3+ patients (clinicaltrials.gov identifier: NCT02297698).

Phase 2 clinical trials with NeuVax are also planned in patients with ductal carcinoma in situ (DCIS), and in patients with gastric cancer.

DESCRIPTION

NeuVax™ (nelipepimut-S) is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. It is the immunodominant peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to specific HLA molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut-S immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. In clinical studies, NeuVax is combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF).

PIPELINE PRODUCT 3:

GALE-301 and GALE-302

GALE-301 Phase 2a portion of the Phase 1/2a clinical trial is ongoing in ovarian and endometrial adenocarcinomas (ClinicalTrials.gov Identifier: NCT01580696);

GALE-301 plus GALE-302 Phase 1b clinical trial is ongoing in breast and ovarian cancers (ClinicalTrials.gov Identifier: NCT02019524).

DESCRIPTION

GALE-301 and GALE-302 are cancer immunotherapies that consist of a peptide derived from Folate Binding Protein (FBP) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in the adjuvant setting. GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as E39'. FBP is a well-validated therapeutic target that is highly over-expressed in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing cancer cells.

INVESTMENT & LICENSING OPPORTUNITY 1:

GALE-401

DESCRIPTION

Available for investment, licensing, clinical collaborations

Investment & Licensing (In/Out) Opportunity 2: Name

NeuVax

GALENA BIOPHARMA

ADDRESS
2000 Crow Canyon Place,
Suite 380
San Ramon, CA
United Kigdom

TELEPHONE
+1 (925)-498-7700

WEBSITE
www.galenabiopharma.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2007

DESCRIPTION

Available for investment, licensing, clinical collaborations
Investment & Licensing (In/Out) Opportunity 3: Name
GALE-301 and GALE-302

DESCRIPTION

Available for investment, licensing, clinical collaborations

ADDRESS
Centre Pierre Potier
1 place Pierre Potier
ONCOPOLE entrée B
BP 50624 - 31106
Toulouse
France

TELEPHONE
+ 33 (0)5 31 61 60 69

WEBSITE
www.gamamabs.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2013

GAMAMABS PHARMA SA

GamaMabs Pharma is a clinical-stage biotech who develops innovative monoclonal antibodies in cancer. GamaMabs' lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in gynecological cancer. The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells.

Gamamabs is also developing an Antibody-Drug conjugate targeting AMHRII.

The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

MANAGEMENT TEAM

Stéphane Degove – CEO (co-founder)

Stéphane has more than 20 years' experience in Biotech/Pharma and Strategy. Graduated from ESCP (majoring in Finance), he worked at Sanofi in Finance and was co- founder and CFO of a biotechnology company in cancer and thrombosis, Endotis Pharma.

JEAN-FRANÇOIS PROST, MD – VP R&D AND STRATEGY

Jean-François is a Senior Executive of the European pharmaceutical industry. Physician specialist in Internal Medicine, Dr. Prost has an experience of 30 years in the industry, having served as Cardiovascular Development Director then Research Director at Servier, R&D Director at Pierre Fabre Medicament and then UCB Pharma, and finally in the last ten years, Scientific and Medical VP at LFB. He discovered, developed and/or registered in Europe/US Protelos, Procoralan, Artex, Valdoxan, Ixel, Keppra and Wilfact. Under his leadership LFB has discovered and developed Emabling with 2 mAbs currently starting their Phase III.

FINANCIAL SUMMARY

- Raised 3,6M€ in a series-A in 2013
- Raised €15m in a series-B in 2015

PIPELINE PRODUCT 1:

GM102 - phase Ia/Ib

DESCRIPTION

GM102 is a first-in-class monoclonal antibody directed against the receptor of the anti-Müllerian hormone (AMHRII / MISRII).

GM102 is a glyco-engineered mAb which unlocks tumor-associated immune effector cells, increasing their ability to destroy tumor. Ovarian cancer is a clinical setting well-suited for GM102, as these effector cells are dominant in patients' samples. In particular GM102 has the ability to re-activate inactive Tumor-Associated Macrophages, which are largely present in ovarian tumors and are associated with bad prognosis.

GM102 displays a high efficacy in multiple relevant patho-mimetic in vivo models. This efficacy is also shown to be synergistic with carboplatin (CT) and paclitaxel (PT), the first lines chemotherapeutic agents, translating into outstanding improvement in Complete Response (CR) and survival in PDX models.

GM102 is phase Ia/Ib stage in France and Belgium.

ADDRESS
Centre Pierre Potier
1 place Pierre Potier
ONCOPOLE entrée B
BP 50624 - 31106
Toulouse
France

TELEPHONE
33 (0)5 31 61 60 69

WEBSITE
www.gamamabs.com

COMPANY TYPE
Private

SECTOR
Biotechnology

PIPELINE PRODUCT 2:

GM103 - preclinicals

DESCRIPTION

GM103 is a AMHRII-targeting ADC with documented efficacy in in vivo models.

PIPELINE PRODUCT 3:

9F7 - mAb targeting HER3 - preclinical stage

DESCRIPTION

9F7 is a HER3-targeting mAb whose activity (thanks to an innovative allosteric binding) is enhanced by the HER3 ligand neuregulin (NRG).

Available results demonstrate the outstanding efficacy of 9F7 in NRG-positive in vivo models, and suggest that 9F7 mAb has the potential to be best-in-class anti HER3 antibodies in neuregulin-positive patients

INVESTMENT & LICENSING OPPORTUNITY 1:

co-development on GM103

DESCRIPTION

Gamamabs wishes to co-develop GM103 with an actor with leading ADC capabilities.

ADDRESS
18, chemin des Aulx
CH-1228 Plan-les-Ouates
Geneva,
Switzerland

TELEPHONE
+ 41 22 794 50 85

WEBSITE
www.geneuro.com

COMPANY TYPE
Listed

COMPANY TICKER
Euronext Paris - GNRO

SECTOR
Biotechnology

YEAR FOUNDED
2006

GENEURO SA

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA; a new frontier pioneered by GeNeuro since 2006 and based on research by Institut Mérieux and INSERM.

GeNeuro's lead product, GNbAC1, is designed to neutralize MSRV-Env, a protein that has been shown to have both a pro-inflammatory action as well as the ability to stop the differentiation of the cells responsible for remyelinating brain lesions. By neutralizing MSRV-ENV, GNbAC1 could block a key factor promoting the inflammation on the plaques, as well as allowing the remyelination repair process to restart. Existing therapies for MS target the immune system of the patient to dampen the severity of the immune-mediated attack, while GNbAC1 seeks to neutralize a potential primary cause of this autoimmune disorder.

MANAGEMENT TEAM

Jesús Martin-Garcia, Chief Executive Officer
Dr. François Curtin, MD, MPhil, MBA, Chief Operating Officer
Dr. Hervé Perron, HDR, Chief Scientific Officer
Prof. Dr. Alois B. Lang, Chief Development Officer
Miguel Payró, Chief Financial Officer
Robert Glanzman, Chief Medical Officer

ADDRESS
Via Albert Einstein 8,
48018 Faenza
Italy

WEBSITE
www.greenbone.it

COMPANY TYPE
Private

SECTOR
Biotechnology
Medical Devices
Regenerative Medicine

YEAR FOUNDED
2014

GREENBONE ORTHO SRL

GreenBone Ortho srl (taly) develops a patented Rattan-derived (a Bamboo related tree), bone regenerative implant for extensive bone damages (medical device). GreenBone biomimetic scaffold is engineered to reflect anatomical and physiological hierarchical structures. GreenBone is obtained from chemical-physical transformation of Rattan wood because of its channel-like porosity very closed to human bone. GreenBone has unique properties needed in non-load and load-bearing bones such as pseudoarthrosis and non-unions fractures, spinal damages, trauma and cancer induced bone loss. Reduction of healthcare costs expected. Scaled up manufacturing completed. Sheep study under completion with excellent interim results performed at Assaf Harofeh Medical Center, Tzrifin Israel in collaboration with Rizzoli Orthopedic Institute Italy. Clinical study planned in 2017 in patients with critical size fractures from trauma in load bearing bones. Follower products development for spinal application in 2017. GreenBone can be also functionalized/loaded to reduce bacteria attachment/growth and deliver therapeutics for specific uses. Orthopedic Biomaterials market forecasted $11,2 billion by 2018 (CAGR 10.78%). GreenBone use in different skeletal applications can reach > $600M. Seed Round of $3,5M successfully closed in 2015. GreenBone management has advanced multiple products from bench-to-market. GreenBone is a TEDxBinnenhof 2016 top 10 best 'Ideas from Europe' (March 31, The Hague https://www.youtube.com/watch?v=fCuB7ymTLHE).

MANAGEMENT TEAM

Dr. Lorenzo Pradella Co-Founder and CEO

Dr. Anna Tampieri Chief Scientist

Ing. Elena Venturelli Head regulatory and Quality

Prof. Marcacci (Rizzoli Orthopedic Institute) Senior Clinical Advisor

HEPTARES therapeutics

ADDRESS
BioPark,
Broadwater Road,
Welwyn Garden City,
Hertfordshire,
AL7 3AX
United Kingdom

TELEPHONE
+ 44 (0)1707 358 628

WEBSITE
www.heptares.com

COMPANY TYPE
Other

SECTOR
Biotechnology

YEAR FOUNDED
2007

HEPTARES THERAPEUTICS

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Kymab, MorphoSys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

MANAGEMENT TEAM

- Malcolm Weir - CEO, Chairman & Co-Founder
- Fiona Marshall - CSO & Co-Founder
- Tim Tasker - CMO & VP Development
- Barry Kenny - CBO
- Miles Congreve - VP Chemistry
- Ali Jazayeri - CTO

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

Selective muscarinic M1, M4 and dual M1/M4 receptor agonists

DESCRIPTION

Portfolio of first-in-class selective muscarinic receptor agonists in clinical and preclinical development as treatments for cognitive impairment and psychoses in Alzheimer's disease and other neurological disorders.

Partnered with Allergan

HEPTARES therapeutics

ADDRESS
BioPark,
Broadwater Road,
Welwyn Garden City,
Hertfordshire,
AL7 3AX
United Kigdom

TELEPHONE
+ 44 (0)1707 358 628

WEBSITE
www.heptares.com

COMPANY TYPE
Other

SECTOR
Biotechnology

YEAR FOUNDED
2007

PIPELINE PRODUCT 2:

Adenosine A2A receptor antagonists

DESCRIPTION

Novel, small molecule adenosine A2A antagonist (HTL1071/AZD4635) in clinical development as novel immune-oncology candidate, with additional compounds in preclinical development

Partnered with AstraZeneca

PIPELINE PRODUCT 3:

CGRP antagonists

DESCRIPTION

Novel, small molecule CGRP antagonists in preclinical development for the treatment of migraine

Partnered with Teva

INVESTMENT & LICENSING OPPORTUNITY 1:

MGlu5 negative allosteric modulators

DESCRIPTION

Potential best-in-class small molecule negative allosteric modulators (NAMs) in early development with potential to treat neurological and psychiatric disorders

INVESTMENT & LICENSING OPPORTUNITY 2:

Orexin OX1 antagonist

DESCRIPTION

First selective orexin OX1 receptor antagonist in preclinical development for the treatment of cocaine addiction and with potential broad applications in substance addictions (nicotine, alcohol) and compulsive disorders (binge eating, gambling)

INVESTMENT & LICENSING OPPORTUNITY 3:

Orexin OX2 agonists

DESCRIPTION

Orally active small molecule orexin OX2 agonists for the treatment of narcolepsy and other sleep disorders caused by diminishing orexin levels.

ADDRESS
14 rue des
Reculettes, 75013
Paris
France

WEBSITE
www.iltoopharma.fr

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2012

ILTOO PHARMA

ILTOO Pharma is a privately-owned, clinical stage (phase 2), biotech company based on a breakthrough discovery in the fields of immunology (Pr. D. Klatzmann, MD, PhD - La Pitié-Salpêtrière hospital, Paris, France). The company is dedicated to the development of biotherapies for the treatment of autoimmune diseases and inflammatory disorders (ADs). The lead project of the company is the development of low dose of human recombinant interleukin-2 (ILT-101) for the treatment of systemic lupus erythematous (SLE) and recently diagnosed type-1 diabetes (T1D). Beyond SLE and T1D, ILT-101 offers the unique opportunity to address a large therapeutic scope amongst ADs.

PIPELINE PRODUCT 1:

ILT-101/Phase 2

DESCRIPTION

Low dose interleukin-2 for the treatment of SLE and T1D

Scientific background:

The discovery of regulatory T cells (Tregs) has been a breakthrough discovery in immunology. It revolutionized the understanding of ADs pathophysiology and paved the way for developing Treg-based therapies. Since Tregs downregulate auto-immune and pro-inflammatory responses and contribute to the induction of tolerance, they play a major role in the control of ADs: 1. Human and mice presenting genetically-induced Treg deficit develop multiple organ-specific ADs; 2. Treg quantitative or qualitative deficit has been described in SLE, T1D, MS, Crohn and Ulcerative Colitis; 3. Addition/restoration of Tregs induces clinical improvements in animal models of ADs and in several clinical studies.

ILT-101:

ILT-101 is a human recombinant interleukin-2 intended to the treatment of autoimmune and inflammatory diseases (ADs) that are all characterized by altered balance of activity between effector (Teffs) and regulatory CD4+ T cells (Tregs). In this context, ILT-101 is of high therapeutic value. It stimulates not only the activation and proliferation of Tregs without affecting activation/proliferation of Teffs but also inhibits the differentiation of T follicular helper (Tfh) and pro-inflammatory Th17 cells. It thus corrects the Treg/Teff imbalance and reinstates immune homeostasis by participating to a regulatory milieu.

Results:

ILT-101 development is supported by numerous nonclinical and clinical efficacy studies. Low dose IL-2 has been evaluated and shown beneficial in more than 20 different animal models including SLE, T1D and EAE. Furthermore, several clinical studies have already brought indications of efficacy in SLE, T1D, GvHD, Vasculitis...

INVESTMENT & LICENSING OPPORTUNITY 1:

ILT-101

DESCRIPTION

Seeking for large biotech / pharma partner for outlicensing ILT-101

INVESTMENT & LICENSING OPPORTUNITY 2:

Technology to deliver biologics by the non injectable route

DESCRIPTION

Seeking for collaboration / in-licensing opportunities regarding delivery of therapeutic proteins via the non injectable route

MR JÉRÉMIE MARIAU, CEO

ADDRESS
GIGA B34
Avenue de l'Hôpital, 1
4000 Sart Tilman
Belgium

WEBSITE
www.imcyse.com/en

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

IMCYSE

IImcyse mission is to develop novel, disease specific immune therapies to cure and to prevent severe, chronic auto immune, inflammatory, infectious, allergic diseases and solid tumors.

KEY INVESTMENT DIFFERENTIATORS:

- Disruptive technology
- Potential of major impact on world health and healthcare
- Numerous indications with demonstrated proof of principle in relevant models
- Huge market opportunities
- Science and differentiation to date well received by prospective major biopharma partners

PEOPLE AND COMPANY: WWW.IMCYSE.COM

- Experienced development team with virtually-integrated clinical and CMC supply chains
- Immunology expertise with peptides and vaccine focus – 22 Drug Discovery FTEs – majority PhDs
- Established Belgian biotech – spun-out 2010 from Catholic University of Leuven (KUL)
- Robust international intellectual property position
- Total funding to-date: 16M€, 40% Public, 40% Private, 20% Partners

Platform: – Next-Generation Active Immuno-Therapeutics

- Proprietary antigenic peptides recognised by CD4+ T-cells
- These peptides induce antigen-specific Cytolytic CD4+ T-cells
- Rapid and long-lasting efficacy heralds potential for cure AND prevention
- Potential for regeneration of cells of the target organs (e.g. pancreas in T1D or myelin in MS) and restoration of normal function
- No impact on other immune system functions and no tolerance generated

Programs and Status:

- Preclinical Proof-of-Concept completed in multiple disease-specific models: type 1 diabetes, multiple sclerosis, myasthenia gravis, prevention of graft rejection, allergies, prevention of immune response to viral vectors
- First in man safety and immune responses trial planned in patients with early-T1D and in patients with MS in H1 2017

INVESTMENT OPPORTUNITY :

- Allocation of funds : conduct of 2 Phase I/II Clinical trials in T1D and MS and continue research programs, up to end 2018.
- Planned capital increase, series B : 30 Million €,

o Tranche 1 : 10M€ Q4 2016

o Tranche 2 : 20M€ H1 2017

- Minimum ticket : 2.5M€
- Investment horizon : minimum 3 years

ADDRESS
GIGA B34
Avenue de l'Hôpital, 1
4000 Sart Tilman
Belgium

WEBSITE
www.imcyse.com/en

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

MANAGEMENT TEAM

Pierre Vandepapeliere, MD, PhD, CEO & CMO

Jean Smal, Bioengineer, PhD, VP head development, former VP Global Head of technical development at GSK Vaccines and former CEO of Eurogenetecs

Marcelle Van Mechelen, PhD, Sr Scientific Advisor, expert immunologist; previously VP Head Immunology Research at GSK Vaccines

Thibault Cloostermans, Financial advisor, Partner DC Corporate Finance, 12 years of relevant experience in the field of M&A and financial advisory

With a management team including a Corporate Services Director, an IP Director, very experienced Project manager and Clinical PM, Two senior scientists working since 20 years on the technology

ADDRESS
JLABS at Texas Medical Center
2450 Holcombe Blvd,
Houston, TX 77021
USA

TELEPHONE
+ 1 919 616 1923

WEBSITE
www.immunomet.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2016

IMMUNOMET THERAPEUTICS, INC.

ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. With our devotion to research and development, we aim to bring multiple metabolic regulators that can be combined with and enhance the current standard-of-care or new therapies to control cancer recurrence.

ADDRESS
Route de l'Ile-au-Bois 1A
1870 Monthey
Switzerland

WEBSITE
www.inflamalps.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2012

INFLAMALPS SA

Inflamalps' mission is to discover and develop novel medicines to treat inflammatory diseases of the eye. Inflamalps has one molecule, INF101, in-preclinical development for the topical treatment of Sjogren's associated dry eye syndrome and intra-vitreal treatment of posterior uveitis. INF101 by modulating the RoRgamma activity inhibits the production of IL-17 and INFg and was shown to be active in an animal model of acute dry eye following eye drop administration with an efficacy comparable to cyclosporine the gold standard therapy in this indication. In addition, it was shown to effectively prevent the retinal damage induced in a model of uveitis in rats in vivo with an efficacy similar to corticosteroids. INF101, on the opposite of corticosteroids, is not expected to increase intra-ocular pressure and could thus become the front line therapy in dry eye and uveitis. Inflamalps has also discovered new patentable derivatives of INF101 with interesting differentiated properties and a mechanism of action possibly involving the RoRg system. Inflamalps' executive management team comprises experienced pharmaceutical industry and biotechnology company managers with significant track record in drug development, management and financing.

MANAGEMENT TEAM

Dr. Vincent Mutel, CEO, co-founder and member of the BoD, was co-founder, CEO and vice chairman of the board of Addex Pharmaceuticals Ltd, a well-established public Swiss biotech, and prior was Research Area Head in the CNS division at the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd where he worked for 13 years. Vincent is a biochemist and pharmacologist by training and has initiated and successfully driven several R&D projects bringing molecules from discovery to advanced clinical trial. In his role at Addex Pharmaceuticals Ltd he led the growth of the organization to up to 140 staff, completed three rounds of venture financing, an IPO and a PIPE, totaling CHF263 million, and signed three major drug development partnerships, two with Merck & Co., Inc. and one with Ortho-McNeil-Janssen Pharmaceuticals Inc., a Johnson & Johnson company, representing more than CHF45 million in realized revenues.

Dr. Andrea Cesura, CSO, is a pharmacologist with more than 25 years of experience in research and drug development in Pharmaceutical and Biotech companies with a track record of several compounds which entered clinical development. Andrea has previously held positions as SVP Preclinical Research at Evotec, where he was responsible for building and advancing the company proprietary CNS R&D pipeline, Associate Director at Serono and Senior Scientist at Hoffmann-La Roche. Andrea has initiated and led a number of projects in inflammatory disorders. These include a program currently under clinical investigation addressing a specific neuroinflammatory component of Alzheimer's disease pathogenesis and a project targeting a specific protein involved in the activation of a subset of T-cells involved in the pathogenesis of multiple sclerosis and type-1 diabetes.

Dr. Eduard Vidovic, CMO, is a medical doctor with 10 years of practicing clinical experience and over 15 years of clinical research and development experience focusing on chronic inflammatory diseases, having held medical leadership roles in global Pharmaceutical and Biotech companies such as Synthelabo Pharma, Sanofi-Aventis and more recently Creabilis SA. His industrial experience spans over early to late stage development and medical affairs. As a CMO of Creabilis he was leading the development of several dermatology drugs in Atopic Dermatitis, Psoriasis, and chronic Pruritus. With significant operating and team leadership experience from organizations with diverse cultures and operating environments he was dealing with the FDA and regulatory authorities in Europe, successfully bringing drug candidates through the different phase of development process. Dr Vidovic received his medical degree from Zagreb University and his Ph.D. from the University of Geneva. He also holds a specialist FMH degree in Pharmaceutical Medicine. Earlier in his career Dr Vidovic was a Senior House Officer at the University Cantonal Hospital in Geneva and a Consultant at La Tour Hospital, Switzerland.

INFLAMALPS

ADDRESS
Route de l'Ile-au-Bois 1A
1870 Monthey
Switzerland

WEBSITE
www.inflamalps.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2012

Dr. Cyril Portmann, Head of Chemistry, is an expert in Natural Product Chemistry holding a Ph.D. from EPFL in Lausanne and Post-Doctoral training at Harvard Medical School in Boston. During his career, Dr. Portmann acquired several years of experience in the area of discovery of new bioactive small molecules from natural origins for different indications like malaria and cancer. Dr. Portmann has published 13 scientific peer-reviewed publications in journal such as PNAS.

FINANCIAL SUMMARY

Inflamalps completed a seed/series A round of financing in summer 2015, raising CHF1.85 million from VC and private investors.

PIPELINE PRODUCT 1:

INF101 for the treatment of Sjogren's associated dry eye and posterior uveitis is in pre-clinical development

DESCRIPTION

INF101 is a small molecule inhibiting the release of IL-17 from Th17 cells probably through the inhibition of RoRgamma activity. In PK experiments in rabbit, it showed a large exposure in cornea and conjunctiva following its eye-drop application in a cyclodextrin-based formulation and very little exposure in the blood if any. Cornea is the target of choice of drugs for the treatment of Sjogren's associated dry-eye but due to the high exposure in conjunctiva it is possible that INF101 may directly prevent the Th17 infiltration of lacrimal gland which is at the origin of the dry eye syndrome in this disease. In addition Inflamalps has developed a micro-crystal based formulation that is suitable for intra-vitreal application for the treatment of posterior uveitis another orphan disease for which few treatment alternatives are available.

Targeted vaccines for life

ADDRESS
Genopole Entreprises - CAMPUS 3
4 rue Pierre Fontaine
91058 EVRY CEDEX
France

TELEPHONE
+ 33 (0)1 80 85 60 83

WEBSITE
www.innavirvax.fr

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2008

INNAVIRVAX SA

InnaVirVax is a clinical stage French privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/ prevention and prognostic of AIDS and HIV infection.

The most advanced project is currently in phase 2a and is named VAC-3S. VAC-3S should become a new paradigm of therapeutic intervention in human immunodeficiency virus (HIV)-infected patients, namely remission or "functional cure", leading to a better quality of life, patient experience and potentially improved life expectancy. It has a blockbuster potential.

MANAGEMENT TEAM

• Joël Crouzet, CEO, 20 years of strong experiences in drug development and R&D in pharmaceutical & Biotechnology companies (Genetica, Rhône-Poulenc Rorer, AP Cells & Neurotech), 4 years as a General Manager of Inserm Transfert. Joël holds a MS in life sciences and a PhD from AgroParisTech (Paris).

• Dr Stephen Becker, CMO, Stephen Becker, MD has been involved in HIV and AIDS clinical care, research and product development for more than 30 years. He was a faculty member at the University of California, San Francisco from 1980 through 2005. He then transitioned to biotechnology, Koronis Pharmaceuticals and AnorMed, where he served as Chief Medical Officer. He spent six years at the Bill & Melinda Gates foundation, where he played a critical role in advancing HIV prevention and treatment technologies.

• Delphine Lucas (Regulatory Affairs, Quality Assurance and Project Management Director), Pharm D, has a strong background in international development and registration of medicinal products, registering several MMAs and NDAs (Onxeo, Agouron/ Pfizer, Servier, Boehringer Ingelheim).

• Nathalie Baran, Finance & Operations Director, PhD, MBA, with 15 years in innovation and entrepreneurship arena as she has been involved in setting up 25 new ventures at the biopark Genopole and worked for the French Innovation Agency (Bpifrance) and oversaw a portfolio of about 100 life sciences companies.

Moreover, the management is working with highly experienced consultants in the various operational segments of InnaVirVax activities, particularly Business Development. An international Clinical Advisory Board composed of influential key opinion leaders is instrumental VAC-3S development.

FINANCIAL SUMMARY

Since 2008, InnaVirVax has quickly developed the VAC-3S project from the bench up to phase II clinical stage and has assets at the non-clinical proof of concept stage.

In order to pursue its development, InnaVirVax needs to achieve a clinical proof of efficacy of VAC-3S and is raising fund for this purpose. This will be a major increase of the company value.

PIPELINE PRODUCT 1:

VAC-3S

Phase 2a

DESCRIPTION

The standard of care for HIV infection is combined anti-retroviral therapy (cART) with a growing market ot $ 16 B. It allows the control of the infection. However, it is a life-long therapy and long term toxicities are associated to cART. Functional cure is a new therapeutic paradigm that will allow patients to control the infection without the use of cART. It will definitely bring an improved quality of life to patients. The HIV functional cure market has a large potential (i.e. it should capture a significant part of the antiretroviral market).

Targeted vaccines for life

ADDRESS
Genopole Entreprises - CAMPUS 3
4 rue Pierre Fontaine
91058 EVRY CEDEX
France

TELEPHONE
+ 33 (0)1 80 85 60 83

WEBSITE
www.innavirvax.fr

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2008

VAC-3S is an immunotherapy and has been administered to more than 100 HIV-infected patients, showing it is safe and well tolerated; most importantly significant effects on three immune restoration markers were observed in phase 1/2a clinical trials; moreover, a significant decrease of the HIV viral reservoir was obtained. The control / elimination of the HIV reservoir is central to functional cure strategies. The VAC-3S outstanding clinical results are totally consistent with the immune restoration properties of VAC-3S and the forecasted use in functional cure, positioning InnaVirVax as a leader in the development of an HIV functional indication.

InnaVirVax is planning to run proof of efficacy studies in the coming 2 years. This would lead to an industrial transaction.

PIPELINE PRODUCT 2:

VAC02

Research

DESCRIPTION

VAC02 is an HIV vaccine that could be used both for prophylactic and for therapeutic purposes. A proof of concept has alrealdy been obtained in animal studies. It is curently at the research level. It is planned to enter preclinical development in a year.

INVESTMENT & LICENSING OPPORTUNITY 1:

Investment opportunity

DESCRIPTION

InnaVirVax is planning to run clinical proof of efficacy studies on VAC-3S for a functional cure indication. This should result in an industrial transaction with one of the leader in HIV therapy.

It is raising fund for to achieve this goal (clinical proof of efficacy and subsequent industrial transaction). This important milestones would definitely increase the value of InnaVirVax.

IO BIOTECH APS

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint cancer vaccines. Checkpoint cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

ADDRESS
IO Biotech ApS
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark

TELEPHONE
+ 45 21 94 78 56

WEBSITE
www.iobiotech.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

ADDRESS
Lytix Biopharma AS
P.O. Box 6447,
NO-9294 Tromsø
Norway

EMAIL
post@lytixbiopharma.com

WEBSITE
www.lytixbiopharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology

LYTIX BIOPHARMA AS

Lytix Biopharma is a private R&D company focused on cancer and immunotherapy.

The company's technology has a broad potential with a robust IP position - broad patent portfolio with cover until 2035

The lead project LTX-315 - a first in class oncolytic peptide immunotherapy

- targets mitochondria in the tumorcell and induces a potent stimulation and a significant increase of tumor infiltrating cytotoxic T cells and systemic T cell clonality, which may explain why LTX-315 acts could be an ideal combination partner to immune checkpoint inhibitors (ICIs) - potential to augment efficacy without adding significant toxicity

Potential for multiple, high value indications, plans include combination trial with ICI in in breast cancer and melanoma

PRE-CLINICAL AND CLINICAL DATA

- strong pre-clinical anti-cancer activity and confirmed synergies with ICIs.
- emerging clinical evidence of anti-tumor and immune effects in phase I monotherapy

Company will raise capital Q4 2016

MANAGEMENT TEAM

Håkan Wickholm, CEO
Oystein Rekdal, CSO (founder)
Andrew Saunders, CMO
Wenche Marie Olsen, COO
Kjetil Vangsnes, CFO

PIPILINE

LTX-315, Ph I/II, an oncolytic peptide cancer immunotherapy

MDxHealth

ADDRESS
15279 Alton Parkway
Suite 100
Irvine, CA 92618
USA

TELEPHONE
+ 1 949 812 6979

WEBSITE
www.mdxhealth.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2003

MDXHEALTH

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.

MANAGEMENT TEAM

- Mr Christopher Thibodeau, Executive VP and CCO
- Mr Joseph Sollee, Executive VP of Corporate Development and General Counsel
- Mr Francis Ota, Executive VP of Finance
- Ms Miriam Reyes, Sr VP of Laboratory Operations

FINANCIAL SUMMARY

Highlights

The number of tests sold for ConfirmMDx for Prostate Cancer continues to evolve in a positive direction, as the ConfirmMDx test is now included in the US National Comprehensive Cancer Network (NCCN) Clinical Guidelines which supports further clinical adoption and facilitates contract negotiations with new payors resulting in increased revenues. To date over 3,000 urologists have ordered ConfirmMDx in a clinical setting on more than 45,000 men at risk for prostate cancer. SelectMDx has been launched in both EU and US, with a pivotal prospective multicenter clinical study published in European Urology. Six payor contracts have been established

H1 2016 PERFORMANCE

• Revenue for the first half up 65% ($12.9M), up 32% sequentially

• Revenues from laboratory testing for ConfirmMDx, SelectMDx, and MGMT represent 83% of total revenue

• Gross Margin improving 68% due to revenue and laboratory automation, and 48% sequentially

• Net loss of ($7.6M) decreased by 15% sequentially

• $20M in cash and cash equivalents

ADDRESS
L'Orée des mas
Avenue du golf
34670 Baillargues
France

TELEPHONE
+ 33 4 67 03 03 96

WEBSITE
www.medesispharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug Delivery
Pharmaceuticals/Licensing

YEAR FOUNDED
2004

MEDESIS PHARMA SA

Medesis Pharma is a Franco-Canadian clinical stage pharmaceutical company specialising in CNS disorders.

Medesis Pharma's lead product, NP03, is being developed for the treatment of psychiatric disorders associated with Alzheimer's and Huntington's diseases.

NP03 has completed phase I clinical trials and is ready to enter into two phase II trials.

NP03 has an orphan drug designation for the treatment of Huntington's disease.

Medesis Pharma is looking to close a financing round of $20m in order to further development of NP03 in these two indications.

MANAGEMENT TEAM

Jean-Claude Maurel MD - President and CEO

Christophe Campos - Vice President and CFO

Patrick Maurel PhD - Vice President and CSO

Assad Singaby - Vice President Corporate Development and Investor Relations

FINANCIAL SUMMARY

Financing Round of $20m open with lead investor secured pending syndication.

PIPELINE PRODUCT 1:

NP03: Phase IIa for the treatment of psychosis associated with Alzheimer's disease

DESCRIPTION

NP03 is based upon the combination of lithium citrate and a novel drug delivery technology. The delivery technology employs a Trojan horse mechanism involving endogenous high density lipoproteins, enabling highly efficient penetration into neurons.

Although lithium is well known as the gold standard for bipolar disorders, extensive research has uncovered strong evidence for the neuroprotective properties of lithium opening up new avenues in the use of lithium in neurodegenerative disorders. Unfortunately, the side effect profiles of standard lithium formulations are too severe to allow lithium to be used as a chronic treatment in neurodegenerative diseases.

The unique mechanism of drug delivery via HDL allows for a significant decrease in the administered doses of lithium providing a treatment for both the course of the disease (disease modifying) and symptoms (psychosis).

The phase II clinical trial will be lead by Profs Serge Gauthier and Jacques Touchon, both world expert's on Alzheimer's disease.

PIPELINE PRODUCT 2:

NP03: Phase II for the treatment of Huntington's disease.

DESCRIPTION

NP03 is based upon the combination of lithium citrate and a novel drug delivery technology. The delivery technology employs a Trojan horse mechanism involving endogenous high density lipoproteins, enabling highly efficient penetration into neurons.

Although lithium is well known as the gold standard for bipolar disorders, extensive research has uncovered strong evidence for the neuroprotective properties of lithium opening up new avenues in the use of lithium in neurodegenerative disorders. Unfortunately, the side effect profiles of standard lithium formulations are too severe to allow lithium to be used as a chronic treatment in neurodegenerative diseases.

The unique mechanism of drug delivery via HDL allows for a significant decrease in the administered doses of lithium providing a treatment for both the course of the disease (disease modifying) and symptoms (psychosis).

The phase II clinical trial will be lead by Prof Guy Rouleau (McGill Montreal).

ADDRESS
L'Orée des mas
Avenue du golf
34670 Baillargues
France

TELEPHONE
+ 33 4 67 03 03 96

WEBSITE
www.medesispharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Drug Delivery
Pharmaceuticals/Licensing

YEAR FOUNDED
2004

INVESTMENT & LICENSING OPPORTUNITY 1:

Participation in current financing round

DESCRIPTION

Financing Round of $20m open with lead investor secured pending syndication. Proceeds will be used to initiate and complete both phase II clinical studies.

MOLOGEN AG

ADDRESS
Fabeckstr. 30,
D- 14195 Berlin
Germany

TELEPHONE
+ 49 (0)30 84 17 88 0

WEBSITE
www.mologen.com

COMPANY TYPE
Listed

SECTOR
Biotechnology
Other Sector
Preclinical and clinical drug development in the areas of cancer and infectious diseases

YEAR FOUNDED
1998

MOLOGEN AG

BRIEF MGN PROFILE

With new and unique technologies and active substances, MOLOGEN is one of the pioneers in the field of immunotherapies. Company's product development helps combat some of the most threatening diseases. Apart from the main focus on oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases. The approach concentrates on drug candidates for which there is a high medical need.

MOLOGEN's strategy program "Next Level" includes a focus of the further development activities centered on the company's lead product and best-in-class TLR9 agonist.

Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mode of action, namely to reactivate the monitoring function of the immune system, lefitolimod (MGN1703) can be recognized as an Immune Surveillance Reactivator (ISR). It has the potential to be applied to various indications. The main focus of MOLOGEN's activities is on continuing the four clinical trials with lefitolimod (MGN1703): the IMPALA, IMPULSE and TEACH studies in the indications colorectal cancer, small-cell lung cancer and HIV, and a combination study which with the immunotherapy Yervoy® (ipilimumab) in patients with advanced solid tumors which started in July 2016. MOLOGEN will also continue to invest in the next-generation, still pre-clinical molecule EnanDIM®, also aimed at the indications cancer and infectious diseases. Therefore, MOLOGEN will be able to exploit the potential of TLR9 agonists' product group fully and to tap additional market potential.

MANAGEMENT TEAM

- Dr. Mariola Söhngen - Chief Executive Officer (CEO)
- Walter Miller - Chief Financial Officer (CFO)

FINANCIAL SUMMARY

Investment & Licensing (In/Out) Opportunity 1: Name

Partnering

OPPORTUNITY 1: DESCRIPTION

MOLOGEN is seeking lincense partners for co-development and marketing for lefitolimod (MGN1703) and its other R&D programmes

MYMETICS

ADDRESS
Route de la Corniche 4
CH-1066 Epalinges
Switzerland

TELEPHONE
+ 41 (0)21 653 45 35

WEBSITE
www.mymetics.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2000

MYMETICS

Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Respiratory Syncitial Virus (RSV) and Chikungunya. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB.

MANAGEMENT TEAM

R. Kempers, CEO and CFO

T. Stegmann, CSO R&D

S. Fleury, CSO

M. Amacker, Head Manufacturing and Quality

FINANCIAL SUMMARY

	2015 (millions)	2014 (millions)
Revenue:	€ 3.154	€ 2.402
EBITDA:	- € 0.390 (loss)	- € 0.667 (loss)

ADDRESS Nouscom AGBäumleingasse 18
CH-4051 Basel
Switzerland

TELEPHONE
+ 41 61 201 18 31

WEBSITE
www.nouscom.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

NOUSCOM AG

Nouscom AG develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.

MANAGEMENT TEAM

CEO and Chairman of the Board: Riccardo Cortese, MD, PhD

CEO Italy: Alfredo Nicosia, PhD

CSO: Elisa Scarselli, MD

COO: Marina Udier, PhD

CTO: Stefano Colloca, MD

Head Immunology: Antonella Folgori, PhD

FINANCIAL SUMMARY

Nouscom is backed by Versant Ventures and LSP (EUR 12M series A announced in May 2016)

novigenix

ADDRESS
Biopôle IV
Route de la Corniche 3B
CH-1066 Epalinges
Switzerland

WEBSITE
www.novigenix.com

COMPANY TYPE
Private

SECTOR
Diagnostics

YEAR FOUNDED
2014

NOVIGENIX SA

Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix's technology is based on a new generation of predictive gene expression profiles of circulating blood cells and tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.

MANAGEMENT TEAM

Dr Brian Hashemi, Executive Chairman

Dr Nicolas Demierre, COO

FINANCIAL SUMMARY

Novigenix is currently financed by private investors. Its lead product is on the market in Switzerland and generate the first sales revenues.

Novigenix is seeking funding (5-6mio) to support the market expansion of its lead product Colox in Europe and prepare for US.

THE PROCEEDS WILL BE USED TO:

- Expand the commercial operations.
- Build market-specific clinical evidence to engage with regulators, payers, and screening programs
- Optimize the product performance to meet market-specific requirements.

PIPELINE PRODUCT 1: NAME/STAGE

Colox is a a new generation blood-based test for early detection of colorectal cancer. It is clinically validated and currently available through clinical laboratories in Switzerland. Colox has proven to have significant benefits:

- It accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer,
- It offers a convenient solution for patients to be tested with no need for bowel or stool preparation,
- It can be ordered by the physician as part of a routine medical check-up,

Colox has been validated through a multi-center clinical study in Switzerland detecting 78% of colorectal cancer patients, and 52% of patients with adenomatous polyps. Less than 1 out of 10 people without any colorectal lesion tested positive5. Individuals testing positive with Colox have high probability to present colorectal lesions and are referred for follow-up diagnostic colonoscopy for final diagnosis. Individuals testing negative with Colox have no colorectal lesion with high probability and should continue periodic testing at intervals recommended by their physician.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Investment

DESCRIPTION

Novigenix is seeking funding (5-6mio) to support the market expansion of its lead product Colox in Europe and prepare for US.

The proceeds will be used to:

- Expand the commercial operations.
- Build market-specific clinical evidence to engage with regulators, payers, and screen-

novigenix

ADDRESS
Biopôle IV
Route de la Corniche 3B
CH-1066 Epalinges
Switzerland

WEBSITE
www.novigenix.com

COMPANY TYPE
Private

SECTOR
Diagnostics

YEAR FOUNDED
2014

ing programs

- Optimize the product performance to meet market-specific requirements.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 2:

Strategic partnership for commercialization

DESCRIPTION

Novigenix is seeking strategic partners to execute the commercial expansion of Colox in Europe, North America, and China with competences and regulatory knowledge to register a diagnostic product in the new territories as well as an established network of certified medical laboratories for implementing and offering testing services to primary care physicians.

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 3:

Strategic partnership for product pipeline

DESCRIPTION

Secondly, Novigenix is seeking strategic partners for product extension onto new technology platforms such as high-sensitivity digital PCR and next generation sequencing or into new clinical indications by leveraging the host-response technology platform of Colox for early detection of other cancers or inflammatory bowel diseases.

Novithera
innovative therapies

WEBSITE
www.novithera.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2016

NOVITHERA

Novithera is a biopharmaceutical company founded with the mission to exploit kinases for the development of small-molecule cancer immunotherapeutics. The company, a joint venture between NovAliX and ProQinase, is based in the BioParc in Illkirch, France. Novithera is led by an industry-experienced team, and is relying on a platform of integrated chemistry, structural biology, kinase expertise, and cancer pharmacology allowing to tackle challenging targets to develop First-in-class / Best-in-class immune-therapy treatments.

MANAGEMENT TEAM

- Dr Luc Van Hijfte, President & CEO, member of the board
- Dr Robert Kramer, CSO
- Dr Selma Boussen, CMO
- Dr Michael Kubbutat, Head of Biology
- Dr Paola Ciapetti, Head of Chemistry
- Stephan Jenn, MBA, member of the board
- Dr Christoph Schächtele, member of the board
- Dr Hubert Roland, member of the board

FINANCIAL SUMMARY

For a more detailed financial summary (prevision up till clinical/development candidate) please have a look at the pdf file in the pipeline download

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

- Pipeline Product 1: Name/Stage
- Inhibitors of MerTK
- Phase : Hit to Lead

DESCRIPTION

- MERTK is a receptor tyrosine kinase (RTK) that shows oncogenic and immuno supressive functions in tumors, and by this represents a very attractive target for the development of low molecular weight inhibitors for cancer treatment.
- We develop selective low molecular weight inhibitors of MERTK for the treatment of cancer in mono- and combination therapies.
- Hits have been identified from an MTS campaign, and the compounds are currently being optimized for activity, selectivity and drug-ability, based on X-ray structural data.

WEBSITE
www.novithera.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2016

INVESTMENT & LICENSING (IN/OUT) OPPORTUNITY 1:

Investment : Funding up to IND

DESCRIPTION

Novithera needs € 5.2 M to advance the MerTK project up to an IND (Investigational New Drug) status over the coming 4 years, and is seeking € 4.7 M in equity funding in a staged manner

- Hit to in vivo POC ; 18 months : € 0.6 M (+ 0.5 M non-dilutive funds from BPI)
- In vivo POC to pre-clinical development candidate ; 21 months : € 1.6M
- Pre-clinical candidate to IND ; 12 months : € 2.5M

NOVOGEN
THE FUTURE OF CANCER THERAPY

ADDRESS
Suite 502
Level 5
20 George Street
Hornsby NSW 2077
Australia

TELEPHONE
+ 61 2 9472 4101

WEBSITE
www.novogen.com

COMPANY TYPE
Listed

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
1994

NOVOGEN LIMITED

Novogen is an oncology-focused, Australian-US drug development company, traded on both the Australian Securities Exchange (NRT) and on NASDAQ (NVGN). We have recently transitioned to a clinical-stage, development-focussed company targeting oncology patients who are poorly served by existing treatment options. Novogen has a lead molecule entering phase I trials in Q4 2016 and we anticipate substantial flow of value-driving milestones over the next 12-18 months.

Novogen has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosin's) with the potential to yield first-in-class agents across a range of oncology indications. We were successful in obtaining Investigational New Drug status from the US Food and Drug Administration for our lead compound, Cantrixil, and have begun executing our Phase I clinical strategy. Our other lead molecules Anisina and Trilexium are in pre-clinical development, with Anisina currently undergoing IND-enabling studies. For more information please visit: www.novogen.com

MANAGEMENT TEAM

• Dr James Garner
MA, MBA, MBBS, BSc (Hons)
Chief Executive Officer
Executive Director
• Dr Andrew Heaton
BSc (Hons), PhD
Vice-President, Drug Discovery
• Dr David Brown
Grad Dip Tech Mgmt, BAppSc (Hons), PhD
Chief Scientific Officer
• Dr Peng Leong
MBA, PhD
Chief Business Officer
• Dr Gordon Hirsch
BSc(Med), MBBCh, FCP(SA), MBA
Chief Medical Officer

FINANCIAL SUMMARY

Market Capitalisation: US$ 31 Million
Listing: ASX: NRT; NASDAQ: NVGN (1:25 ratio)
Average daily volume: ASX: ~570,000 /day; NASDAQ: ~50,000 ADRs /day
Shares on issue: 450 Million
Outstanding Options/Warrants: 74 million
Cash at bank: US$ 25 million

PIPELINE GRAPHIC



NOVOGEN
THE FUTURE OF CANCER THERAPY

ADDRESS
Suite 502
Level 5
20 George Street
Hornsby
NSW 2077
Australia

TELEPHONE
+ 61 2 9472 4101

WEBSITE
www.novogen.com

COMPANY TYPE
Listed

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
1994

PIPELINE PRODUCT 1:

CANTRIXIL (TRX-E-002-1)/Phase I

DESCRIPTION

• Designed to be injected into the peritoneal cavity of ovarian cancer patients with the aim of inducing cell death in both differentiated cancer cells and cancer initiator cells

• Filed for an IND with the US FDA and received a "May Proceed" notification which enables us to execute our clinical strategy for the TRXE-002-1 Phase I clinical trial

• cGMP-grade TRXE-002-1 drug substance and drug product has been manufactured for our Phase I clinical trial.

PIPELINE PRODUCT 2:

ANISINA (ATM-3507)/Pre-clinical (IND-enabling)

DESCRIPTION

• First in class targeted cytotoxic. Targets tropomyosin cancer associated isoform Tpm3.1 and disrupts microfilament function in cancer cells

• Proof-of-concept studies confirm that IV administered ATM-3507 is active as a monotherapy in animal models of prostate cancer, melanoma and prostate cancer and enhances the anti-tumour effect of anti-microtubule agents when dosed in combination.

• Safety studies in rats and dogs indicate that the clinical formulation of ATM-3507 has minimal effects on body weight, haematology and serum chemistry in either species and is not associated with any cardiovascular toxicity, is non-mutagenic and non-clastogenic.

• ATM-3507 drug substance can be manufactured to GLP and cGMP standards. The drug product has been manufactured to GLP standards and is currently being used in our IND-enabling studies.

ONCONOVA THERAPEUTICS

ONCONOVA THERAPEUTICS

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells.

ADDRESS
375 Pheasant Run
Newtown, PA
18940
USA

WEBSITE
www.onconova.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

PANTARHEI ONCOLOGY

ADDRESS
Pantarhei Bioscience
Boslaan 11
3701 CH Zeist
The Netherlands

TELEPHONE
+ 31 (0)30 6 985 020

WEBSITE
www.pantarheibio.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

COMPANY DESCRIPTION

Pantarhei Oncology BV (PRO) is a limited liability company ("Besloten Vennootschap") located in the Netherlands with an innovative approach towards drug development in Immunotherapeutic & Endocrine Cancer (IEC). PRO has developed a sustainable product pipeline based on its ability to identify and prove novel medical uses for existing drugs, hormones, other endogenous human biologicals and combinations thereof in IEC.

BUSINESS CONCEPT

The business concept of PRO is to develop patentable new treatment concepts using existing compounds up to proof-of-concept (PoC) in the human (phase II). Using known compounds provides first evidence of safety. The business model is based on internal project management and outsourced research and development activities. Once patent approval is received and supportive clinical data are generated, new concepts are licensed out for completion of clinical development (phase III), regulatory approval and sales and marketing. Out-licensing contracts will generally include a signing fee, milestone and royalty payments.

DEVELOPMENT STRATEGY

The main focus of PRO is IEC and addresses specific medical areas such as breast cancer, prostate cancer, pancreatic cancer and ovarium cancer.

PRODUCT PIPELINE

The current pipeline includes estetrol (E4) for breast and prostate cancer and zona pellucida (ZP)immunotherapy for pancreatic and prostate cancer. ZP for ovarian cancer has been sold to HRA Pharma (France) in October 2014, whereas the other applications were retained by PRO. All rights on E4 have been sold to Mithra Pharmaceuticals (Belgium) in March 2015, whereas PRO has licensed back all rights on oncological applications.

MANAGEMENT TEAM

Eric M. van der Aa, PhD, CEO

Carole Verhoeven, PhD, CSO

Yvette Zimmerman, PhD, COO

PIPELINE PRODUCT 1:

Estetrol in prostate and breast cancer (Phase I/II)

DESCRIPTION

Estetrol (E4) is an estrogenic steroid, produced exclusively by the human foetal liver during pregnancy. Estetrol is orally bioavailable with an elimination half-life of 28 hours and acts as an estrogen on vagina, uterus, bone and brain, but surprisingly as an oestrogen-antagonist on the breast and can therefore be characterised as a "Natural SERM" (selective oestrogen receptor modulator). Estetrol has demonstrated safety in toxicology, pharmacology and human studies without relevant side effects. This natural SERM is suitable for among others oral contraception, menopausal HT, prevention of osteoporosis, and for breast cancer (BC) and prostate cancer (PC) treatment.

PRO IS DEVELOPING APPLICATIONS FOR DIFFERENT PATIENT POPULATIONS IN BC AND PC:

1) E4 for breast cancer

• Primary cancer treatment of patients with advanced oestrogen receptor positive BC, who became resistant to anti-oestrogen therapies and in addition improving quality of

PANTARHEI ONCOLOGY

ADDRESS
Pantarhei Bioscience
Boslaan 11
3701 CH Zeist
The Netherlands

TELEPHONE
+ 31 (0)30 6 985 020

WEBSITE
www.pantarheibio.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

life of these patients by the HT effects of E4.

• Add-back in BC for the treatment of the serious complaints due to oestrogen deficiency caused by anti-oestrogen treatments with tamoxifen or aromatase inhibitors, thereby also improving compliance to the cancer treatments.

• Low dose E4, not proliferating the endometrium and therefore not requiring co-treatment with a progestogen, is considered suitable for the treatment of vulvovaginal atrophy during anti-oestrogen treatments.

2) E4 for prostate cancer

• Combination treatment with androgen deprivation therapy (ADT). The aim of this therapy is to develop E4 for the treatment of serious side effects due to oestrogen loss caused by the ADT and to further lower the level of testosterone in men with PC.

• ADT for advanced disease. The aim is to investigate the potential of high dose E4 as stand-alone ADT for the primary treatment of patients with advanced PC and concomitantly improve the quality of life of these patients by the HT effects of E4.

PIPELINE PRODUCT 2:

Zona Pellucida Immunization in prostate and pancreatic cancer (preclinical)

DESCRIPTION

Zona pellucida (ZP) is a glycoprotein matrix around the oocyte (egg cell) and involved in the acrosome reaction during fertilisation, allowing only one sperm cell to fertilize the oocyte. The zona pellucida and its ZP glycoproteins (ZP1-4) are specific for the ovary. ZP3, the most immunogenic ZP antigen, was also found (by immunohistochemistry) in 2/3 of tested metastasized granulosa cell and epithelial cell ovarian cancers as well as in pancreatic and prostate cancer cells. Immunization against this protein might be used as a new therapeutic approach for these cancers. The presence of the ZP3 antigen in tumour cells functions as a biomarker for patients to be treated. Proof of principle of ZP induced immunotherapy was obtained in a transgenic animal mouse model for granulosa cell ovarian cancer. A mixed humoral/cellular response was demonstrated reducing the formation of tumours (preventive model) as well as reducing the size of existing tumours (therapeutic model) significantly and no metastases were found. Recently HRA also found that ZP3 immunization in animals induces a strong immune reaction, both cellular (T-cells) and humoral (B-cells). PRO is developing ZP3 immunization for ZP3 positive metastasized pancreatic and prostate cancer.

ADDRESS
850 Boulevard Sébastien
Brant 67400 Illkirch
France

EMAIL
ontact@peptimimesis.com

WEBSITE
www.peptimimesis.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2015

PEPTIMIMESIS

PeptiMimesis exploite a cutting-edge approach to inhibit validated targets via the disruption of dimerization. A large majority of receptors needs to dimerize to be activated. PeptiMimesis has a proprietary know-how to design and develop the next generation of therapeutic peptides via the disruption of the receptor dimerization.

Animal POC and in-depth characterization of tool peptides have already been generated by academic founders on 3 targets, demonstrating that such breakthrough strategy can deliver therapeutic candidates.

PeptiMimesis is currently launching its platform to deliver valuable clinical assets on validated targets.

KEY COMPETITIVES FEATURES:

- Exclusive licence on know-how and existing patents
- Experienced scientific and management team
- Operational platforms and validated assays
- Broad spectrum of activity (target receptor AND co-receptors) for a better efficacy and to block resistance
- Low immunogenicity
- Specificity/selectivity
- Rapid drug design process

RECENT CORPORATE HIGHLIGHTS:

- February 2016: IPSEN collaboration and option agreement
- March 2016: €1.2m seed fund closing
- April: Recruitment of 1st salary and kick-off on internal HER2 program
- May 2016: Collaboration agreement with founder laboratory

FUND RAISING OBJECTIVES:

To identify VC partners to invest €28m to support R&D efforts with the objective at 5 years:
- 3 clinical stage assets in onco and immuno-onco
- 3 candidates on 3 targets ready to enter IND-stage
- Patent portfolio generated

MANAGEMENT TEAM

Marjorie Sidhoum, PhD, President
Pascal Neuville, President of Strategic Committee
Jean-François Rax, Board Member,
Financial Summary
5 years financial needs:
€3.5m (€1.2m already secured) to reach in vivo POC in 18 months
€9m to reach first IND in 18 months
€16m to reach clinical phase I/II with first programs in 24 months

PIPELINE PRODUCT 1:

HER2 peptides for Trastuzumab resistant breast cancer

DESCRIPTION

Transmembrane peptides able to inhibite HER2 receptor through a broad spectrum of dimers.

ADDRESS
Smørblomstvegen 36
9102 Tromsø
Norway

TELEPHONE
+ 47 92 48 14 32

WEBSITE
www.pharmasum.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2014

PHARMASUM THERAPEUTICS AS

Pharmasum Therapeutics is a private, Norwegian pharmaceutical company focused on the discovery and development of novel human niche medicines for the treatment of autoimmune and brain diseases. The Company shall develop drugs to at least Proof-of-Concept stage, but will be seeking strategic partnerships with larger pharmaceutical companies potentially for early-stage collaborations, late-stage development and marketing.

MANAGEMENT TEAM

Anders Fugelli, Ph.D., Chief Executive Officer

John Sigurd Svendsen, Ph.D., Chief Scientific Officer

Pauline Stewart-Long, Ph.D., Project Management

Henning Mork, CFO;

FINANCIAL SUMMARY

Company has pre-foundation sunk costs investment of MNOK 25.

In 2015, equity and public funds comitted was approx MNOK 20.

We will raise 15-20 MNOK in Seed funding to progress our drug into Lead Optimsation and match public funds.

PIQUR
TARGETED CANCER THERAPIES

ADDRESS
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland

TELEPHONE
+ 41 61 633 29 29

WEBSITE
www.piqur.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Pharmaceuticals/Licensing

YEAR FOUNDED
2011

PIQUR THERAPEUTICS AG

PIQUR Therapeutics is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR's pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds.

MANAGEMENT TEAM

Dr. Vladimir Cmiljanović - Chief Executive Officer
Frances Betts - Chief Operating Officer
Dr. Ruggero Della Bitta - Chief Medical Officer
Dr. Saša Dimitrijević - Chief Development Officer
Dr. Doriano Fabbro - Chief Scientific Officer
Hervé Girsault - Chief Business Officer
Gaudenz von Capeller - Chief Financial Officer

PIPELINE GRAPHIC



PIPELINE PRODUCT 1:

PIQUR's lead compound, PQR309, is a novel, oral, balanced pan-PI3K/mTOR inhibitor with excellent prospects to become a powerful anti-cancer drug. In 2014, PIQUR has successfully concluded the first Phase 1 trial of PQR309. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary end-points of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. Since Q2/2015, PIQUR is conducting several Phase 2 trials with PQR309 in selected cancer indications.

PREXTON THERAPEUTICS

ADDRESS
14 chemin des Aulx
1228 Plan les
Ouates, Geneva
Switzerland

TELEPHONE
+ 41 22 706 90 10

WEBSITE
www.prextontherapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2012

PREXTON THERAPEUTICS

Recently founded in Geneva, Switzerland, Prexton Therapeutics is developing novel mGluR4 PAM series, which were originally developed by Merck Serono, an affiliate of Merck KGaA in Darmstadt, Germany. The compounds show high potency on the mGluR4 target and selectivity over the other mGluR subtypes. The Phase I has been completed recently and the Phase II is in preparation. We believe that the lead compound represents a unique opportunity for Parkinson's disease treatment.

MANAGEMENT TEAM

Francois Conquet, CEO

Delphine Charvin, CSO

Mark Watling, CMO

FINANCIAL SUMMARY

€13M raised so far with contribution from private investors and the Michael J Fox Foundation

PIPELINE PRODUCT 1:

PXT002331/Phase II ready

DESCRIPTION

mGluR4 PAM

ProAxsis
a NetScientific portfolio company

ADDRESS
63 University Road
Belfast
BT7 1NF
United Kigndom

TELEPHONE
+ 44 28 95 21 8400

WEBSITE
www.proaxsis.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Diagnostics

PROAXSIS LTD.

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. Our rapid and easy-to-use tests incorporate patented "ProteaseTags®"; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as respiratory, oncology and cardiovascular disease.

ProAxsis launched its first laboratory-based immunoassay for the measurement of active neutrophil elastase as a biomarker of lung inflammation and infection in 2015. This immunoassay has now been included in a number of pharmaceutical and academic research trials. Launch of the company's first point-of-care test is planned for 2017.

PIPELINE PRODUCT 1: DESCRIPTION

Plasmin is a serine protease, whose primary physiological function is to degrade fibrin clots. Released into the circulation as an inactive zymogen, namely plasminogen, this protease is converted to the active form by several activators, including urokinase and tissue plasminogen activator, two additional serine proteases. Although tightly regulated under normal circumstances, numerous medical conditions are characterised by elevated plasmin levels, with increased urinary excretion observed in nephrotic syndrome (NS), and diabetes mellitus (DM). A similar trend has also been reported in pre-eclampsia (PE), with significant increases in plasmin levels detected from the third trimester onwards.

provecs medical

ADDRESS
Martinistr. 64
20251 Hamburg
Germany

WEBSITE
www.provecs.com

COMPANY TYPE
Private

SECTOR
Biotechnology
Bioinformatics
Pharmaceuticals/Licensing

YEAR FOUNDED
2007

PROVECS MEDICAL GMBH

Provecs Medical is a biopharmaceutical company specialized in the development of novel immunotherapies addressing the cancer microenvironment.

Based on its ENVIRO technology platform, the Provecs team has developed solutions to re-program the barriers between the immune system and severe diseases like cancer. In 2015 Provecs Medical has established a first pharma partnership, solid financing plus novel facilities. The company is open to partnering in other distinct cancer indications.

Provecs Medical addresses novel targets in the disease microenvironment by its ENVIRO technology. This novel class of immunotherapeutics enables the combined administration of immunoactive biologicals based on a proprietary adenoviral delivery platform.

First product Immunalon® is being developed for treatment of a wide range of solid cancers with a focus on urinary bladder cancer.

Provecs Medical´s EXVIRO platform is a unique primary cancer tissue testing platform for ex vivo PD and PK studies. This 3D tissue culture system enables studies on the tumor microenvironment in its spatial context, without disruption the cellular relationships.

The EXVIRO platform delivers comprehensive expression data, cellular profiles and molecular biomarker signatures upon bioinformatics based transcriptome studies and immune cell phenotyping.

Today, 70 patients have been enrolled in the ex vivo tissue study with more than 400 tissue specimens studied in individual conditions, e.g. dosing, target cell profile, immune activation and associated pathway analyses.

With this unique data set, Provecs Medical provides a solid basis for target indication screening and clinical development.

MANAGEMENT TEAM

Management

- Dr. Frank Schnieders, CEO
- Nicolas Mohr, Managing Director
- Andrea Miegel, COO

BOARD OF DIRECTORS

- Prof. David Curiel, St. Lous, USA
- Prof. Bernhard Fleischer, Hamburg, Germany
- Dr. Elke Helftenbein, Stuttgart, Germany
- Dr. Rainer Dickhardt, Hamburg, Germany

FINANCIAL SUMMARY

Provecs Medicla is exclusively financed and held by management and private investors. Provecs has raised more than € 7 Mio. in investments, revenues and grants.

Pipeline Product 1: Name/Stage

Immunalon®-BC, preclinical.

Pipeline Product 1: Description

Indication Urothelial Bladder Carcinoma.

PoC in ex vivo study in human urothelial cancer explants.

PIPELINE PRODUCT 2:

Immunalon®-02, preclinical.

DESCRIPTION

Solid tumors.

PROVECTUS BIOPHARMACEUTICALS, INC.

WEBSITE
www.pvct.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2002

PROVECTUS BIOPHARMACEUTICALS, INC.

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

MANAGEMENT TEAM

Timothy Scott, Ph.D. - President

Eric Wachter, Ph.D. - Chief Technology Officer

Peter R. Culpepper, CPA, MBA - Interim CEO & COO

John R. Glass, CPA - Interim CFO

ADDRESS
31 Habarzel St.
Ramat Hachayal
Tel-Aviv 69710
Israel

TELEPHONE
+ 972-722419061

WEBSITE
www.rddpharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

RDD PHARMA

RDD Pharma is a specialty pharma, developing targeted pharmacological treatments for lower gastrointestinal (GI) disorders such as anal fissures, fecal incontinence and pruritus ani.

PIPELINE WITH TWO CLINICAL STAGE PRODUCTS:

RDD 1219 in Anal Fissure

Ongoing Phase 3 for lead product, using novel drug delivery Capository™ for targeted, slow-release therapy. Phase 3 ongoing.

RDD 0315 in Fecal Incontinence - Completed successful Phase 2a. There are NO approved Rx products for FI.

TWO ADDITIONAL PRECLINICAL ASSETS IN:

Radiation Proctitis and Pruritus Ani

Experienced team and BoD, co-located in the US and Israel

Efficient 505(b)2 regulatory strategy; with strong IP for drug-device Capository™

MANAGEMENT TEAM

Jason Laufer Chief Executive Officer

- Over 25 years in healthcare commercial operations
- Global BD & Licensing at URL Pharma (acquired by Takeda for $800M)
- Managing Director at CELLGRO® (acquired by Corning)
- CEO at Elutex
- Clinical - Regulatory Affairs (Pfizer)

PIPELINE PRODUCT 1:

RDD 1219 in Anal Fissure - Phase 3 Ongoing Ini

DESCRIPTION

RDD-1219 : Patient-Administered Nifedipine Capository™

- Efficacy of Ca++ channel blockers for anal fissure is demonstrated in the literature through randomized trials
- No commercial products exist: rectal formulations are provided off-label by compounding pharmacies.
- Ca++ channel blockers relax sphincter, decrease internal anal pressure
- Promotes rapid pain relief, increased blood flow and healing
- RDD-1219: Drug-Capository provides slow-release and precise anatomic delivery, to optimize treatment
- Comfortable applicator – patients need not apply by hand
- RDD-very well tolerated, <5% headache rate
- In contrast, Rectiv/Rectogesic®, (the only approved Rx for anal fissure), is associated with headache in 64% of subjects. Also requires patients to insert fingers into rectum several times/day

ADDRESS
31 Habarzel St.
Ramat Hachayal
Tel-Aviv 69710
Israel

TELEPHONE
+ 972-722419061

WEBSITE
www.rddpharma.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2009

PIPELINE PRODUCT 2:

RDD 0315 in Fecal Incontinence - Phase 2a.

DESCRIPTION

RDD 0315 in Fecal Incontinence

- RDD 0315 , a long-lasting alpha agonist, increases resting anal pressure.
- RDD 0315, as a topical agent, showed a 25% reduction (p = 0.021) in the number of fecal incontinence episodes (gas, liquid, solid) at 8 and 12 hours post-administration of drug, meeting primary efficacy goal.
- Good tolerability and excellent safety profile were observed.
- pK Study – no systemic absorption. All samples found to be below level of detection (1 ng/ml).
- We believe that higher doses to be evaluated in Phase 2b will provide even greater efficacy.
- Can likely escalate dose ~5-10 fold.

RELIEF THERAPEUTICS HOLDING AG

Relief Therapeutics Holding AG (SIX: RLF) is a Swiss-based publicly-traded drug development company focusing primarily on the clinical development of peptides and proteins of natural or engineered origin to address unmet medical needs. Our expertise covers the entire R&D lifecycle up to market approval.

ADDRESS
Bodmerstrasse 2
8002 Zurich
Swizerland

WEBSITE
www.reliefftherapeutics.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2013

MANAGEMENT TEAM

Raffaele Petrone, Chief Executive Officer
Tim Snyder - Chief Financial Officer
Gael Hedou - Chief Operating Officer
Yves Sagot - Chief Scientific Officer
Michel Dreano - Chief Business Officer
Dorian Bevec - Chief Development Officer

RXi Pharmaceuticals
Next Generation in RNAi

ADDRESS
257 Simarano Drive
Suite 101
Marlborough, MA 01752
USA

TELEPHONE
+1 508-767-3861

WEBSITE
www.rxipharma.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2011

RXI PHARMACEUTICALS, INC.

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary self-delivering RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.

MANAGEMENT TEAM

Geert Cauwenbergh, President and CEO

Pamela Pavco, Chief Development Officer

Lyn Libertine, VP Medical Affairs & Safety Assessment

Karen Bulock, VP Research

ADDRESS
1025 Alameda
De Las Pulgas
Suite 126
Belmont, CA 94002
USA

WEBSITE
www.selonterra.com

COMPANY TYPE
Private

SECTOR
Biotechnology

SELONTERRA

Selonterra pursues a transformative approach to the development of therapies of Alzheimer's disease and Parkinson's disease. We harness human genetics, molecular pathway analysis and gene regulatory networks to identify proprietary disease-causing mechanisms and molecular targets, and exploit these to discover effective therapeutics.

In Alzheimer's disease (AD), we focus on the dominant genetic cause, the APOE4 variant. We discovered a novel, proprietary and unexpected role of APOE4 linking its function to gene regulation. We will develop therapies targeted at this APOE4-mediated dysfunction with the potential to delay AD onset and to prevent its progression.

In Parkinson's disease (PD), we focus on genetic determinants of familial and idiopathic PD. Our genetic and gene regulatory analyses led to the discovery of a novel, unexploited mechanism common to LRRK2 and SNCA (alpha-synuclein). Therapies developed against this pathological mechanism have the potential for disease-modification.

MANAGEMENT TEAM

Dr. Roman Urfer, Co-founder and CEO

Dr. Anne Urfer-Buchwalder, Co-founder and CSO

FINANCIAL SUMMARY

Selonterra is currently engaged in a Series A fundraising campaign.

PIPELINE PRODUCT 1:

Alzheimer's disease program / Pre-clinical

DESCRIPTION

Alzheimer's disease is a progressive neurodegenerative disorder affecting 35 million people worldwide. An extreme focus on just a handful of therapeutic approaches has not led to disease-modifying drugs.

The key role of genetics in AD has long been recognized. However, there has been a lack of clear functional links of gene variants to the disease. Consequently, known disease genes have not translated to therapeutics.

Selonterra's novel approach to AD addresses this issue and integrates gene variants, pathway analyses and gene regulatory networks. We identified a novel, unexpected and proprietary mechanism for the APOE4 variant, the dominant genetic component of AD.

Exploiting this mechanism and its associated molecular targets will lead potentially to disease-modifying therapies because the approach is rooted in the genetics causing neuronal dysfunction.

PIPELINE PRODUCT 2:

Parkinson's disease / Pre-clinical

DESCRIPTION

Parkinson's disease (PD) is a neurodegenerative disorder affecting more than 4 million people worldwide and its prevalence is expected to rise in the coming decades. Despite intense efforts there is at present no disease-modifying or curative treatment available.

Our genetic and gene regulatory analysis of familial and idiopathic PD led to the dis-

ADDRESS
1025 Alameda
De Las Pulgas
Suite 126
Belmont, CA 94002
USA

WEBSITE
www.selonterra.com

COMPANY TYPE
Private

SECTOR
Biotechnology

covery of an unexploited disease mechanism common to disease-associated genes including SNCA (alpha-synuclein) and LRRK2.

Therapies directed at this mechanism will have the potential for disease-modification and could fundamentally transform PD therapy.

INVESTMENT & LICENSING OPPORTUNITY 1:

Selonterra Series A Investment

DESCRIPTION

Selonterra is seeking a US$ 6 MM Series A investment.

Transformative approach to Alzheimer's and Parkinson's diseases.

Approach will potentially lead to disease-modifying therapies because it is rooted in the genetics of AD and PD.

Significant value creation possible in short period of time, high likelihood of partnership with global pharmas.

Multiple exit strategies.

INVESTMENT & LICENSING OPPORTUNITY 2:

Alzheimer's program licensing

DESCRIPTION

Selonterra seeks a corporate partner for advancement of its Alzheimer's disease program.

Value proposition:

(1) Transformative approach to AD - rooted in dominant genetics;

(2) Early access to an emerging field in neurodegeneration - establishment of leadership position;

(3) Unexploited targets - potential for disease modification

INVESTMENT & LICENSING OPPORTUNITY 3:

Parkinson's program licensing

DESCRIPTION

Selonterra seeks a corporate partner for advancement of its Parkinson's disease program.

Value proposition:

(1) Unified and unexpected mechanism for dominant genetic components - LRRK2 and SNCA;

(2) Unexploited mechanism - establishment of leadership position;

(3) Unexploited targets - potential for disease modification

ADDRESS
375, rue du Professeur
Joseph Blayac
34080 MONTPELLIER
France

TELEPHONE
+ 33 4 67 20 77 30

WEBSITE
www.sensorion-pharma.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2009

SENSORION SA

Sensorion is a biopharmaceutical company committed to finding targeted and innovative treatments for inner ear disease. Sensorion develops innovative therapies dedicated to the treatment of vestibular and cochlear pathologies. Our scientists are focused on : relieving acute symptoms such as vertigo and tinnitus, reducing impairments (loss of balance, hearing loss ...) related to permanent damage of the inner ear, restore, to the extent possible, the functions already impacted.

Sensorion operates an internal screening platform and progresses a pipeline of drug candidates in clinical development. The two most advanced pograms have completed phase 1 clinical trials.

MANAGEMENT TEAM

Laurent Nguyen, CEO

PIPELINE PRODUCT 1:

SENS-111 : phase 1 completed

DESCRIPTION

SENS-111 is the first representative of the histamine type 4 receptor antagonist class tested in inner-ear pathologies. This drug candidate displays a neuromodulation effect of the neurosensorial inner ear cell function and is being developed for the symptomatic treatment of vertigo crises or tinnitus. SENS-111 is a small molecule that can be taken orally or via a standard injection, and has been successfully assessed in humans in phase 1b.

PIPELINE PRODUCT 2:

SENS-218 : phase 1 completed

DESCRIPTION

SENS-218 is a drug candidate that aims to treat acute or chronic lesions of the inner ear, both vestibular or cochlear in origin, and related symptoms such as vertigo crisis, hearing loss and tinnitus. SENS-218 is a small molecule that can be taken orally or via a standard injection, and has been successfully assessed in humans in phase 1.

strekin

STREKIN AG

Strekin AG is a start-up Life Sciences Company headquartered in Basel, Switzerland. Strekin AG focuses on discovering the untapped therapeutic potential in existing molecules to transform the lives of patients with diseases of cell stress-related inflammatory pathways.

ADDRESS
Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel
Switzerland

TELEPHONE
+ 41 616 332 971

WEBSITE
www.strekin.com

COMPANY TYPE
Private

SECTOR
Biotechnology

ADDRESS
Kloosterstraat 9
5349 AB Oss,
Netherlands

TELEPHONE
+ 31 88 022 4505

WEBSITE
www.synaffix.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

SYNAFFIX BV

Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure.

Presentation Time and Location >>> 1:45p | Track C | 28th Sept | Darwin Room

MANAGEMENT TEAM

Peter van de Sande - CEO
Floris van Delft - Founder & CSO
Sander van Berkel - Founder & Director, R&D Operations
Anthony DeBoer - Director, Business Development
Financial Summary
not disclosed

ADDRESS
Nine Edinburgh Bioquarter
9 Little France Road
Edinburgh
EH16 4UX
United Kingdom

TELEPHONE
+ 44 (0) 131 658 5301

WEBSITE
www.synpromics.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2010

SYNPROMICS LTD.

Synpromics is developing a strategic portfolio of valuable synthetic promoters for specific application across its target markets, such as cell & gene therapy, bio-manufacturing and industrial & agricultural biotechnologies. Synpromics was founded in 2010 to commercialise proprietary and patent-pending technology, developed by Dr Michael L Roberts, in the emerging field of synthetic biology. This is a highly disruptive technology putting the power to control gene expression in almost any condition of interest into the hands of scientists developing next generation technologies, therapeutics and diagnostics.
Website:

MANAGEMENT TEAM

Dr David Venables, CEO

Dr Michael Roberts, CSO

ADDRESS
Lilleakerveien 2 C
NO-0283 Oslo
Saukonpaadenranta 2
FI-00180 Helsinki
Finland

TELEPHONE
+35 810 279 4000

WEBSITE
www.targovax.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2010

TARGOVAX ASA

Targovax: harnessing the immune system to fight cancer.

Targovax is a clinical stage immuno-oncology company dedicated to the development of targeted immunotherapy treatments for cancer patients.

Targovax is a leader in the immuno-oncology field born out of the merger in July 2015 of Targovax of Norway and Oncos Therapeutics of Finland. Targovax is headquartered in Oslo with offices also in Helsinki.

The new company is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient's own immune system to fight the cancer.

Targovax's lead peptide-based targeted immunotherapy, TG01, is currently in a phase II clinical study in resected pancreatic cancer, following a Phase I study which demonstrated immune responses in all patients (6). Its lead adenoviral product, ONCOS-102, has also successfully completed Phase I clinical studies and confirmed its tumor specific and systemic activity. ONCOS-102 will enter further clinical studies in the near future for the treatment of solid tumors such as melanoma, malignant pleural mesothelioma, and ovarian cancer.

Targovax has Orphan Drug Designation with the FDA and EMA for TG01 in pancreatic cancer and ONCOS-102 in mesothelioma, ovarian cancer and soft tissue sarcoma.

Targovax remains committed to the discovery, development and delivery to patients of its first-in-class therapeutic cancer treatments.

MANAGEMENT TEAM

Gunnar Gårdemyr, CEO
Øystein Soug, CFO
Jon Amund Eriksen, COO
Magnus Jäderberg, CMO
Antti Voulanto, EVP
Tina Madsen, VP QA
Peter Skorpil, VP BD
Nikolaj Knudtzon
Ann-Kirsti Aksnes, Head HR, VP

FINANCIAL SUMMARY

In July 2015, in relation to the merger between Targovax ASA and the Finnish company Oncos Therapeutics, Targovax performed a successful private placement.

EUR 20m was raised, ensuring the first stage of an extensive clinical development program with 8 read-outs over the next two years.

With the planned upcoming IPO , Targovax will complete funding for its clinical development program consisting of six ph I/II studies in different indications. Two of six studies are externally sponsored.

PIPELINE PRODUCT 1:

TG01 Phase I/II Pancreatic Cancer

DESCRIPTION

TG01 is evaluated in an ongoing open label, phase I/II of TG01/GM-CSF treatment and gemcitabine as adjuvant therapy for treating patients with resected adenocarcinoma of the pancreas. In a first cohort, 19 patients have received the combined treatment and of the 18 patients eligible for immune response assessment, 15 (83%) have established a detectable immune response.

ADDRESS
Lilleakerveien 2 C
NO-0283 Oslo
Saukonpaadenranta 2
FI-00180 Helsinki
Finland

TELEPHONE
+358 10 279 4000

WEBSITE
www.targovax.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2010

PIPELINE PRODUCT 2:

ONCOS-102 Phase I/II Mesothelioma

DESCRIPTION

This trial will be a randomized phase I/II open label study with a Phase Ib safety lead-in of ONCOS-102 and standard of care chemotherapy in patients with unresectable malignant pleural mesothelioma. The study is planned to include 6 patients in the safety cohort and approximately 24 patients in the randomized phase II part. In February 2016, Targovax announced the submission of the study protocol to the regulatory authorities in Spain in January. According to plan, the trial is planned to commence during the first half of 2016.

PIPELINE PRODUCT 3:

ONCOS-102 Pase I/II Melanoma

DESCRIPTION

This trial will be an explorative open-label study to determine anti-tumor immune activation and clinical response of ONCOS-102 given with pembrolizumab, a checkpoint inhibitor (human programmed PD-1-blocking antibody) in patients with advanced melanoma who have stopped responding to prior treatment with check point inhibitors. The goal of the study is to investigate whether these patients will start responding again to a checkpoint inhibitor after ONCOS-102 treatment. The trial is planned to include approximately 12 patients in the US and will commence in the second half of 2016.

ADDRESS
4 Rue Blaise Pascal, 67081
Strasbourg
France

TELEPHONE
+33 3 68 85 00 00

THERANEXX PROGRAM - UNIVERSITY OF STRASBOURG

Theranexx is a start-up company in foundation that strives to become a key player in the discovery and preclinical development of novel therapeutic strategies for liver fibrosis and for the chemoprevention of hepatocellulular carcinoma (HCC) due to viral hepatitis, alcohol and nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) diseases with major global health impact.

Theranexx offers state-of-the-art technologies for fast-track drug discovery and for the development of novel therapeutic strategies for NASH and liver fibrosis as well as preventive strategies for HCC. While traditionally drug development has been achieved through the identification of individual targets or proteins, Theranexx has developed a unique approach that targets the clinical cell circuits underlying disease progression and carcinogenesis. Theranexx has developed a unique cell culture model that recapitulates a clearly defined and clinically relevant gene signature, which has been shown to predict and drive liver disease progression for all major viral or metabolic etiologies. With its unique features this novel high-throughput screening (HTS) technology overcomes the hurdles that have hampered drug development for liver disease and HCC until now. The drug discovery platform is built on a tractable, simple and robust human liver cell-based system that enables rapid identification of promising drugs through the detection of functional liver regeneration.

Within its first projects, Theranexx has demonstrated that its innovative HTS technology can rapidly discover compounds that alleviate steatosis and fibrosis in state-of-the-art animal models for liver disease. Using in silico prediction models provided by our collaborators, 28 compounds were tested in our drug discovery platform. We identified several small molecules that reversed the liver disease high risk signature, all showing a significant and marked enhancement of the liver disease low risk signature, linked with functional liver regeneration. Furthermore, the power of the drug discovery platform is highlighted by the identification with high confidence of molecules with established anti-fibrotic activity such as captopril.

Using this smart clinical signature-based drug discovery platform Theranexx has also discovered a monoclonal antibody against claudin-1 that reverses steatosis in a state-of-the-art animal model for liver disease progression and aims to develop its lead candidates for the treatment of NASH and fibrosis.

PIPELINE PRODUCT:



TM3THERAPEUTICS

WEBSITE
www.tm3therapeutics.com

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2016

TM3 THERAPEUTICS

TM3 Therapeutics is developing treatments for rare neurodegenerative and metabolic disorders related to Coenzyme A metabolism.

TM3 Therapeutics is currently in the process of incorporation as new business venture, based on years of research in CoA metabolic disorders by its parent company Acies Bio and in collaboration with the leading Key Opinion Leaders in this field. The specialized pharma biotech company TM3 Therapeutics will particularly target severe rare diseases related to malfunctions of the Coenzyme A metabolism as well as other CoA-related clinical indications of broader scope and with unmet medical needs.

The lead compound CAB1803 is currently undergoing preclinical evaluation for an ultra-rare children's neurological disorder Pantothenate Kinase Associated Neurodegeneration (PKAN), which is caused by a mutation of one of the key enzymes responsible for CoA biosynthesis. Based on very promising in vivo efficacy and current preclinical data, European Commission and European Medicines Agency granted an Orphan drug designation status for CAB1803 for treatment of PKAN in April 2016. In addition to PKAN, TM3 Therapeutics is developing a platform therapy for a number of additional clinical indications related to CoA metabolism disorders.

MANAGEMENT TEAM

Enej Kuscer, PhD

Mario Gobbo, PhD

Angelina Sekirnik, PhD

Financial Summary

Seeking 8-10M EUR Series A funding

TONIX PHARMACEUTICALS

ADDRESS
509 Madison Avenue
Suite 306
New York, NY 10022
USA

TELEPHONE
+1 (212) 980-9155

WEBSITE
www.tonixpharma.com

COMPANY TYPE
Listed

SECTOR
Biotechnology

YEAR FOUNDED
2007

TONIX PHARMACEUTICALS HOLDING CORP.

Tonix is developing next-generation medicines for common disorders of the central nervous system, with its lead program focusing on PTSD. This disorder is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.

MANAGEMENT TEAM

Seth Lederman - Co-Founder, CEO & Chairman

Bruce L. Daugherty - Chief Scientific Officer Gregory Sullivan - Chief Medical Officer Bradley Saenger - Chief Financial Officer

PIPELINE PRODUCT 1:

TNX-102 SL is being developed for the treatment of PTSD. The development of TNX-102 SL in PTSD is supported by both clinical and mechanistic rationales. In May 2016, Tonix announced positive topline results from a Phase 2 study, referred to as AtEase, for the treatment of military-related PTSD.

Our experienced team has a strong track record of success in drug development, regulatory approvals, and product launch activities.

INVESTMENT & LICENSING OPPORTUNITY 1:

TNX-102 SL

DESCRIPTION

TNX-102 SL is being developed for the treatment of PTSD. The development of TNX-102 SL in PTSD is supported by both clinical and mechanistic rationales. In May 2016, Tonix announced positive topline results from a Phase 2 study, referred to as AtEase, for the treatment of military-related PTSD.

TRISKEL BIOPHARMACEUTICALS AG

Triskel Biopharmaceuticals AG, headquartered in Basel, Switzerland is specialised in the development of late stage and clearly differentiated biotechnology drugs, with a focus on the very sizeable speciality hospital pediatric market. The lead compound in development by Triskel Bio is TB 101, an innate recombinant-human enzyme, identified by the company as serving an underserved therapeutic area of high unmet medical need, namely in preventing and reducing long-term chronic respiratory morbidity (CRM) in the population of prematurely born neonatal patients. Other clinical indications for TB 101 are also subsequently envisaged.

COMPANY TYPE
Private

SECTOR
Biotechnology

YEAR FOUNDED
2006

HOST SPONSOR

Basel

RECEPTION SPONSOR

Kanton Basel-Stadt

SILVER SPONSOR

Drooms

DROOMS AG

https://www.drooms.com/en

Drooms is the leading provider of data rooms in Europe. The specialized software facilitates highly secure access to confidential documents, as well as the ability to exchange them safely with third parties beyond company firewalls. Drooms allows for the transparent, efficient and secure management of confidential business processes such as commercial real estate sales, mergers and acquisitions, NPL transactions and board communications. Drooms' clients include the world's leading real estate companies, consulting and law firms and corporations such as METRO GROUP, Evonik, Morgan Stanley, JLL, JP Morgan, CBRE, Rewe and UBS.

SILVER SPONSOR

PROVECTUS BIOPHARMACEUTICALS, INC.

www.pvct.com

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

SILVER SPONSOR

ROCHE

www.roche.com

A Pioneer in Healthcare.

We have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.

SILVER SPONSOR

TORREYA PARTNERS

TORREYA PARTNERS LLC

http://www.torreyapartners.com

Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.

BRONZE SPONSOR

NOVASECTA LTD.

www.novasecta.com

Novasecta is a specialist management consulting firm for pharmaceutical companies. Novasecta's clients are primarily CEOs, Commercial Heads and R&D Heads. We provide them with practical solutions based on a profound understanding of their unique businesses and their industry context. We deliver the strategic counsel, insight, and change that they need to drive performance improvement and sustainable growth.

MEDIA SUPPORTER

biopharmadealmakers
From the publishers of Nature

BIOPHARMA DEALMAKERS

biopharmadealmakers.nature.com

Biopharma Dealmakers, a partnering supplement to Nature Biotechnology and Nature Reviews Drug Discovery, covers the partnering strategies of the industry's movers and shakers, the deals that are shaping our field, the best emerging biotech and academic innovators, and the contract services that support them.

SUPPORTING ORGANISATIONS

BERLIN PARTNER

www.berlin-partner.de

First choice: Berlin Partner for Business and Technology

Business and technology support for companies, investors and scientific institutions in Berlin – this is the Berlin Partner für Wirtschaft und Technologie GmbH mission. With customized services and an excellent science and research network, our many experts provide an outstanding range of programs to help companies launch, innovate, expand and secure their economic future in Berlin.A unique public-private partnership, Berlin Partner for Business and Technology collaborates with the Berlin State Senate and over 200 companies dedicated to promoting their city. Berlin Partner is also responsible for marketing the German capital to the world, for example with the successful “be Berlin” campaign.

SUPPORTING ORGANISATIONS

BIOPHARM INSIGHT

www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive and customizable online interface, BioPharm Insight provides an unrivalled capability to segment and analyse the industry with detailed and searchable profiles.

SUPPORTING ORGANISATIONS

BIOTECHGATE

www.biotechgate.com

Your source for life science companies and licensing information. If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems - and even more.

SUPPORTING ORGANISATIONS

Citigate Dewe Rogerson

CITIGATE DEWE ROGERSON

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world's leading strategic communicationsconsultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo – NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A). Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

SUPPORTING ORGANISATIONS

CUKIERMAN & CO. LIFE SCIENCES

www.cukiermanlifesciences.com

Cukierman & Co. Life Sciences (CLS) delivers high quality, senior level advice to global Life Sciences sectors, including biotechnology and pharmaceuticals, medical devices and healthcare information technology.

Established in 2006 as the Life Sciences Corporate Finance arm of Cukierman & Co. Investment House, CLS provides investment banking services to public & private companies at different stages of development. We are engaged in debt and equity transactions, M&A, IPO advisory services, Corporate Partnering and Licensing Agreements.

SUPPORTING ORGANISATIONS

EDISON

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison's largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

SUPPORTING ORGANISATIONS

FREEMIND
Non-Dilutive Funding Specialists

FREEMIND

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.FreeMind's knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

SUPPORTING ORGANISATIONS

Embassy of Israel in Switzerland
Economic & Trade Dept.

THE ECONOMIC & TRADE DEPARTMENT OF THE EMBASSY OF ISRAEL

www.itrade.gov.il/switzerland/

The Economic & Trade Department of the Embassy of Israel promotes, enhances and facilitates trade, investment and industrial R&D between Switzerland and Israel.

We offer Israeli companies a wide range of business development services to connect with partners in Switzerland. Our activities include business seminars, delegations, investment events, market briefings, and business meetings scheduling.

The Economic & Trade Department offers Swiss companies access to Israeli technology and Innovation through events, exhibitions, delegations and investment events. We also facilitate scouting for cutting-edge technologies and access to business opportunities from Israel.

SUPPORTING ORGANISATIONS

GoingPublic Life Sciences Serie

THE LIFE SCIENCES-SERIES

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment – the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter LifeSciencesUpdate.

SUPPORTING ORGANISATIONS

INSTINCTIF PARTNERS

INSTINCTIF PARTNERS

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.

SUPPORTING ORGANISATIONS

LABIOTECH.EU

www.labiotech.eu

LaBiotech.eu is the free and extensive European biotechnology news website. Launched in September 2014, this young and dynamic media is the best way for you to keep a watch on the business and innovations of biotechnologies. Thanks to our partnerships with major European biotech events we are also your dedicated website for event summaries and agenda. You can also subscribe to our weekly newsletter to receive the latest news.

SUPPORTING ORGANISATIONS

LIFE SCIENCE AUSTRIA

www.lifescienceaustria.at

Life Science Austria - LISA - is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria. Working with all existing life science clusters in the Austrian regions – ecoplus, human. technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development.Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

SUPPORTING ORGANISATIONS

ONE NUCLEUS

www.onenucleus.com

About One Nucleus: One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe's largest life science and healthcare cluster.

Vision: For One Nucleus and our members to be the top European life science and healthcare network.

Mission: We will achieve this by maximising the global competitiveness of our members.

Organisation History: Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation and located in Cambridge and London – the centre of Europe's leading life science and healthcare cluster.

The company has over 470 organisations as members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus's mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people's lives around the world. For our business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

SUPPORTING ORGANISATIONS

SWISS BIOTECH

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaseIArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland's profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotechs' mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

SUPPORTING ORGANISATIONS

TIBEREND STRATEGIC ADVISORS, INC.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

EXHIBITORS

BACHEM

BACHEM AG

www.bachem.com

CONTACTS
Dr. Thomas Früh
CEO

ADDRESS
Hauptstrasse 144
4416 Bubendorf
Switzerland

TELEPHONE
+41 58 595 2021

FAX
+41 58 595 2040

EMAIL
sales.ch@bachem.com

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

EXHIBITORS

BETRACE

www.betrace.be

CONTACTS
Pierre Vanderdonck
Managing Director

ADDRESS
Rue de Rodeuhaie, 6
1348 Louvain-la-Neuve
Belgium

TELEPHONE
+32 10 23 22 90

EMAIL
bis@betrace.be

BETRACE provides unique security and traceability solutions for unit-based storage and unit-based dispensing of pharmaceutical specialties in highly challenging and regulated modern medical environments such as operating rooms, intensive care units and emergency areas. Through the patented Electronic Drug Detection (EDD) sensors, Betrace offers the optimal market solutions for single unit drug traceability. The highly efficient “Grab and Go” working environment also improves work flow by freeing medical staff from repetitive time consuming tasks, implementing user-friendly systems and, most importantly, refocussing attention on patient care and safety. Securing and tracing every drug movement and providing real time stock levels through state-of the art reporting, the Betrace solutions also insure strict compliance with regulations while optimizing decentralized pharmacy management.

EXHIBITORS

DROOMS AG

www.drooms.com

CONTACTS
Miss Luisa Henk
Senior Manager Business Development

ADDRESS
Eschersheimer Landstraße 6
60322 Frankfurt
Germa**NY**

TELEPHONE
+49 69 478 640 0

EMAIL
office@drooms.com

SECTOR

• Biotechnology

COMPANY PROFILE

Drooms is a leading European provider of secure cloud solutions. The software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as due diligence for funding rounds, license negotiations, M&A activities or protection of intellectual property are handled securely, transparently and efficiently with Drooms.

Headquartered in Frankfurt, Drooms is expanding its global market presence with offices in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is has deep experience facilitating large-scale local and multi-jurisdictional transactions. Their expertise, combined with innovative processes and relentless customer focus have laid the groundwork for Drooms' excellent reputation.

PIPELINE

Drooms

Drooms' core competence is the configuration and administration of virtual data rooms, which gives users secure 24/7 online access to confidential documents. State-of-the-art security technology provides a powerful platform for sensitive and closely-controlled document exchange between internal and external resources, e.g. during online due diligence processes. Digital rights management determines who can review, print or save selected documents. Recording of all data room activities through detailed real-time reporting allows for monitoring of all activity in the data room. This functionality supports strategic decision making as well as supporting a company's compliance and risk management policies.

EXHIBITORS

EVALUATE LTD.

www.evaluategroup.com

CONTACTS
Alex Karle
CEO

ADDRESS
Evaluate Ltd., 11-29 Fashion Street,
London E1 6PX
United Kingdom

TELEPHONE
+44 (0)20 7377 0800

FAX
+44 (0)20 7349 5157

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams, their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data, insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and med-tech sectors. Our Custom Services group delivers project based analytical and data services. Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis.

EXHIBITORS

GENECODE LTD.

www.genecode.com

CONTACTS
Mehis Pilv
Partner

Dr Yulia Sidorova
Partner

ADDRESS
Ahtri 8
Tallinn 10151
Estonia

EMAIL
info@genecode.com

COMPANY PROFILE

Genecode Ltd is a private biotech company focusing on the discovery and development of new platforms on the drug development. The main therapeutic targets are various neurodegenerative diseases and viral infections.

The pipeline in preclinical phase includes a number of drug candidates: (a) small-molecule neurotrophic factor GDNF mimetics against Parkinson's disease, (b) small-molecule neurotrophic factor artemin mimetics against neuropathic pain; (c) antisense therapeutics against hepatitis C virus based on GeneCode's novel gene-silencing platform; (d) small-molecule Chikungunya virus nsP2 protease inhibitors.

OPPORTUNITIES

GDNF mimetics against Parkinson's disease Genecode's original Glial cell line-derived neurotrophic factor small-molecule mimetics lead to genuinely disease modifying therapy for Parkinson's disease. Like neurotrophic factor itself, the mimetic compounds support the survival as well revitalization of the neurons in brain. The pharmacodynamic and pharmacokinetic profiles of the compounds, e.g. the penetration of the blood-brain barrier are good. The proof-of-principle animal tests confirm the in vivo activity of the compounds at the same level as the native ligand. Genecode, Ltd. is looking for a Partner/Investor to complete the preclinical studies and enter the Phase I clinical trials.

ARTN mimetics against neuropathic pain

Genecode's original neurotrophic factor Artemin small-molecule mimetics enable disease modifying therapy for neuropathic pain. Like neurotrophic factor itself, the mimetic compounds support the survival as well revitalization of the peripheral neurons related to the pain. The pharmacodynamic and pharmacokinetic profiles of the compounds are good. The proof-of-principle animal tests confirm the in vivo activity of the compounds at the same level as the native ligand. Genecode, Ltd. is looking for a Partner/Investor to complete the preclinical studies and enter the Phase I clinical trials.

HCV antisense antivirals

GeneCode Ltd. has introduced a new technology platform is based on oligonucleotide analogs that contain specifically modified DNA bases and that are bound to organic complexes of lanthanides with highly selective artificial nuclease activity. The active doses of these compounds in in vivo animal tests on hepatitis C virus constructs are as low as 40...60 mkg/kg. Genecode, Ltd. is looking for a Partner/Investor to complete the preclinical studies and enter the Phase I clinical trials.

EXHIBITORS

HOFFMANN & CO AG

www.hoffmann-partner.com/en

CONTACTS
Patrick Schacher
Partner

ADDRESS
Lautengartenstrasse 14
CH – 4052 Basel
Switzerland

TELEPHONE
+41 61 485 93 00

FAX
+41 61 485 93 10

EMAIL
info@hoffmann-partner.com

We are a leading professional services company offering a comprehensive range of support in the areas of valuations, mergers and acquisitions as well as accounting and tax services. As an independent company, we are free from conflicts of interest and remain objective in all assessments.

Professional service provider of following financial services:

- customised CFO-Services (also part-time), incl. but not limited to Financial Planning, Controlling, Payroll, Accounting and Tax
- Valuation Services (specialised in valuation for life-sciences purposes)
- IFRS-Accounting Services

EXHIBITORS

LIFE SCIENCE ZURICH YOUNG SCIENTIST NETWORK

www.lszysn.ch

CONTACT
Daniel Gaul
Chairman

ADDRESS
c/o University of Zurich
Winterthurerstrasse 190
CH-8057 Zurich
Switzerland

EMAIL
info@lszysn.ch

We are the Young Scientist Network, a non-profit organization created and run by a group of graduate students & post-docs of the University and the ETH Zurich. Young Scientist Network operates under the wing of Life Science Zurich culminating in our acronym LSZYSN.

We strive to reduce the existing gap between academic research and the life science industry.

We host events to allow young academics to explore the world of biotechnology and to stimulate constructive interactions between people from various life science sectors.

We envision that our efforts will contribute to the formation of a well-informed, competitively skilled and well-connected local and global life science community.

EXHIBITORS

PROVECTUS BIOPHARMACEUTICALS, INC.

www.pvct.com

CONTACT
Peter R. Culpepper
Interim CEO & COO

ADDRESS
7327 Oak Ridge Highway
Knoxville, TN 37931
USA

TELEPHONE
+1 866 594 5999

FAX
+1 866 998 0005

EMAIL
info@provectus.com

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

SACHS ASSOCIATES

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on bio-pharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-TO-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online one to one meeting system, allowing you to set up, accept or decline private one to one meetings with other conference attendees. These meetings are scheduled at your convenience in private meeting rooms and last 30 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your position your company in this market.

Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

- Conference Sponsor – including workshops and social events
- Exhibition stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities,
please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.

WE LOOK FORWARD TO SEEING YOU AT:

10TH ANNUAL

EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION

PARTNERING & INVESTING IN BIOTECH & PHARMA INDUSTRY

6TH – 7TH MARCH 2017, HILTON ZURICH AIRPORT HOTEL, SWITZERLAND

2ND ANNUAL

NEUROSCIENCE BIOPARTNERING & INVESTMENT FORUM

SHOWCASING EARLY & LATE STAGE INVESTMENT OPPORTUNITIES

27TH MARCH 2017, NEW YORK ACADEMY OF SCIENCES, USA

5TH ANNUAL

CANCER BIOPARTNERING & INVESTMENT FORUM

SHOWCASING EARLY & LATE STAGE INVESTMENT OPPORTUNITIES

28TH MARCH 2017, NEW YORK ACADEMY OF SCIENCES, USA


SACHS
ASSOCIATES
www.sachsforum.com